






Longitudinal associations between 











A Thesis submitted for the degree of  
Doctor of Philosophy 
 











Longitudinal associations between 





















Context: The plausibility of a bidirectional link between periodontitis and type 2 diabetes 
has recently been acknowledged. However, little is known of the relationship between the 
two conditions at an earlier stage in the dysglycaemia continuum. 
 
Objective: To describe the natural histories of periodontitis and dysglycaemia over 12 years 
through the third and fourth decades of life, to identify predictors of both conditions, and to 
explore the bidirectional relationship between them. 
 
Methods: This study used data from the Dunedin Multidisciplinary Health and Development 
Study (DMHDS), a long-running prospective study of a birth cohort, and the utilisation of 
advanced statistical techniques to analyse these data. Both periodontal and glycated 
haemoglobin (HbA1c) data were gathered during the age-26, age-32 and age-38 
assessments. Group-based trajectory analysis (GBTM) was used to assign Study members to 
trajectories of (a) periodontal experience (using mean % of sites with 4+mm attachment loss) 
and (b) dysglycaemia experience (using mean HbA1c). Generalisations of the model allowed 
the statistical linking of baseline characteristics to group membership probability, and 
identified effect modifiers associated with deviations from the group trajectory.  
 
Results: Prevalence, extent and severity of periodontitis, and mean HbA1c, all increased 
with age, as did the prevalence of prediabetes, type 2 diabetes and dysglycaemia. Both 
periodontitis and dysglycaemia were highly prevalent by age 38, and health status at 26 
predicted health status at 38. Four periodontal trajectory groups were identified: “Very low” 
54.0%, “Low” 31.3%, “Medium” 11.3%, and “High” 3.5% (with mean % of sites with 
4+mm attachment loss at age 38 of 0.0%, 2.9%, 19.6% and 64.4% respectively). Periodontal 
status, male sex, smoking, marijuana use, low SES, high plaque score and episodic use of 
dental services at age 26 were found to be predictors of poorer periodontal status 12 years 
later. Three HbA1c trajectory groups were identified: “Low” 11.0%; “Medium” 54.0%; and 
“High” 35.0% (with mean HbA1c at age 38 of 29.9 mmol/mol, 34.2 mmol/mol and 38.5 
mmol/mol respectively). HbA1c levels, male sex, smoking, high waist circumference and 
high waist-height ratio at age 26 were predictors of dysglycaemia 12 years later. The 
influence of dysglycaemia at age 38 on the extent of periodontitis was found to be minimal 
and inconsistent, and periodontitis was found to have no influence on HbA1c at any age.  
                                                                                                                                                                                  Dara Shearer 
ii 
 
Conclusions: Trajectories of both periodontitis and HbA1c begin relatively early in 
adulthood with a greater risk of poor outcomes being established in the middle of the third 
decade of life. Periodontal and glycaemic health status at 38 were predicted by periodontal 
and glycaemic health status respectively at 26. Both conditions were highly prevalent by age 
38. No relationship was found between periodontitis and dysglycaemia at this stage in the 
life course. The findings reinforce the importance of smoking and central adiposity as risk 
factors for poor health outcomes; they establish that health status at 26 has an influence 12 
years later; and recommend that planning for the future burden of disease, early 
cardiometabolic screening, smoking reduction policies, and measures to tackle the 
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1 Introduction and literature review 
1.1 Introduction 
Reports of the association between periodontal and systemic health date back to the late 19th 
century (Miller, 1891; Williams, 1928), and the evidence linking the two has accumulated 
since then, particularly over the past two decades. Associations have been suggested between 
periodontal disease and a range of disorders including diabetes mellitus (and its 
complications), cardiovascular disease (CVD), pre-term birth, low birth-weight, respiratory 
disorders and rheumatoid arthritis (Cullinan et al., 2009; D'Aiuto et al., 2005; Kuo et al., 
2008; Linden et al., 2013). However, the evidence is particularly strong for periodontal-
diabetes mellitus and periodontal-cardiovascular disease associations (Kuo et al., 2008). 
 
Diabetes mellitus is a clinically and genetically heterogeneous group of metabolic diseases 
of multiple aetiology characterized by chronic hyperglycaemia (an abnormal elevation in 
blood glucose levels) with disturbances of carbohydrate, fat and protein metabolism resulting 
from defective insulin secretion whereby not enough insulin is produced, insulin resistance 
whereby cells do not respond to the insulin that is produced, or both (World Health 
Organization, 1999). Reduced insulin levels and/or insulin resistance prevent the conversion 
of glucose into glycogen, with resultant hyperglycaemia. In many cases, prediabetes 
(dysglycaemia or abnormal glucose metabolism) may be an undetected feature for some time 
before diabetes becomes evident.  
1.1.1 Diabetes prevalence and burden of disease 
The World Health Organisation estimates 346 million people (approximately 5%) worldwide 
had diabetes in 2011 (World Health Organization, 2011c). In the United States, 25.8 million 
(8.3%) of the total population had diabetes in 2010 (Centers for Disease Control and 
Prevention, 2011). This figure included seven million with undiagnosed diabetes. Adults 
accounted for the vast majority of cases with 25.6 million (11.5%) of the population age 20 
and over with diabetes. About 1.9 million people age 20 years or older were newly 
diagnosed with diabetes in 2010 (Centers for Disease Control and Prevention, 2011). Some 
68,905 people died of diabetes-related complications in the US in 2010 (Murphy et al., 
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2012). In New Zealand, it is estimated that the number of people diagnosed with diabetes 
exceeded 200,000 (4.6% of total population) people in 2010, with approximately another 
100,000 people with undiagnosed diabetes (Ministry of Health, 2010b).  
 
The prevalence of prediabetes is not as clear as it is a largely asymptomatic condition that 
does not present early, and may go undetected for years. In any case, in the years 
2005−2008, it was estimated some 35% of U.S. adults aged 20 years or older had 
prediabetes, and half of those age 65 years or older had prediabetes (Centers for Disease 
Control and Prevention, 2011). If this percentage is applied to the entire U.S. population in 
2010, it yields an estimated 79.0 million Americans aged 20 years or older with prediabetes 
(Centers for Disease Control and Prevention, 2011). If this is added to the 25.6 million age 
20 years or older with diabetes, the total number of adults with dysglycaemia is about 104.6 
million (about a third of the total population, or almost half the adult population). The 
situation is no better in New Zealand; a recent study found the prevalence of prediabetes to 
be 25.5% for the total NZ population over the age of 15 (Coppell et al., 2013). Of particular 
concern is the increasing number of adolescents with prediabetes (Cali and Caprio, 2008). 
Studies examining trends among U.S. adolescents found the prevalence of adolescents with 
prediabetes or diabetes (mostly prediabetes) to have increased markedly from 9.0% to 23.0% 
between 1999 and 2008 (May et al., 2012);  another study found the prevalence of 
prediabetes to be 16.1% in 2006 in this age group (Li et al., 2009). 
 
Treatment of type 2 diabetes consists of management of hyperglycaemia and prevention of 
secondary conditions. These include microvascular (retinopathy, nephropathy, and 
neuropathy) and macrovascular (ischemic heart disease, peripheral vascular disease, and 
cerebrovascular disease) complications, and result in organ and tissue damage, increased 
morbidity and mortality (Stratton et al., 2000). Research suggests that individuals with 
diabetes with sustained hyperglycaemia suffer more severe diabetic complications than those 
with better glycaemic control (Daneman, 2006; Stratton et al., 2000); and those with diabetes 
who benefit from early intensive treatment of hyperglycaemia will experience a reduced risk 
of complications in the long-term (Callaghan et al., 2012; Genuth, 2006). Nor are 
complications exclusively predicted by the presence or absence of diabetes as such with 
prediabetes being found to be a risk factor for endothelial dysfunction1, increased arterial 
                                                 
1 Endothelial dysfunction is an early sign of atherosclerosis (Landmesser and Drexler, 2005).   
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stiffness2, and future cardiovascular events (DeFronzo and Abdul-Ghani, 2011; Shin et al., 
2011; Su et al., 2008). 
 
 The morbidity and mortality associated with diabetes is substantial. Diabetes mellitus is the 
seventh leading cause of death in the United States in 2010 (Murphy et al., 2012). Globally 
diabetes is the fifth leading cause of death (Roglic et al., 2005). However, diabetes is likely 
to be underestimated as a cause of death as individuals with type 2 diabetes do not 
necessarily have the disease entered on their death certificate (Cheng et al., 2008; Will et al., 
2001). 
 
The burden of diabetes and its complications, and the rate of death attributable to diabetes is 
increasing globally, mainly in developing countries (Dalal et al., 2011; Hossain et al., 2007; 
Misra and Khurana, 2008; Ueshima et al., 2008). The prevalence of diabetes is predicted to 
be 366 million worldwide by 2030 (Wild et al., 2004); this may well prove to be an 
underestimate. The International Diabetes Federation predicts the prevalence to be 522 
million by 2030 (The International Diabetes Federation's Diabetes Atlas.).  The present 
economic cost of diabetes, and its secondary conditions, on individuals, communities and 
health care systems is already substantial (Centers for Disease Control and Prevention, 
2011). This cost is projected to rise significantly in the future, with consequential suffering, 
reduced productivity, and increased use of scarce resources (American Diabetes Society, 
2008; Davis et al., 2006; Fradkin and Rodgers, 2008; Huang et al., 2009). The management 
of diabetes, the effective management of its risk factors, and the prevention of its 









                                                 
2 Increased arterial stiffness is associated with atherosclerosis (Hamilton et al., 2007; Herrington et al., 2004). 
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1.1.2 Diabetes, tests for diabetes, and diabetic states 
Normally, the classification of diabetes is based upon its pathophysiology. While some 
authors have proposed changes to this categorisation, the customary classification is outlined 
here (Wilkin, 2007).  
 
1.1.2.1 Diabetes 
Type 1 diabetes results from a T-cell-mediated autoimmune destruction of the insulin-
producing β-cells of the islets of Langerhans in the pancreas, usually leading to absolute 
insulin deficiency (American Diabetes Association, 2011). The lack of insulin production in 
patients with type 1 diabetes makes the use of exogenous insulin necessary to prevent the 
development of hyperglycaemia and life-threatening ketoacidosis. The incidence of type 1 
diabetes reaches a peak at puberty, and has been thought to decline rapidly thereafter. 
However, it occurs in older people too with some researchers reporting a peak before 
puberty, and again during or after the fifth decade (Haller et al., 2005; Karjalainen et al., 
1989; Thunander et al., 2008). 
 
Type 2 diabetes is characterized by insulin resistance which is the impairment of the 
responsiveness of body tissues to endogenously produced insulin. In the early stages, insulin 
levels may be raised as more insulin is produced to compensate for insulin resistance. This 
may be followed by a decrease in insulin secretion due to the sustained increase in secretory 
demand with many individuals eventually requiring insulin therapy to manage their 
condition (although some capacity for some insulin production remains). Hyperglycaemia 
has a gradual onset, and is generally asymptomatic initially. At this early stage, it may be 
reversed by dietary measures (at least in the short term), weight loss, exercise, bariatric 
surgery and medication (American Diabetes Association, 2010; Lim et al., 2011; Umpierre 
et al., 2011). Type 2 diabetes accounts for between 90-95% of those with diabetes (American 
Diabetes Association, 2011).  
 
Gestational diabetes is another type of diabetes which develops only during pregnancy, and 
is a risk factor for later development of Type 2. Rarer forms include diabetes due to genetic 
defects of the β-cell, genetic defects in insulin action, pancreatic disease, endocrinopathies, 
drug- or chemical-induced diabetes and infections. 
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1.1.2.2 Tests for diagnosis of diabetes   
Diabetes is characterized by persistent hyperglycaemia, and diagnosis generally involves one 
of the following tests. 
Fasting plasma glucose (FPG) test 
This test measures blood glucose in a person who has had no caloric intake for at least eight 
hours prior to the test. It is most reliable when done in the morning. The FPG test is 
convenient (apart from the necessity of fasting) and low cost. However, it will miss some 
diabetes or prediabetes that can be found with the oral glucose tolerance test (OGTT). 
Impaired fasting glucose (IFG) is defined as a fasting plasma glucose level of 5.6 mmol/l - 
6.9 mmol/l. IFG indicates prediabetes, and increases the risk of developing type 2 diabetes. 
A FPG above 6.9 mmol/l indicates diabetes (Table 1.1).  
 
Oral glucose tolerance test (OGTT)  
An OGTT measures the body’s ability to metabolize glucose. The patient is instructed to 
have no caloric intake for at least eight hours prior to the test. A liquid containing 75 grams 
of glucose dissolved in water is drunk, and blood levels are checked two hours later. While 
the OGTT is more sensitive than the FPG test for diagnosing prediabetes it is less 
convenient, it costs more, is time-consuming, and is less reproducible. These limitations 
make the OGTT inappropriate for use in epidemiological research. If the blood glucose level 
is 7.8 mmol/l - 11.0 mmol/l two hours after drinking the liquid, the patient has a form of 
prediabetes called impaired glucose tolerance (IGT). Having IGT, like having IFG, means an 
individual has an increased risk of developing type 2 diabetes. Above 11.0 mmol/l, a 
diagnosis of diabetes is made (Table 1.1). 
 
Glycated haemoglobin (HbA1c) 
HbA1c is a reliable measure of glycaemic levels over time as it measures the average plasma 
glucose concentration over the previous four weeks to three months. It is convenient as 
fasting is not required and the OGTT’s two-hour wait is not necessary. It captures chronic 
hyperglycaemia much better than FPG and OGTT as it is not influenced by transient 
episodes of illness or stress. HbA1c is reported in two different units: the National 
Glycohemoglobin Standardization Program (NGSP) reference system (%) and the 
International Federation of Clinical Chemistry (IFCC) reference system (mmol/mol). 
According to the NGSP system, prediabetes is implied when HbA1c levels of 5.7% – 6.4%, 
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and diabetes is 6.5% and above (Table 1.1). Measured by the IFCC system, prediabetes is 
HbA1c levels of 39 mmol/mol – 47 mmol/mol, and diabetes at 48 mmol/mol and above 
(American Diabetes Association, 2012). The HbA1c measures, as well as the dysglycaemia 
category cut-points used, are discussed in more detail in the Methods section. 
 
 
Table 1.1. Tests for diagnosis of prediabetes and diabetes 
 
Normoglycaemia Prediabetes Diabetes 
FPG1 <5.6 mmol/l 5.6 mmol/l -6.9 mmol/l (IFG2)   ≥7.0 mmol/l  
OGTT3 <7.8 mmol/l 7.8 mmol/l - 11.0 mmol/l (IGT4) ≥11.1 mmol/l  
HbA1c5    
ADA values6    
NGSP7 <5.7% 5.7% – 6.4% ≥6.5%   
IFCC8 <39 mmol/mol 39 mmol/mol – 47 mmol/mol ≥48 mmol/mol  
NZ values9    
IFCC7 <40 mmol/mol 40 mmol/mol – 49 mmol/mol ≥50 mmol/mol  
1Fasting Plasma Glucose test. Fasting is defined as no caloric intake for at least 8 hours. 
2Impaired Fasting Glucose. 
3Two-hour plasma glucose Oral Glucose Tolerance Test using a glucose load containing the equivalent of 75 g 
  anhydrous glucose dissolved in water.  
4Impaired Glucose Tolerance. 
5Glycated Haemoglobin. 
6Anerican Dental Association values. 
7Assayed using the National Glycohemoglobin Standardization Program (NGSP) reference system.  
8Assayed using the International Federation of Clinical Chemistry (IFCC) reference system. 





1.1.2.3 Diabetic states 
Prediabetes 
Prediabetes is a condition in which individuals have glycaemia levels that are considered 
higher than normal, but not high enough to be classified as diabetes (Table 1.1). Individuals 
with prediabetes are considered to be at greater risk of developing type 2 diabetes in the 
future (American Diabetes Association, 2011; de Vegt et al., 2001; Inoue et al., 2008); 
moreover, prediabetes may be an independent risk factor for CVD (Hanna-Moussa et al., 
2009). Prediabetes can be IFG or IGT (or both), depending on which test was used. If the 
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FPG test is used for diagnosis, it will be referred to as impaired fasting glucose (IFG). If the 
OGTT test is used, it’s called impaired glucose tolerance (IGT). Or it may be diagnosed 
using HbA1c levels.  
 
The American Diabetes Association (ADA) recently recommended a range of 39 mmol/mol 
– 47 mmol/mol for  prediabetes (American Diabetes Association, 2011); previously, the 
recommended lower cut-off point was 42 mmol/mol (2009). This value of 39 mmol/mol, 
compared with other cut points, has been found to have a good combination of sensitivity 
and specificity to identify cases of prediabetes (American Diabetes Association, 2011; 
Cheng et al., 2011; Choi et al., 2011a). Furthermore, it was found to be cost-effective to 
target preventive interventions from the 39 mmol/mol point and above (Zhuo et al., 2012). 
However, the importance of regarding the range of HbA1c values from normal through 
various levels of dysglycaemia as a continuum of risk must be emphasised, and the practice 
of defining cut-off points for normoglycaemia, prediabetes and diabetes should be seen as 
somewhat arbitrary. Risk does not suddenly increase as an individual moves from one 
category to the next. Rather there is a gradual rise in CVD risk as glycaemia increases, and a 
gradual rise in type 2 diabetes risk as glycaemia increases across the spectrum of prediabetes 
towards the diabetes threshold. Most recently, the New Zealand Society for the Study of 
Diabetes (NZSSD) has recommended a range of 41 mmol/mol – 49 mmol/mol for 
prediabetes (Braatvedt et al., 2012; New Zealand Society for the Study of Diabetes, 2011). 
This pragmatic approach recognises that the values “40 and below” for minimal risk, and 
“50 and above” for high risk, are more likely than other values to be easily remembered by 
patients (Table 1.1). 
 
Individuals with prediabetes who lose weight using dietary, physical activity, or behavioural 
interventions have a consequent decrease in the risk for progression to type 2 diabetes 
(Norris et al., 2005). Prediabetes is associated with obesity (particularly abdominal obesity), 
high serum triglycerides, low HDL cholesterol, and hypertension. These are the components 
of metabolic syndrome. 
 
Metabolic Syndrome 
Metabolic syndrome (MeS) may be best seen as a clustering of certain cardiometabolic risk 
factors rather than a “syndrome” as such as its causes are not well understood, and no clear 
basis exists for the algorithm that defines it (Kahn, 2007; Mann, 2012). Although its clinical 
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utility is questioned, it does help to define a cluster of disorders that often occur together, 
and put individuals at higher risk of CVD and type 2 diabetes (Alberti et al., 2009; Gami et 
al., 2007). Insulin resistance has been suggested as a possible linking factor (World Health 
Organization, 1999). Some authorities suggest that these disorders are multiplicative – 
together they pose a higher risk over and above that posed by the individual disorders; others 
argue that “the whole is not greater than the sum of the parts” (Kahn, 2006). In addition, its 
diagnostic criteria are disputed with different diagnostic criteria proposed by different 
organisations (Table 1.2).  
 
The first formal definition of metabolic syndrome was published by the World Health 
Organisation (WHO) in 1999 (World Health Organization, 1999); this definition required 
insulin resistance as a component. This was followed by the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP, ATP III) criteria in 2001 (National Cholesterol 
Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III), 2002). This definition did not 
require evidence of insulin resistance. Two more definitions followed, one from the 
International Diabetes Federation (IDF) (Alberti et al., 2005), and the other from the 
American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLB) 
(Grundy et al., 2004; Grundy et al., 2005). These differed with respect to waist 
circumference (Table 1.2). 
 
Debate continues as to whether MeS represents a specific syndrome or simply a cluster of 
factors that increases risk, and precisely what those factors should be (Kassi et al., 2011). 
The feasibility of using HbA1c as a component of MeS is being examined (Ong et al., 2010). 
Management of the component conditions (weight loss coupled with lifestyle changes and/or 
medication to lower hypertension, improve lipid profiles, and reduce hyperglycaemia will 
reduce this risk (Grundy et al., 2004). The prevalence of MeS depends on which definition is 
used, but it is clear that the prevalence is high. For example, depending on the population 
studied, and the criteria used, estimates range from 4.6% to 29.4% in the U.S (Ford, 2004); 
and in India from 8.0% to 46.0% (Cameron et al., 2004). Furthermore, it is likely the 
prevalence is increasing (Ford et al., 2004). 
 
                                                                                                                                                                                  Dara Shearer 
9 
 
Table 1.2. Diagnostic criteria for metabolic syndrome proposed by different organisations (essential components shaded) 
 WHO 
Insulin resistance or 
dysglycaemia is an essential 
component plus any 2 of the 
others 
NCEP, ATP III 
Three or more of any 
components 
IDF 
Abdominal obesity is an 
essential component plus any 2 
of the others 
 
AHA/NHLB 





Type 2 diabetes, IFG or IGT or 
impaired disposal of glucose 
under hyperinsulinemic, 
euglycemic conditions. 
Fasting glucose ≥ 6.1 mmol/L Fasting glucose ≥ 5.6 mmol/L Fasting glucose ≥ 5.6 mmol/L 
Abdominal 
 Obesity  
W/H >0.9 (M) 
W/H >0.85 (F) 
And/or BMI >30 kg/m2 
Waist >102 cm (M) 
     Waist >88 cm (F) 
  Europeans ≥94 cm (M) 
        ≥80 cm (F) 
    South Asians/Chinese 
        ≥90 cm (M) 
                    ≥80 cm (F) 
Waist >102 cm (M) 
         Waist >88 cm (F) 
Elevated 
triglycerides ≥1.7 mmol/L ≥1.7 mmol/L ≥1.7 mmol/L 
≥1.7 mmol/L 
Or drug treatment for elevated 
triglycerides 
Low HDL <0.9 mmol/L (M),           <1.0 mmol/L (F) 
<1.0 mmol/L (M), 
          <1.3 mmol/L (F) 
<1.03 mmol/L (M), 
         <1.29 mmol/L (F) 
<1.03 mmol/L (M), 
         <1.3 mmol/L (F) 
Or drug treatment for low HDL 
Hypertension ≥ 140/90 mmHg 
≥130/85 mmHg 
Or drug treatment for 
hypertension 
≥130/85 mmHg 
Or drug treatment for 
hypertension 
≥130/85 mmHg 
Or drug treatment for 
hypertension 
Other components Microalbuminuria    
Note: IFG, Impaired fasting glucose; IGT, Impaired glucose tolerance; W/H, Waist/hip ratio; BMI, Body mass index; M, Male; F, Female; HDL, High-density lipoprotein.




Periodontal diseases are a group of diseases characterized by inflammation of the surrounding 
and supporting structures of the teeth: the gingiva, periodontal ligament, cementum, and 
alveolar bone. While the term periodontal disease includes localized juvenile periodontitis, 
pericoronitis, acute necrotising gingivitis and acute periodontitis, it is generally used for the 
most common form – chronic periodontitis. This highly prevalent, chronic inflammatory 
disease results in the formation of soft tissue pockets between the gingiva and the tooth, loss of 
connective tissue and eventual bone destruction, and is a major cause of tooth loss in adults.   
 
1.1.3.1 Periodontitis prevalence and burden of disease 
Estimates of the prevalence and incidence of periodontitis are complicated by a lack of 
standardisation and agreement in establishing criteria for the diagnosis of the condition 
(Hugoson and Norderyd, 2008; Leroy et al., 2010; Page and Eke, 2007). In addition, different 
indices have been used to record clinical assessment of periodontitis including the community 
periodontal index of treatment needs (CPITN or CPI), Russell’s periodontal index, clinical 
attachment loss (AL) and pocket depth (PD), and radiographic examination (Savage et al., 
2009). Examinations may be full-mouth or part-mouth, and recordings may be made for 
between one to six sites per tooth. So comparisons between countries, and between studies, are 
problematic. 
 
The Study of Health in Pomerania (SHIP) is an East German prospective cohort study which 
accessed the prevalence of periodontitis in adults age 20-81 years using PD and AL between 
1997-2001 (Hensel et al., 2003). In this population, 89.7% had one or more sites with 3mm or 
more AL, 71.4% had one or more sites with 4mm or more AL, 54.0% had one or more sites 
with 5mm or more AL, and 39.1% had one or more sites with 6mm or more AL (Holtfreter et 
al., 2009). The 2009 New Zealand Oral Health Survey found 49.9% of adults age 18 and over 
had one or more sites with 4mm or more AL, 27.5% had one or more sites with 5mm or more 
AL, and 13.4% had one or more sites with 6mm or more AL (Ministry of Health, 2010a). This 
is a markedly lower prevalence than was observed in the SHIP study, but it does tally well 
with the findings from the 2004-06 Australian National Survey of Adult Oral Health in which 
the percentage of the Australian population age 15 and over with AL of 4mm or more was 
42.5% (AIHW Dental Statistics and Research Unit, 2007). In the U.S. 2009-2010 National 
Health and Nutrition Examination Survey (NHANES), over 63.0% of adults age 30 and over 
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had one or more sites with 4mm or more AL, and 43.4% had one or more sites with 5mm or 
more AL (Eke et al., 2012). In each of these surveys, prevalence increased with age with older 
age groups experiencing more severe disease. 
 
The future burden of periodontitis is clear when the consequence of ageing populations having 
greater expectations of retaining a functional dentition for life is considered (Kassebaum et al., 
2014; Shearer et al., 2011). The combination of increases in life expectancy, effective 
population-based oral health strategies in most developed countries over the past 40 years, a 
trend of decreasing edentulism, and advances in restorative dentistry means that more elderly 
people are now retaining teeth which would have been previously lost to dental caries. 
Essentially, more teeth are at risk of periodontal disease for longer (Shearer et al., 2011). 
Although periodontitis is largely painless, individuals with advanced disease may suffer the 
discomfort of loose teeth, difficulties with mastication, sensitivity, halitosis, and unaesthetic 
appearance; indeed, periodontitis may have a direct effect on quality of life (Cunha-Cruz et al., 
2007; Jansson et al., 2014; Needleman et al., 2004). However, the greatest burden of 
periodontal disease may be only now becoming apparent as evidence mounts for associations 
between periodontal disease and inflammatory-driven systemic disease (Cullinan et al., 2009; 
D'Aiuto et al., 2005; Kuo et al., 2008; Yoon et al., 2012). The relationship with type 2 diabetes 
is particularly strong (Kuo et al., 2008; Lakschevitz et al., 2011; Lalla and Papapanou, 2011; 
Mealey, 2006; Mealey and Oates, 2006; Preshaw and Bissett, 2013; Taylor, 2001); and the 
possible bidirectional link between periodontal disease and diabetes mellitus suggests that a 
higher prevalence of periodontal disease in a population may adversely affect its overall 
health, with consequential suffering, costs, and use of scarce resources. 
 
1.1.3.2 Periodontitis aetiology and risk factors 
Periodontitis is a chronic inflammatory disease that stems from a complex polymicrobial 
infection, leading to tissue destruction as a consequence of the interaction between pathogenic 
dental plaque microorganisms and the host defences in susceptible individuals (Sanz and van 
Winkelhoff, 2011). The microorganisms involved are primarily gram-negative anaerobic 
bacteria, predominantly Aggregatibacter actinomycetemcomitans and Porphyromonas 
gingivalis, although Prevotella intermedia, Tannerella forsythia and Treponema denticola 
(amongst others) are also implicated (Dumitrescu and Ohara, 2010; Van der Velden et al., 
2006). While some harm to the periodontium is caused by direct infection via a range of 
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cellular or toxic processes, it is believed that most of the tissue injury in periodontitis is due to 
an autoimmune mechanism whereby the host’s inflammatory response to the bacterial 
challenge causes the destruction of the periodontium. As plaque accumulates, and the bacterial 
load increases, bacterial enzymes and metabolic end products trigger an exaggerated 
inflammatory response leading to production of high levels of the pro-inflammatory cytokines, 
interleukin 1 beta (IL-1β), interleukin-6 (IL-6), interferon-gamma-γ, and tumour necrosis 
factor alpha (TNF-α), the chemokine interleukin-8 (IL-8), prostaglandin E2 (PGE2), and other 
pro-inflammatory agents; these initiate connective tissue breakdown and loss of bone. 
Overproduction of these cytokines continues, and along with the action of a family of enzymes 
called matrix metalloproteinases (MMP), leads to further breakdown of extracellular matrix 
proteins, and alveolar bone loss. 
 
In addition to pathogenic microorganisms in the biofilm, a range of risk factors contribute to 
the cause of chronic periodontitis. Important non-modifiable risk factors include age, gender, 
ethnicity, family history and genetic and other heritable factors. The most important 
modifiable risk factors are smoking (including cannabis use), oral hygiene status expressed in 
terms of supragingival plaque accumulation and subgingival calculus, and diabetes (Gelskey, 
1999; Löe, 1993; Mealey and Ocampo, 2007; Preshaw et al., 2012; Shearer et al., 2011; 
Thomson et al., 2007; Thomson et al., 2008; Torrungruang et al., 2005). Other putative factors 
include subgingival presence of A. actinomycetemcomitans and P. gingivalis,  stress, 
socioeconomic status (SES), education, use of dental services, the presence of chronic disease 
characterised by underlying systemic inflammation (CVD, hypertension, adverse birth 
outcomes), and obesity (Chaffee and Weston, 2010; Dye, 2012; Kuo et al., 2008; Modeer et 
al., 2011; Peruzzo et al., 2007; Thomson et al., 2004; Torrungruang et al., 2005; Torrungruang 
et al., 2009). 
 
1.1.4 Summary  
This brief prologue has introduced diabetes and periodontitis – two very common, chronic 
conditions – and has mentioned associations between them. The literature review that follows 
is in eight parts. First is an overview of how the concept of links between diabetes and 
periodontitis evolved over the past 135 years. This is followed by a short synopsis of some of 
the literature concerning diabetes and glycaemic control as a risk factor for periodontitis. A 
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detailed review of the research to date investigating periodontitis as a risk factor for 
dysglycaemia (or poor glycaemic control in those with diabetes) forms the main part of the 
literature review. This is complemented by an outline of trials using animal models, and by a 
review of the literature on associations between periodontitis and diabetes complications, the 
effect of periodontal treatment on glycaemic control, and associations between periodontitis 
and metabolic syndrome.  
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1.2 Literature Review 
1.2.1 Background 
Recognition of the links between diabetes and periodontitis is not new. In 1928, JB 
Williams described “diabetic periodontoclasia”, his term for the oral manifestations of 
diabetes mellitus (Williams, 1928). He referred to academic publications which recorded the 
condition as far back as 1888, and observed that the statement “teeth became loose in 
diabetes” first appeared in the Encyclopedia Britannica in 1877 (Williams, 1928). 
Hirschfeld expanded on the theory in 1934 by reporting on five cases of oral manifestations 
of type 2 diabetes (Hirschfeld, 1934). 
 
At the same time, there was also an understanding that periodontitis could influence the 
management of diabetes. The American dentist, Willoughby D. Miller, was likely the first to 
suggest that “pyorrhea alveolaris” (chronic periodontitis) should be regarded as detrimental 
to systemic health, maintaining that the “evil results of allowing this disease to gain the 
upper hand” may result in “fever, loss of appetite, stiffness, severe disturbances of the 
alimentary canal, insomnia …” (Miller, 1891). Miller’s seminal paper led to the focal 
infection theory, a phrase coined by Frank Billings in 1912 (Billings, 1912). This theory was 
further disseminated by Billings in the Lane lectures at the Stanford University Medical 
School in September, 1915 where he made mention of the oral cavity, and pyorrhea 
alveolaris in particular, as foci of infection (Billings, 1917) as outlined in (Focal Infection. 
The Lane Medical Lectures, 1917). What followed was an enthusiastic increase in the 
number of dental extractions (often without evidence of infection) in an attempt to cure a 
variety of poorly understood disorders (Gibbons RV, 1998; Haden RL, 1936). However, this 
was not accompanied by a consequent decline in disease, and the theory gradually fell out of 
favour (Reimann and Havens, 1940). The exception to this trend was the recommendations 
made by the American Heart Association for the prevention of infective endocarditis in 
individuals with congenital heart disease or post-rheumatic fever valve damage (Committee 
on Prevention of Rheumatic Fever and Bacterial Endocarditis and American Heart 
Association, 1960). 
 
Nevertheless, the notion that periodontitis may have systemic effects was presented again in 
1960 when Williams and Mahan found reductions in insulin requirements in individuals 
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with type 1 diabetes following periodontal therapy (Williams and Mahan, 1960). The non-
randomly selected sample comprised only nine people however, and no control was used.  
 
The publication of two Finnish case-control studies in 1989 suggesting periodontitis to be 
associated with elevated levels of von Willebrand antigen3 levels and cerebral infarction 
began a resurgence of interest in oral-systemic associations (Mattila et al., 1989; Syrjänen et 
al., 1989). Both studies used the same small sample of 40 people, and randomly selected 
controls. Miller et al. conducted a pilot study to examine the effect of periodontal therapy on 
HbA1c in nine Texan patients; an association was found between periodontal bleeding 
improvements and glycaemic control improvements (Miller et al., 1992). Indeed, Papapanou 
was prompted to remark in his 1996 review article that we cannot predict to what extent 
“the old concept of focal infections” will be reactivated in periodontal research, and that the 
mouth “belongs to and interacts with the human body” (Papapanou, 1996). The time had 
come for a re-evaluation of the role the oral cavity plays in systemic health.   
1.2.2 Diabetes as a risk factor for periodontitis 
Concurrently, research into the effect of diabetes on the periodontium continued, and 
following decades of research (much of it longitudinal), it is now thoroughly documented 
that those with poorly controlled diabetes are at greater risk of periodontitis than those 
without diabetes. In recent years, numerous review articles have summarised the abundant 
evidence for this association (Azarpazhooh and Tenenbaum, 2012; Bascones-Martinez et 
al., 2011; Cullinan et al., 2009; D'Aiuto et al., 2005; Grossi and Genco, 1998; Kandelman et 
al., 2008; Khader et al., 2006; Kuo et al., 2008; Lakschevitz et al., 2011; Lalla and 
Papapanou, 2011; Löe, 1993; Mealey, 2006; Mealey and Oates, 2006; Mealey and Ocampo, 
2007; Papapanou, 1996; Preshaw et al., 2012; Salvi et al., 2008; Taylor, 2001; Williams et 
al., 2008) (Chapple et al., 2013). Indeed, Löe asserted periodontitis should be regarded as 
the “sixth complication of diabetes mellitus” (Löe, 1993).  
 
Evidence-based medicine places systematic reviews and meta-analyses at the pinnacle of the 
evidence hierarchy (Greenhalgh, 1997). Prospective studies are essential for assessing 
temporality. Khader and associates’ comprehensive meta-analysis of heterogeneous studies 
published between 1970 and 2003 was based on 18 cross-sectional studies, three prospective 
                                                 
3 Elevated von Willebrand antigen levels are commonly observed in association with endothelial cell damage, 
and may predict adverse clinical outcomes and mortality after myocardial infarction  (Spiel et al., 2008). 
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observational studies, and baseline data from two clinical trials (Khader et al., 2006). 
Studies on both Type 1 and Type 2 diabetes were included. While those with diabetes and 
healthy individuals were found to experience the same extent of periodontitis, individuals 
with diabetes suffered more severe disease (as measured by PD and AL), and had worse oral 
hygiene. No pattern of less favourable bleeding on probing (BOP) score, plaque index and 
pocketing measures was found according to glycaemic control. There were three 
prospective studies included in this meta-analysis (Firatli, 1997; Pohjamo et al., 1995; 
Tervonen and Karjalainen, 1997). However, one study described as prospective reported 
periodontal data from one time point only (the longitudinal aspect of the study examined use 
of dental services) and so would be better categorised as cross-sectional (Pohjamo et al., 
1995). A 1997 Turkish paper reported a significantly higher AL in children and adolescents 
with Type 1 diabetes over five years compared to healthy controls, and a positive correlation 
between AL and duration of diabetes (Firatli, 1997). The study did have a large rate of 
attrition over the five years, and therefore its representativeness must be questioned. The 
third prospective study was a Finnish pilot study involved individuals with Type 1 diabetes; 
the response to periodontal therapy for well-controlled, variable-controlled, and poorly-
controlled individuals was examined (Tervonen and Karjalainen, 1997). It was found that 
those with poorly-controlled type 1 diabetes and those with multiple diabetic complications 
had a higher risk of periodontal disease than those with well-controlled and variable-
controlled diabetes. Those with poorly-controlled diabetes had more severe periodontitis to 
start with, and showed least improvement after therapy over the long term.  
 
Taylor’s 2001 systematic review appraised 45 studies involving individuals with either Type 
1 or Type 2 diabetes, and a range of age groups from children through to the elderly (Taylor, 
2001). All except three studies reported greater prevalence, extent or severity of one or more 
periodontal measures in those with diabetes than those without diabetes; these three studies 
were all cross-sectional (Benveniste et al., 1967; Goteiner et al., 1986; Hove and Stallard, 
1970). There were seven prospective studies reviewed; four found those with diabetes to 
suffer greater severity or greater extent of attachment loss than healthy individuals (Cohen 
et al., 1970; Firatli, 1997; Novaes et al., 1996; Tervonen and Karjalainen, 1997); and three 
found those with diabetes to experience a higher incidence of radiographic alveolar bone 
loss than healthy individuals (Nelson RG et al., 1990; Taylor et al., 1998a; Taylor et al., 
1998b). Of these prospective studies, the findings for four were limited by small sample 
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sizes (Cohen et al., 1970; Firatli, 1997; Novaes et al., 1996; Tervonen and Karjalainen, 
1997), and case definitions for periodontitis varied between studies. 
 
A dose-response relationship between exposure and outcome is indicative of the strength of 
an association, and may suggest causality. Taylor’s review also evaluated nine prospective 
studies which examined the relationship between poorer glycaemic control and poorer 
periodontal status (Ainamo et al., 1990; Firatli, 1997; Karjalainen and Knuuttila, 1996; 
Novaes et al., 1996; Seppälä et al., 1993; Seppälä and Ainamo, 1994; Taylor et al., 1998a; 
Tervonen and Karjalainen, 1997). However, a relationship between poorer glycaemic 
control and periodontal status is not specifically mentioned in the Firatli paper (only 
between duration of type 1 diabetes and periodontal status), so this one must be discounted 
(Firatli, 1997). As outlined above, a Danish study examined the healing of periodontal 
pockets following therapy, and found those with poorly-controlled type 1 diabetes were at 
greater risk of periodontitis than those with well-controlled diabetes (Tervonen and 
Karjalainen, 1997). Novaes reported differences in AL between those with type 2 diabetes 
and those without, and differences in both PD and AL in the participants with type 2 
diabetes according to glycaemic control (Novaes et al., 1996). The Pima Indians of the Gila 
River Indian Community in Arizona have been participants in studies of the aetiology of 
type 2 diabetes since 1965 (Knowler WC et al., 1978; The National Institute of Diabetes and 
Digestive and Kidney Diseases.). A 1998 paper noted an association between poorer 
glycaemic control and an increased risk of alveolar bone loss over a couple of years in a 
sample drawn from the Pima Indian community (Taylor et al., 1998a). The Ainamo et al. 
paper essentially describes two case studies featuring rapid periodontal destruction over 
time associated with poor glycaemic control (Ainamo et al., 1990). Two Finnish studies 
found poor glycaemic control to be related to gingivitis, BOP, attachment loss and alveolar 
bone loss; however, they did suffer a poor retention rate, and no adjustment for confounders 
was done (Seppälä et al., 1993; Seppälä and Ainamo, 1994). Karjalainen and Knuuttila 
examined children and adolescents with Type 1 diabetes, and found gingival bleeding to be 
associated with glycaemic control (Karjalainen and Knuuttila, 1996).  Generally, these 
prospective studies do suggest a dose-response relationship between poorer glycaemic 
control and poorer periodontal status. 
 
Gingival bleeding has long been observed in young people with type 1 diabetes. In fact, 
periodontal destruction in children with type 1 diabetes (as measured by AL) may begin at a 
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younger age than previously assumed (Lalla et al., 2006; Lalla et al., 2007). Children with 
Type 1 diabetes between ages six and eleven were found to have a significantly greater risk 
of AL of 2+mm or more on 1+ sites on 2+ teeth compared with healthy controls (Lalla et al., 
2007). This risk was independent of confounding factors age, gender, ethnicity, plaque 
index and use of dental services. However, duration of diabetes and HbA1c were not found 
to be related to AL (Lalla et al., 2006).  
 
Despite shortcomings in individual studies, the absolute weight of evidence linking diabetes 
and periodontitis is convincing. By the end of the 20th century, it was generally accepted 
that those with poorly controlled diabetes were at greater risk of periodontitis than those 
with well-controlled diabetes and healthy individuals. That this risk is related to metabolic 
control and disease duration had also been established. More recently, investigators have 
instead focussed on investigating the mechanisms whereby diabetes impacts on 
periodontitis. Research has been conducted into associations between diabetes, periodontitis 
and IL-1β  (Engebretson et al., 2004),  IL-1β and IL-6 (Duarte et al., 2007), collagenase 
activity in gingival crevicular fluid (GCF) (Safkan-Seppala et al., 2006), IL-1β, IL-8 and 
matrix metalloproteinases4 (Salvi et al., 2010), a variant IL-1 genotype, AGEs (Takeda et 
al., 2006), adiponectin and resistin (Saito et al., 2008),  PGE2, IL-1β, and TNF-α (Salvi et 
al., 1998), TNF-α (Engebretson et al., 2007; Genco et al., 2005; Nishimura et al., 2003; 
Pacios et al., 2012; Takano et al., 2010), and oxidative stress (Bullon et al., 2009).   
1.2.3 Periodontitis as a risk factor for dysglycaemia  
Interest in periodontitis as a risk factor for poor glycaemic control has been rekindled in the 
past twenty years with the acknowledgement of the plausibility of a bidirectional link 
between the two conditions. The associations between background low-grade systemic 
inflammation and dysglycaemia are well recognised (Pitsavos et al., 2007; Wellen and 
Hotamisligil, 2005). The chronic inflammation of periodontitis may influence glycaemic 
control in susceptible individuals via pro-inflammatory mediators interleukin 1 beta (IL-1β), 
interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α), and other pro-inflammatory 
agents. Subsequently, this glycaemia can lead to a further deterioration in periodontal status 
which then increases the risk of worsening glycaemia, and so on. Each condition potentially 
                                                 
4 MMPs are proteolytic enzymes involved in normal extracellular matrix remodeling, but have also been 
implicated in impaired wound healing, tumour progression, and destructive conditions (Salvi et al., 2010)  
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worsens the other, and a detrimental sequence ensues. Of particular importance in 
elucidating these relationships are the small number of longitudinal studies that specifically 
looked at the influence of periodontitis as a risk factor for type 2 diabetes, prediabetes and 
glycaemic control (Collin et al., 1998; Demmer et al., 2008; Demmer et al., 2010; Ide et al., 
2011; Morita et al., 2012; Saito et al., 2004; Taylor et al., 1996). 
 
The first of these was a longitudinal examination was carried out by Taylor and colleagues 
in 1996 using a sample from the Pima Indians study (Taylor et al., 1996). They found severe 
periodontitis at baseline to be associated with an increased risk for poorer glycaemic control 
within a couple of years as measured by HbA1c; this finding was independent of baseline 
type 2 diabetes severity (measured using OGTT) and baseline HbA1c (Taylor et al., 1996). 
Baseline periodontitis was measured both by clinically assessed attachment loss, and by 
radiographic evidence of bone loss (different sample sizes for each). Their findings also 
suggested the effect of baseline severe periodontitis on poor glycaemic control risk 
decreased as age increased, and baseline smoker status increased risk. A range of putative 
confounders and effect modifiers were assessed at baseline (age, sex, smoking status, 
alcohol consumption, prevalence of retinopathy, systolic blood pressure, diabetes severity 
and duration, insulin use, hypoglycaemic use, and abnormality on resting ECG). Other 
potential confounders not included were lifestyle factors such as diet, and general 
attitude/health behaviours in managing type 2 diabetes and oral health. The sample sizes 
were relatively small, and healthy individuals were not included. The HbA1c variable was 
dichotomised which introduces the potential for misclassification, as well as the loss of 
information (Altman and Royston, 2006). However, this study is important in that it implies 
a temporal association between periodontitis and poorer glycaemic control.  
 
Taylor’s study was followed two years later by a Finnish study which classified  periodontal 
condition (as measured by alveolar bone loss and pocket depth) in 25 patients with Type 2 
diabetes and 40 healthy controls into three categories: “Good condition”, “Moderate 
periodontitis” or “Advanced periodontitis” (Collin et al., 1998). Individuals with diabetes 
and advanced periodontitis were found to have experienced an increase in HbA1c over two 
or three years, whereas individuals with diabetes and moderate periodontitis or a healthy 
periodontium experienced a decrease. This study had significant limitations. As for the Pima 
Indians study above, there was the potential for misclassification and loss of information 
with the categorisation of the continuous variables. The convenience sample was small, and 
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the findings were not generalizable to other populations. Multivariate analyses were not 
performed, so spurious associations could not be excluded. The periodontal examination 
was at one point in time only; as periodontal status at baseline was unknown, so too was the 
direction of the association. 
 
Recently, a systematic review of observational studies concluded a small body of evidence 
suggests periodontitis may have an adverse effect on glycaemic control (Borgnakke et al., 
2013). Nevertheless, it did also assert that the research to date is scant, periodontal and 
metabolic outcome parameters varied widely between studies, and there is a need for 
prospective observational studies of long duration. 
 
While some researchers have examined the impact of periodontitis on those with type 2 
diabetes, others have considered whether periodontitis also affects glycaemia in healthy 
individuals and those with prediabetes. The Hisayama study is a population-based 
prospective study examining the morbidity and mortality of cardiovascular disease and its 
risk factors in the town of Hisayama in southern Japan. Full community surveys of the 
residents aged 40 years and over have been done since 1961. Saito and associates carried 
out a retrospective cohort study on 591 Hisayama study participants in 1998, and found a 
fifth of those with NGT (as measured by OGTT) in 1988 had progressed to IGT or type 2 
diabetes over the ten-year period; increased risk of progression was associated with greater 
pocket depth (Saito et al., 2004). In addition, analyses found each additional millimetre in 
mean pocket depth in 1998 corresponded to a 0.13% increase in HbA1c between 1988 and 
1998. IGT correlates age, sex, BMI, exercise frequency, alcohol consumption and smoking 
were included in the multivariate analysis, but metabolic biomarkers and hypertension were 
not. No such associations were found for attachment loss, the authors suggesting attachment 
loss may be associated with a lower bacterial load than deep pocketing. While OGTT and 
HbA1c data were collected at two points, periodontal status was assessed at one point only 
(in 1998). The possibility that periodontal status measured then was quite different from 
periodontal status in 1988 cannot be excluded. Participation rates were very low, 
particularly for the periodontal assessments, so the findings are not generalizable to the 
source population.  
 
However, the following year, Saito et al. reported no associations between IGT (as 
measured by OGTT) and either deep pocketing or severe attachment loss (Saito et al., 
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2005). This was in contrast to their previous study whereby deep pockets were closely 
related to both current glucose tolerance status and the development of IGT (Saito et al., 
2004). Again the sample was derived from the Hisayama study, but this later study differed 
in that only women were examined, the study was cross-sectional, and covariates plaque 
index and occupation along with either BMI, body fat or waist-hip ratio were controlled for 
in the multivariate analyses. The participants were grouped into quintiles according to their 
two periodontal measurements: mean pocket depth and mean attachment loss. However, 
these quintiles were further grouped into two categories (the most severe quintile as group 1, 
and the other four together as group 2) effectively resulting in loss of information, and 
under-utilisation of the data. The HbA1c levels were not included in the multivariate 
analyses; this is a pity as HbA1c data was collected, and it would have been of interest to 
see if this measure of chronic glucose exposure was more useful regarding the presence of 
dysglycaemia than the OGTT. 
 
Saito and co-workers again investigated associations between periodontitis and IGT in a 
survey of defence force men (Saito et al., 2006). This time periodontitis was measured by 
alveolar bone loss determined by panoramic radiograph, and an association was found 
between this and prevalence of IGT as measured by OGTT. A second analysis found no 
association between alveolar bone loss and type 2 diabetes (although this may have been 
due to Type 2 error as the sample size in this analysis was small). Clearly, temporality was 
not shown as the study was cross-sectional, and the findings not generalizable as the 
participants were all men aged 50-55 from the Japanese Self-Defence Force. Another 
consideration is that radiographic evidence of alveolar bone loss may reflect resolved 
periodontitis rather than current disease; no measurement of pocket depth or bleeding was 
done in this study.   
 
It is appropriate to mention here a novel classification of periodontitis, the periodontal 
inflamed surface area (PISA) which has recently been developed in an attempt to quantify 
the area of inflamed periodontal tissue, and thus reflect the inflammatory burden generated 
by periodontitis (Nesse et al., 2008). PISA reflects the surface area of bleeding pocket 
epithelium in mm2. While PISA may not precisely measure the amount of inflamed tissue, it 
is likely the most accurate tool available at this time. Interestingly, researchers found a dose-
response relationship between PISA and HbA1c in participants with type 2 diabetes (Nesse 
et al., 2009). This was important as such a relationship may indicate a causal relationship 
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between PISA and HbA1c. The findings were independent of sex, oral hygiene, BMI, SES 
and duration of diabetes. Unfortunately, the study was cross-sectional only, had a small 
convenience sample, and most of the participants were women. So temporality could not be 
established, and the findings were not generalizable to a wider population. Moreover, the 
participants all had Type 2 diabetes; it would be worthwhile to investigate if such a dose-
response relationship was also seen in healthy individuals and those with prediabetes.  
 
Healthy participants in the NHANES I study formed the basis of a longitudinal study 
investigating associations between periodontitis and incident Type 2 diabetes (Demmer et 
al., 2008). Some 9296 individuals had a baseline periodontal examination between 1971 and 
1976, and a follow up examination between 1982 and 1992. Diabetic status was assessed on 
both occasions, but periodontal status at baseline only. An association between baseline 
periodontitis and incident diabetes 6 - 21 years later was found. This association was 
independent of age, sex, ethnicity, SES, education, BMI, skinfold measurements, physical 
activity, cholesterol, hypertension, smoking, and 24-hour dietary record, and the large 
sample was reasonably representative of the US population aged 25-74 years. 
Unfortunately, diabetic status was measured either by death certificate (in the case of the 
follow up), diagnosis of type 2 diabetes from a health facility, or self-reported physician 
diagnosis requiring medication. The latter category excluded those with diabetes treated by 
lifestyle modification. Without an objective measure of glycaemia, the potential for 
misclassification of diabetic status is evident, particularly those with undiagnosed type 2 
diabetes being categorised as healthy. However, an attempt to minimise this bias was made 
by excluding participants who reported incident diabetes within one year of baseline from 
analyses. In addition, a subgroup analysis restricted to incident diabetes occurring ten or 
more years after baseline left the findings essentially unchanged. Russell’s Periodontal 
index which was used to classify periodontitis is no longer considered valid as it assumes 
gradually progressive disease, measures pocket depth only (and not as a continuous 
measure), and ignores attachment loss (Dhingra and Vandana, 2011; Dye, 2012; Russell, 
1956). Furthermore, one of the analyses used missing teeth as a surrogate for periodontitis. 
While this is not a reasonable assumption as many teeth would have been lost to caries, to 
some extent it is supported by research linking tooth loss and cardiovascular disease 
(Desvarieux et al., 2003). The authors speculated on tooth loss acting both as a consequence 
of periodontitis and as a preventive measure for future periodontal risk due to bacterial 
exposure, and tooth loss occurring early in life might confer some protection. This is a very 
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valid point, and relates well to the concept of PISA (Nesse et al., 2008; Nesse et al., 2009). 
Other interesting ideas proposed included a possible threshold level of periodontitis above 
which risk of incident diabetes increases markedly, and the notion that common 
genetic/family history susceptibility underlies both periodontitis and type 2 diabetes.  
 
Demmer and colleagues addressed many of the limitations of their 2008 paper with a 
longitudinal analysis of periodontal and HbA1c data from the Study of Health in Pomerania 
(SHIP), an East German prospective cohort study (Hensel et al., 2003; John et al., 2001). 
They found periodontitis (as measured by attachment loss and pocket depth) at baseline in 
healthy participants to be associated with HbA1c progression five years later whereby those 
with more severe periodontitis at baseline experienced greater increases in HbA1c (Demmer 
et al., 2010). Furthermore, those with baseline periodontitis that had deteriorated over that 
time experienced the greatest increase of all. The latter associations were true for worsening 
attachment loss, but not for worsening pocket depth. Participants who were edentulous at 
baseline experienced increases in HbA1c of the same order as the most severe periodontitis 
category.  Diabetic status at baseline was assessed by HbA1c measurement, self-reported or 
physician prevalent type 2 diabetes. Periodontal status and HbA1c were both assessed twice 
– at baseline and at follow up five years later. Importantly, temporality was established in 
that periodontitis preceded the change in HbA1c; type 2 diabetes was eliminated as a 
contributor to baseline periodontitis as only healthy individuals were included. Confounders 
controlled for were age, sex, education, region, BMI, waist-hip ratio, smoking, 
hypertension, triglycerides, fibrinogen, C-reactive protein, white blood cell count, and 
family history of type 2 diabetes. Interaction models were done for fibrinogen, C-reactive 
protein, and white blood cell count, and found effect modification between periodontal 
status and C-reactive protein only. The original sample of 7,008 was representative; 
however, the low participation rate (68.8%) for baseline raises doubts about the study’s 
generalizability. In addition, the follow up rate of 83.6% of the baseline sample was further 
reduced by exclusions due to missing data. In effect, analyses were carried out on 2793 
individuals (71.8% of the baseline participants, and only 39.9% of the original randomly 
chosen sample). An analysis of how the non-participants differed from those who did take 
part would have been of interest. The finding that individuals who were edentulous at 
baseline experienced increases in HbA1c of the same order as the most severe periodontitis 
category led the authors to further speculate on the role tooth loss plays as it appears to 
contradict the notion of PISA (Nesse et al., 2008; Nesse et al., 2009). It is possible that 
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infection-induced systemic damage is not entirely reversible, or systemic inflammation due 
to periodontitis may not fully subside after extraction (Desvarieux et al., 2003).  
 
A pilot study in a Minnesota School of Dentistry clinic investigated whether healthy 
individuals with periodontitis had higher HbA1c compared with healthy (no diabetes) 
controls without periodontitis (Wolff et al., 2009). While the study did find periodontitis 
prevalence to be associated with a slightly higher HbA1c, it had some significant 
shortcomings. It was cross-sectional, and so offered a low level of evidence. The 
convenience sample was not representative of the clinic population, much less a wider 
population. Some controls had received periodontal treatment in the past (more than six 
months prior to the study) and the possibility that systemic damage due to past periodontitis 
was still having an impact at the time of the study could not be excluded (Desvarieux et al., 
2003). Periodontal status was not assessed by clinical examination; instead existing clinical 
and radiographic records were used. Obviously, this introduces the potential for serious 
error as the examiners (it is not known how many examiners were involved) were not 
calibrated. The study examined HbA1c levels in people with “undiagnosed diabetes” as 
opposed to healthy individuals. It’s difficult to see the value of this as some participants had 
elevated HbA1c, and indeed had undiagnosed type 2 diabetes. These individuals should 
have excluded from the analyses as it would have been more useful to involve healthy 
individuals only. Correlates included in the multivariate analysis were limited to age, 
gender, BMI and smoking. A point-of-care device (A1cNow) was used to measure HbA1c. 
Some researchers reported a good correlation between A1cNow and laboratory values 
(Arrendale et al., 2008; Chang et al., 2010). However, others did not (Lenters-Westra and 
Slingerland, 2010). The worst correlation between A1cNow and laboratory values was seen 
for HbA1c values below 7.0% (Arrendale et al., 2008). Therefore, the instrument wasn’t 
particularly accurate for the range of HbA1c values in this paper (5.66% ± 0.56% for cases, 
and 5.51% ± 0.44% for controls). A1cNow is designed to be used in a clinical setting and 
for patient self-monitoring, not for epidemiological research. Due to the study’s serious 
limitations, its findings do not carry much weight. 
 
A Japanese study carried out between 2005-2006 on associations between periodontal status 
and HbA1c in healthy individuals contributed little more than the Minnesota study as it too 
was cross-sectional, and it’s unclear how the sample was selected (Hayashida et al., 2009). 
A relationship was found between the two variables, with a range of confounders (age, 
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gender, BMI, smoking, alcohol, and exercise) controlled for. The community periodontal 
index (CPI) score was used to record periodontal status. The shortcomings of the CPI are 
well known. It does not measure attachment loss, and its validity has been questioned 
(Leroy et al., 2010; Lewis et al., 1994). Statistical analysis was done using ANCOVA for 
HbA1c and a 3-category periodontal variable (“Healthy”, “Mild/moderate” and “Severe”) 
but no post-hoc comparisons were done to clarify which of the categories differed. 
 
An analysis of data from the NHANES III found a dose-response relationship between 
periodontitis (measured by AL and PD) and IFG (Choi et al., 2011b). The associations 
remained for both IFG and type 2 diabetes following adjustments for a comprehensive range 
of covariates. The study was cross-sectional only, and a partial mouth examination was used 
to assess periodontitis. Zadik et al. also examined links between periodontitis (measured by 
radiographic alveolar bone loss) and IFG in healthy individuals, finding cross-sectional 
associations between the two (Zadik et al., 2010). However, the sample was not 
representative, and no multivariate analysis was done. 
 
In addition to the 2005 Saito paper, a couple of other recent studies also found no 
relationship between IGT and periodontitis. A Japanese case-control study measured 
alveolar bone loss using panoramic radiographs, and found type 2 diabetes, but not IGT, to 
be associated with alveolar bone loss (Marugame et al., 2003). Interestingly, this is the 
opposite of what Saito et al. found (Saito et al., 2005). A non-representative, middle-aged, 
male-only sample was used. Prevalence of bone loss was high, with the “severe alveolar 
bone loss” cases making up three-quarters of the sample. The authors suggested possible 
reasons for the lack of association between IGT and periodontitis. Only IGT individuals 
with a propensity to progress to type 2 diabetes develop alveolar bone loss. Or the 
dysglycaemia in those with IGT has been of short duration, and thus had not had time to 
impact on the alveolar bone (severe alveolar bone loss being a feature of advanced 
periodontitis). Furthermore, as radiographic evidence of alveolar bone loss may reflect past 
disease rather than current, the precise nature of the associations (or lack thereof) is unclear. 
It is also possible there may have been insufficient statistical power in the study to detect an 
association between IGT and periodontitis. 
 
In Japan, employees who are regularly employed by a company undergo mandatory annual 
medical tests. As a result Japanese researchers have access to limited (the data is collected 
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for health insurance, rather than research, purposes) longitudinal data on both periodontitis 
and diabetes. Ide and associates found no overall independent association between 
periodontitis and incident type 2 diabetes over a seven year period in a large sample of 
Japanese civil servants, although an association was found between moderate periodontitis 
and incident diabetes in women (Ide et al., 2011).  Because both individuals with confirmed 
and undiagnosed type 2 diabetes were excluded at the baseline stage, temporality was 
established (that is, periodontitis preceded incident diabetes). Confounders controlled for 
were age, sex, smoking, BMI, triglycerides, hypertension, HDL, y-glutamyl transpeptidase. 
The study had some limitations. The sample was not representative of the Japanese 
population, periodontal data was collected at baseline only (so a substantial improvement in 
periodontal health over the study period could not be excluded), and the CPI score was used 
to record periodontal status. The weak points of the CPI have been outlined above. Most of 
the continuous variables were dichotomised resulting in significant loss of information 
(Altman and Royston, 2006). Fasting plasma glucose (FPG) was used to diagnose incident 
diabetes; although considered the gold standard for diagnosis, this test is subject to several 
limitations (Sacks, 2011). The study participant had to have been fasting at the time the 
blood sample was taken, and a lack of reproducibility could have been a problem. While no 
method of measurement is perfect, some organizations are recommending that HbA1c be 
used for screening and diagnosis of type 2 diabetes (American Diabetes Association, 2011; 
2009).  
 
Another Japanese paper outlined two studies using two separate samples (Morita et al., 
2012). It seems the samples were derived from the same population of Japanese civil 
servants as used by Ide and colleagues, although this is not clear. Study 1 involved HbA1c 
and periodontal data being gathered at baseline with periodontal data gathered again about 5 
years later. Individuals with periodontitis at baseline were excluded, and the associations 
between baseline HbA1c and incident periodontitis were examined. Study 2 involved 
HbA1c and periodontal data being gathered at baseline with HbA1c data gathered again 
about 5 years later. In this case, individuals with type 2 diabetes at baseline were excluded, 
and the associations between baseline periodontitis and HbA1c elevation were examined. 
Both studies had large sample sizes (5,856 and 6,125 participants respectively). 
Associations were found between higher HbA1c at baseline and the risk of having 
developed periodontitis five years later, and between periodontitis at baseline and the risk of 
elevated HbA1c five years later. Confounders controlled for were age, sex, BMI, alcohol 
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consumption and smoking; metabolic biomarkers and hypertension were not. The use of the 
CPI score to record periodontal status was a limitation. The findings were not generalizable 
even to the civil servant population from which the sample was derived much less to the 
general Japanese population. There was some confusion with respect to terminology with 
the study variously referred to as a “prospective cohort analysis” and “a “case-control cohort 
study”. Despite these limitations, this important paper suggests a bi-directional relationship 
between periodontitis and elevated HbA1c.  
 
Three other cross-sectional studies should be mentioned as they demonstrate the conflicting 
results that are seen in periodontal and prediabetes research. Lamster and colleagues found 
that those with newly identified prediabetes experienced a level of periodontitis (as 
measured by the extent of teeth with 5mm+ pocket depth) between that experienced by 
normoglycaemic individuals and those with type 2 diabetes (Lamster et al., 2014). These 
findings were limited by the cross-sectional design, a lack of generalisability, the use of a 
point-of-care device to record HbA1c levels, and the fact that attachment loss data were not 
recorded. Nonetheless, these findings do strengthen the concept that periodontal disease 
may be an early indicator of dysglycaemia. Conversely, a SHIP-Trend study found no 
association between prediabetes and the extent of teeth with 4mm+ AL or mean probing 
depth (Kowall et al., 2015). Incidentally, the SHIP-Trend study did find mean AL to be 
associated with poorly-controlled type 2 diabetes, but not with well-controlled diabetes. 
This was a large population-based study, and adjustment was made for a comprehensive of 
range of confounders. However, it was limited by its cross-sectional design, a poor response 
rate, and that the periodontal examination was half-mouth only. Another cross-sectional 
study using data from the Continuous NHANES 2009-2010 survey found associations 
between severe periodontitis and IGT, but not IFG; and no associations between moderate 
periodontitis and either IGT or IFG (Arora et al., 2014).  
 
On a practical note, some authors propose that dentists and other oral health-care 
professionals may have a role to play in identifying individuals with undiagnosed diabetes 
or prediabetes thus enabling early treatment of hyperglycaemia, and the minimisation of 
future diabetic complications (Lalla et al., 2011). It is suggested that greater collaboration 
between dental and medical professionals is required so that periodontitis and diabetes can 
be managed in a timely fashion (Iacopino, 2009).  
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In conclusion, the possibility of periodontitis being a risk factor for dysglycaemia must be 
acknowledged. Some studies have suggested a temporal relationship whereby periodontitis 
preceded dysglycaemia or deterioration in glycated hemoglobin (HbA1c) levels (Demmer et 
al., 2010; Morita et al., 2012; Taylor et al., 1996). It is clear that there has been little 
research to date in this field, and the need for long-running prospective observational studies 
is evident. 
1.2.4 Animal studies 
For ethical and pragmatic reasons, periodontitis or diabetes cannot be experimentally 
induced in humans. Nor can some confounding factors be easily accounted for in human 
studies. To resolve these difficulties, two recent studies used animal models to research the 
relationship between induced periodontitis and prediabetes, and periodontitis and insulin 
resistance (Pontes Andersen et al., 2007; Watanabe et al., 2008). Zucker rats are an animal 
model for research on obesity, prediabetes and hypertension, and there are two types: the 
lean Zucker rat, and the characteristically obese Zucker fatty rat (ZFR). The former study 
induced periodontitis in half the ZFRs and in half their lean littermates, using the 
periodontitis-free ZFRs and the periodontitis-free leans as controls (Pontes Andersen et al., 
2007). After four weeks, they found periodontitis to be associated with a worsening of 
prediabetes in ZFRs; it was also associated with glycaemic dysfunction in the lean rats, but 
not to the same extent. In addition, the ZFRs with prediabetes and periodontitis were found 
to have more severe alveolar bone loss than the healthy leans with periodontitis. Therefore, 
periodontitis worsened prediabetes, and prediabetes worsened periodontitis, indicating a bi-
directional link between the two conditions in these animals. A very similar study design 
was followed by the Illinois study, although a substrain of ZFR, Zucker fatty rats (ZDF) 
with diabetes was used (Watanabe et al., 2008).  ZDFs with induced periodontitis who were 
also fed a high-fat diet suffered earlier and more severe insulin resistance than high-fat diet 
ZDFs without periodontitis, or low-fat diet ZDFs with or with our periodontitis. The authors 
suggest the influence of periodontitis on insulin resistance may be most evident when 
insulin action or secretion is already compromised, as would be when a high-fat diet is 
consumed (Watanabe et al., 2008).   
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1.2.5 Periodontitis and diabetes complications 
Poor glycaemic control, sustained over the long term, has been closely linked to 
macrovascular (cardiovascular, cerebrovascular, and peripheral vascular disease) and 
microvascular (retinopathy, nephropathy, and neuropathy) complications (Daneman, 2006; 
Diabetes Control and Complications Trial Research Group, 1993; 1994; Stratton et al., 
2000). With the growing accumulation of evidence for periodontitis as a risk factor for poor 
glycaemic control it is plausible that periodontitis has an influence on diabetes 
complications. Two longitudinal studies using data from the Pima Indians study examined 
the relationship between periodontitis and overt nephropathy and end-stage renal disease 
(Shultis et al., 2007); and between periodontitis and mortality due to cardiorenal (a grouping 
of ischaemic heart disease or diabetic nephropathy or both) complications (Saremi et al., 
2005).   
 
The Shultis et al. study followed 529 participants without baseline nephropathy, as 
measured by the albumin/creatinine ratio5 (ACR) and the glomerular filtration rate6 (GFR). 
Periodontitis was assessed by the number of teeth, and alveolar bone loss determined by 
radiograph. Over a median follow-up period of 9.4 years, 193 people developed 
macroalbuminuria, and 68 developed end-stage renal disease (ESRD) over a median follow-
up of 14.9 years. It was found that moderate or severe periodontitis, or edentulism, predicted 
both overt nephropathy and ESRD in a dose-dependent manner, after adjustment for 
common risk factors age, sex, diabetes duration, BMI and smoking, but not glycaemic 
control (Shultis et al., 2007).  
 
In addition to the above risk factors, the comprehensive Saremi et al. analysis also adjusted 
for glycaemic control (as measured by either HbA1c or FPG), macroalbuminuria, 
cholesterol, hypertension and electrocardiograph abnormalities (Saremi et al., 2005). In the 
sample of 628 people, 204 died over the median follow-up period of 11 years. It was 
reported the death rate from cardiorenal complications in participants with severe 
periodontitis (as measured by attachment loss, and alveolar bone loss determined by 
radiograph) was 3.5 times as high in those with no, mild or moderate periodontitis. 
Unfortunately, this is somewhat unclear as while the text reports this finding as “3.5 times 
as high”, the abstract reports it as “3.2 times the risk”. Nonetheless (and while association 
                                                 
5 The albumin/creatinine ratio is a measure of macroalbuminuria, a marker for nephropathy 
6 The glomerular filtration rate is a measure of kidney function 
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does not infer causality, and unmeasured common risk factors cannot be excluded) these 
intriguing findings do suggest the possibility of periodontitis severity having an independent 
effect on diabetes complications prevalence.  
  
1.2.6 Effect of periodontal treatment on glycaemic control 
Complementing the observational studies on the bidirectional link between periodontitis and 
glycaemic control, there has been a number of intervention trials on the effect of periodontal 
treatment on glycaemia. While most of this research has been in recent years, Williams and 
Mahan’s 1960 study which found reduced insulin requirements in individuals with type 1 
diabetes following periodontal therapy was an early investigation of this effect (Williams 
and Mahan, 1960). In the past few years, meta-analyses have been undertaken on trials 
conducted since 1992 (Darre et al., 2008; Janket et al., 2005; Simpson et al., 2010; Teeuw et 
al., 2010). Most recent was the thorough Cochrane review which concluded there was some 
evidence of glycaemic control improvement following periodontal treatment (Simpson et 
al., 2010).  
 
The Pima Indian community again contributed to periodontal research in the 1997 Grossi et 
al. study (Grossi et al., 1997). Participants with Type 2 diabetes were randomised into five 
different groups which each received mechanical therapy combined with different 
antimicrobial therapies (the control group received a placebo only); at 3 months post-
treatment all five groups showed an improvement in periodontal health with the three 
groups receiving systemic doxycycline also experiencing significant reductions in HbA1c.  
 
Al-Mubarak and colleagues examined the effect of sub-gingival water irrigation as an 
adjunct to mechanical therapy in people with Type 1 or Type 2 diabetes (Al-Mubarak et al., 
2002). They found no significant difference in HbA1c between the groups after 12 weeks 
(although there was a non-significant reduction in the test group), despite the treatment 
group showing a significant improvement in some periodontal parameters and systemic 
inflammatory markers. However, it is possible that the change in HbA1c was attenuated by 
the inclusion of those with Type 1 diabetes. Type 2 diabetes is thought to be inflammatory 
in nature, whereas Type 1 is believed to be an autoimmune condition, and thus less reactive 
to a reduction in the inflammatory burden (although they will still have deterioration in 
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glycaemic control when they get an inflammatory condition). Furthermore, glycaemia in 
Type 1 diabetes is generally tightly controlled by frequent monitoring and insulin 
administration.  
 
Rodrigues et al. found significant reductions in HbA1c in individuals with Type 2 diabetes 
three months after mechanical therapy for both the treatment group who had systemic 
antimicrobial adjunctive therapy (amoxicillin/clavulanic), and the control group who had 
mechanical therapy only (Rodrigues et al., 2003). Interestingly, the control group showed a 
more favourable response then the treatment group. Furthermore, those with the most poorly 
controlled diabetes at baseline showed the greatest response of all.  
 
Two years later, Kiran and associates reported a significant reduction in HbA1c in the 
treatment group (mechanical therapy) three months post-therapy, whereas the control group 
(no treatment) showed a slight increase in HbA1c (Kiran et al., 2005). In accordance with 
Kiran et al., another trial found HbA1c levels to decrease significantly in a treatment group 
which had full mouth mechanical therapy compared with a control group which had 
supragingival plaque and calculus removal only (Koromantzos et al., 2011).   
 
On the other hand, a RCT involving participants with poorly-controlled type 2 diabetes 
found no significant benefit (although a trend was seen) for mechanical therapy with 
chlorhexidine and systemic doxycycline compared to a “health care as usual or no 
treatment’ control after four months (Jones et al., 2007). It is possible this nonsignificant 
finding was due to pre-notification of participants’ normal doctor (thus informing the doctor 
their patient was poorly controlled which may have resulted in more aggressive treatment of 
glycaemic control, and biasing the results towards the null).  
 
In 2007, Yun et al. reported on a RCT which evaluated the effect of mechanical therapy plus 
systemic doxycycline versus a control group receiving systemic doxycycline only (Yun et 
al., 2007). Both the treatment and control group showed significant reductions in HbA1c; 
however, there was no significant difference between the two groups. A more recent trial 
found that mechanical therapy followed by adjunctive sub-antimicrobial-dose doxycycline 
taken for three months resulted in a 0.9% reduction in HbA1c  (Engebretson and Hey-
Hadavi, 2011). This was a much more favourable response than for a group taking 
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antimicrobial-dose doxycycline for two weeks following mechanical therapy (0.3% change), 
and a placebo control who had mechanical therapy only (no change).  
  
There has been some debate as to what actually constitutes periodontal treatment, and 
whether extractions and endodontic treatment should be included along with mechanical 
therapy (scaling and root curettage or planing), systemic or local antimicrobial therapy, 
periodontal surgery and oral hygiene instruction (Friedlander, 2010a; b). The effect of the 
most radical form of treatment, the extraction of periodontally compromised teeth, in 
addition to scaling, root curettage, and oral hygiene instruction was examined in a trial in 
2001 (Stewart et al., 2001). A marked improvement in HbA1c was found in the treatment 
group. However, these findings were limited by the small sample size, selection bias, and 
non-randomisation (the treatment group was matched to historical controls). More recently, 
Khader et al. reported a marked reduction in HbA1c in individuals with Type 2 type 2 
diabetes following full-mouth tooth extraction   (Khader et al., 2010). The mean reduction in 
the treatment group was 1.23% at three months, and 1.37% at six months. This compared to 
a mean reduction of 0.28% at both three and six months in the control group who were not 
treated. These studies suggest the extraction of the worst periodontally involved teeth may 
be a valid treatment option for those with Type 2 diabetes. 
 
Other investigators have considered the effect of periodontal treatment on systemic 
inflammatory markers which are thought to play a role in the bidirectional link between 
periodontitis and glycaemia. Katagiri and associates found that mechanical therapy 
combined with topical administration of minocycline in periodontal pockets reduced HbA1c 
levels in individuals with type 2 diabetes only when hs-CRP levels were also reduced 
(Katagiri et al., 2009). This may partly explain the inconsistent effects of periodontal 
therapy on glycaemia. Those individuals who experienced the greatest reductions in HbA1c 
also had the greatest inflammatory burden at baseline (as assessed by BOP), and may have 
been more likely to benefit from antimicrobial treatment. A study found periodontal 
treatment (mechanical therapy and oral hygiene instruction) significantly reduced the level 
of serum TNF-α in those with well-controlled and poorly-controlled type 2 diabetes, and in 
healthy individuals (Dag et al., 2009). However, only the well-controlled diabetes group 
achieved significant reductions in HbA1c suggesting that careful glycaemic control may be 
necessary to optimise the effect of periodontal therapy. A recent RCT found the serum 
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levels of hs-CRP, TNF-α, IL-6, FPG, HbA1c, fasting insulin and HOMA-IR7 were reduced, 
and serum levels of adiponectin were slightly increased, in a periodontal treatment group 
compared to an untreated control group (Sun et al., 2011). The participants had poorly 
controlled Type 2 diabetes, and treatment involved mechanical therapy and oral hygiene 
instruction, periodontal surgery, extractions and systemic antimicrobial medication.  
 
More recently, the United States Diabetes and Periodontal Therapy Trial (DPTT) published 
findings from a 6-month randomised clinical trial to determine if periodontal treatment 
reduced HbA1c levels in individuals with Type 2 diabetes with a diagnosis of moderate to 
advanced periodontitis (Engebretson et al., 2013). Periodontal treatment was confined to 
scaling/root planing, oral hygiene instruction and chlorhexidine oral rinse. Enrolment into 
the trial was terminated early due to futility. Within 6 months the treatment group had a 
0.17% increase in mean HbA1c while the control group had a 0.11% increase in mean 
HbA1c. This was despite an improvement in the periodontal parameters in the treatment 
group compared with the control group. The authors concluded non-surgical periodontal 
treatment did not improve glycaemic control in this sample. This study provoked quite a 
strong response from other researchers who did not agree with its conclusions (Borgnakke et 
al., 2014). They were concerned the non-surgical periodontal treatment provided had failed 
to control the periodontal infection and associated inflammation (there was minimal 
reduction in bleeding on probing following treatment), and that baseline glycaemic control 
in the treatment group was generally good (meaning a substantial improvement could not be 
expected). In addition, the treatment group had a high mean BMI (mean 34.7 kg/m2). There 
is some evidence that the inflammatory state associated with obesity would overwhelm any 
reduction in inflammation associated with periodontal treatment. In other words, periodontal 
treatment may have an attenuated effect on HbA1c levels in those individuals with Type 2 
diabetes who are also obese (Offenbacher et al., 2009; Zhu and Nikolajczyk, 2014).  
 
While controlled trials give some insight into the relationship between periodontal therapy 
and glycaemia the findings of many have been limited by small sample sizes, lack of power, 
lack of randomisation and bias. Conflicting findings may be attributed to differences in 
sample sizes and makeup, in methodology, and in periodontal therapy provided. This is a 
                                                 
7 HOMA-IR. Homeostasis model of assessment – insulin resistance. An empirical mathematical formula based 
on fasting plasma glucose and fasting plasma insulin levels that was developed as a surrogate measurement of 
in vivo insulin sensitivity (National Diabetes Education Initiative.).  It is used to quantify insulin resistance. 
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field that is currently attracting a great deal of interest, and the need for carefully conducted 
trials with large sample sizes is a priority (Engebretson and Kocher, 2013).  
1.2.7 Periodontitis and metabolic syndrome 
The studies outlined so far suggest the possibility that periodontitis may have an effect on 
diabetes status, prediabetes or HbA1c levels. Some researchers have focussed instead on the 
associations between periodontitis and metabolic syndrome (of which prediabetes is a 
component). Most of this research has been cross-sectional (Chen et al., 2011; D'Aiuto et 
al., 2008; Han et al., 2010; Khader et al., 2008; Morita et al., 2009; Shimazaki et al., 2007; 
Timonen et al., 2010). Associations were found between MeS and periodontitis in each of 
these studies. Generally, the greater the number of MeS components, the more severe the 
periodontitis, or the stronger the association between the two conditions. Five studies 
demonstrated a significant association between the dysglycaemia component of MeS and 
periodontitis (D'Aiuto et al., 2008; Han et al., 2010; Khader et al., 2008; Morita et al., 2009; 
Shimazaki et al., 2007); one study found no association (Timonen et al., 2010); and one 
reported unadjusted associations only between periodontitis and individual MeS 
components (Chen et al., 2011). The findings of two studies were limited by the use of the 
CPI score to record periodontal status (Han et al., 2010; Morita et al., 2009).  Many of the 
samples were not representative of the general population (Chen et al., 2011; Han et al., 
2010; Khader et al., 2008; Morita et al., 2009; Timonen et al., 2010); one was (D'Aiuto et 
al., 2008); and one sample was female only (Shimazaki et al., 2007). All adjusted for some 
confounding factors. The different studies used different case definitions to categorise 
periodontal status, and the cross-sectional design of these studies meant temporality could 
not be implied. 
 
Nibali et al. compared some MeS markers (serum triglycerides, HDL and glucose levels) 
and inflammatory markers (total and differential leukocyte counts) in people with and 
without severe periodontitis (Nibali et al., 2007). They found those with severe periodontitis 
(cases) had higher serum glucose levels and leukocyte counts, and worse dyslipidaemia 
profiles, when compared with those without severe periodontitis (controls). The study was 
described as “case-control”. While a control (people without severe periodontitis) was used, 
both the blood sampling and periodontal examinations were carried out at the same point in 
time, so this study may be better described as cross-sectional. Case-control study designs 
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generally involve “working backwards in time” to determine exposure information. In any 
case, no conjectures relating to temporality can be raised by this study. 
 
Morita and associates carried out a prospective cohort study over four years to examine the 
impact of periodontitis on the development of MeS (Morita et al., 2010). Periodontal status 
(as measured by CPI score) at baseline was found to predict the number of MeS components 
four years later. These associations were independent of age, gender, smoking, exercise and 
eating habits and weight. Individuals with any of the MeS components at baseline were 
excluded, so a temporal relationship between the two conditions was demonstrated with 
periodontitis preceding conversion to one or more MeS components. Unfortunately, the 
follow-up periodontal data were not presented, and it is possible participants’ periodontal 
status had changed over the four years. With respect to conversion to individual 
components, periodontitis predicted hypertension and dyslipidaemia, but not obesity or 
hyperglycaemia. The participants in this study were derived from the 2009 study sample 
(Morita et al., 2009); and the later study had the same shortcomings of lack of 
generalizability and use of the CPI score (Morita et al., 2010). 
1.2.8 Two-way links between dysglycaemia and periodontitis  
This literature review has shown there is firm support for the notion that chronic 
hyperglycaemia in type 2 diabetes contributes to periodontitis; that periodontitis can 
negatively influence glycaemic control which, in turn, leads to a further periodontal 
deterioration. It is plausible that each condition exacerbates the other. In the words of Grossi 
and Genco, it is a “self-feeding” system of “catabolic response and tissue destruction” 
(Grossi and Genco, 1998).  
 
Attempts to further clarify the bidirectional relationship between type 2 diabetes and 
periodontitis should consider at what stage in the dysglycaemia continuum this relationship 
begins. For example, is there a bidirectional link between prediabetes and periodontitis? The 
possibility that an individual with prediabetes has an increased risk of periodontitis, and 
subsequently this periodontitis increases the risk the prediabetes will eventually progress to 
type 2 diabetes, is an intriguing one. It is also one with profound public health implications, 
yet has received scant attention to date.   
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This review has highlighted some other gaps in the research to date. The revised American 
Diabetes Association recommendation for lower HbA1c cut-off points for prediabetes and 
type 2 diabetes (and the rationale behind this) reflects the fact that people with lower levels 
of dysglycaemia are at risk of poor cardiometabolic outcomes. Therefore prevalence and 
incidence data for these populations are a priority. There is an urgent necessity to track the 
evolution of early dysglycaemia as it progresses to further disease (or to resolution), and 
determine the factors that contribute to the eventual outcome. Studies have examined 
dysglycaemia in children and adolescents; however, there is little research following 
populations from young adulthood onwards in early middle age – a crucial time for 
preventive intervention. 
1.2.9 Research objectives 
The study will use data from the Dunedin Multidisciplinary Health and Development Study 
(DMHDS) to explore the two-way relationship between periodontal disease and glycaemia 
over twelve years. The DMHDS is a longitudinal epidemiological study of a birth cohort 
with a large, representative sample size, and an excellent retention rate. Data have been 
gathered through the life course with both glycaemic and periodontal data collected at ages 
26, 32 and 38. Data have also been collected over the years on a wide range of potential 
risk, ameliorating, exacerbating and confounding factors. 
 
The thesis has the following objectives: 
• Glycaemia data (HbA1c assays) collected during assessments at ages 26, 32, and 38 
will be used to assess the incidence, prevalence and natural history of dysglycaemia 
(encompassing both prediabetes and type 2 diabetes) in the cohort. With three time 
points, trajectories can be identified by trajectory analysis. Associations with other 
variables would be identified. 
• Periodontal data (combined AL) collected during assessments at ages 26, 32, and 38 
will be used to assess the incidence, prevalence and natural history of periodontitis 
in the cohort. With three time points, trajectories can be identified by trajectory 
analysis. Associations with other variables would be identified. 
• HbA1c levels/dysglycaemia will be examined as a risk factor for periodontal disease 
from age 26 through to age 38.  
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• Periodontal disease will be examined as a risk factor for HbA1c levels/dysglycaemia 
from age 26 through to age 38.  
 
Two hypotheses will be tested (1) that dysglycaemia is a risk factor for periodontal disease 
from age 26 through to age 38; and (2) that periodontal disease is a risk factor for 
dysglycaemia from age 26 through to age 38. 
 
In view of the prevalence of both periodontal disease and type 2 diabetes (and the burden of 
diabetes complications), research to investigate these two-way relationships is crucial.  The 
DMHDS is particularly well placed to elucidate the bidirectional links and complex 
associations between periodontal disease and dysglycaemia, and will provide a unique 
opportunity to explore the temporal relationship between them. This study is both essential 
and timely, and may contribute to the future management of prediabetes, diabetes, and 
diabetic complications. If this is the case, the public health significance will be substantial. 
 




2.1 The participants 
This study used data collected during the age-26, age-32 and age-38 assessments of the 
Dunedin Multidisciplinary Health and Development Study (DMHDS), and the utilisation of 
novel and advanced statistical techniques to analyse these data. The DMHDS is a 
longitudinal health and behavioural epidemiological study of a birth cohort of 1,037 
children born in Dunedin, the major city of the province of Otago in the South Island of 
New Zealand, between 1 April 1972 and 31 March 1973. A total of 1661 children were born 
at the Queen Mary Hospital, the only maternity hospital in Dunedin, between these dates. 
Perinatal, demographic and anthropometric data were collected for these children at birth. 
By age three, twelve children had died, and 510 were no longer living in Otago. The 1037 
children represent 91% of the 1139 eligible (still living in Otago at age three) children born 
between these dates (McGee and Silva, 1982). In terms of prenatal, birth and neonatal 
characteristics, the 102 (9%) who declined participation at age three did not differ from 
those who did enrol in the longitudinal study (Poulton et al., 2015; Silva and McGee, 1984). 
Nor did they differ from the 522 who were either deceased, or no longer living in Otago 
(McGee and Silva, 1982). The children were assessed at the DMHDS research Unit for the 
first time within a month of their third birthday, and subsequently at ages 5, 7, 9, 11, 13, 15, 
18, 21, 26, 32 and 38 years, thus spanning the life course from birth to adulthood (Poulton et 
al., 2015). The original cohort was made up of 1013 singletons and 24 twins. The sample at 
age three consisted of 535 (51.6%) boys and 502 (48.4%) girls. Of these children, 1000 
were still alive in 2015. The 7.5% who self-identified as Maori matches the ethnic make-up 
of the South Island of New Zealand (Poulton et al., 2015). Ethics approval for each 
assessment phase was granted by the Otago Research Ethics Committee, and study members 
gave informed consent before participating.   
 
Great importance is placed on the retention of study members. A total of 980, 972 and 961 
individuals participated in the age 26, age 32 and age 38 assessments respectively; this 
exceptionally high retention rate represents over 95% of the surviving cohort.  
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At each assessment, Study members come to the DMHDS Unit for a full day of 
examinations and interviews (a few study members were interviewed by unit staff 
elsewhere). Potential barriers to Study members’ participation were reduced by the Study 
Unit covering members’ costs (travel from anywhere in the world, accommodation, child 
care and car parking). In addition, participants could choose their preferred assessment day. 
The Study has a large, representative sample size enabling statistical estimations with good 
power with data collected over the years on a comprehensive range of physical, mental and 
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2.2 Measurement of exposure and outcome variables 
The age 26 assessments were carried out in 1998-99, the age 32 assessments in 2003-2005, 
and the age 38 assessments in 2010-2012. Periodontal data and glycaemic data (along with 
data on a range of potential risk and confounding factors) were collected at each assessment. 
2.2.1 Periodontal measurements  
Periodontal examinations were conducted at ages 26, 32 and 38, with half-mouth 
examinations at age 26 but full-mouth examinations at ages 32 and 38. Calibrated examiners 
carried out the periodontal examinations at each assessment. Third molars and implants 
were not included in the periodontal examinations. If a tooth was absent, the reason for its 
absence was determined (by asking the study member) and the age at which the tooth was 
lost was recorded. 
 
2.2.1.1 Age 26 
Three calibrated examiners carried out periodontal examinations on 918 of the 980 Study 
members who attended the age 26 assessment. Of the 980, two Study members were 
edentulous, 45 either declined to have an oral examination or could not attend for one, and 
15 were excluded due to a history of cardiac valvular abnormalities or rheumatic fever. The 
examiners assessed 85%, 10% and 5% respectively of the Study members. Due to time 
limitations, periodontal measurements were made in two quadrants; the upper right and 
lower left quadrants for those whose Study ID number was odd, and the upper left and lower 
right for those whose Study ID number was even. The mix of odd and even numbers was 
approximately even. Three sites (mesio-buccal, buccal and disto-lingual) per tooth were 
examined. A NIDR probe (the Hu-Friedy PCP-2) was used; this has 6 alternating 2mm 
bands and a rounded tip. Midbuccal measurements for molars were made at the midpoint of 
the mesial root, and measurements were rounded down to the nearest whole millimeter. Two 
measures were recorded: gingival recession (GR; the distance in millimetres from the 
gingival margin to the cemento-enamel junction) and probing depth (PD; the distance from 
the gingival margin to the tip of the probe). Gingival recession was recorded as a negative 
where the gingival margin was situated more than 1mm coronally to the cemento-enamel 
junction (as would be the case in gingival hyperplasia). The attachment loss (AL) for each 
site was computed by summing the GR and PD measurements.  
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Gingival bleeding on probing was assessed for each tooth by observing the presence or 
absence of bleeding at each of the three probing sites. If bleeding was observed 10 seconds 
after probing, then “bleeding on probing” (BOP) was recorded for that tooth. From this, the 
percentage of teeth which bled on probing was computed for each Study member.  
 
A modified version of the simplified oral hygiene index was used to quantify plaque 
accumulation (Greene and Vermillion, 1964). Six index teeth were scored according to the 
amount of plaque detectable with an explorer. No detectable plaque scored 0, plaque 
covering no more than the cervical third of the tooth scored 1, plaque covering more than 
the cervical third of the tooth but no more than two-thirds scored 2, and plaque covering 
more than two-thirds of the tooth scored 3. The overall plaque score was the sum of the 
scores divided by the number of teeth scored. In addition, Study members were categorised 
according to their plaque score at all three ages 26, 32 and 38: score 0 to 0.5 “Very low”; 
score >0.5 to 1.0 “Low”; score >1.0 to 1.5 “Moderate”; and score >1.5 “High”. 
 
2.2.1.2 Age 32 
The Phase 32 assessments commenced in November 2003 and ran until the middle of 2005. 
During this time, 972 current study members (almost 96% of the surviving 1015) were 
assessed. At this assessment, three Study members were edentulous, 34 either declined to 
have an oral examination or could not attend for one, and 17 were excluded due to a history 
of cardiac valvular abnormalities or rheumatic fever. The remaining 918 participants had a 
periodontal examination in which the clinical procedures were the same as at age 26, except 
that a full-mouth examination was possible this time; three sites per tooth were examined in 
all four quadrants. Measures for gingival bleeding on probing, and plaque score, were also 
recorded. This time, two calibrated examiners were used, and they examined 53% and 47% 
of Study members respectively. The second examiner was the same one who had carried out 
85% of the examinations at age 26.   
 
2.2.1.3 Age 38 
At age 38, the clinical procedures were identical to the age 32 assessment. Three calibrated 
examiners were used; they examined 58%, 39% and 3% of Study members respectively (the 
former two had undertaken the age 32 examinations). By this time, seven Study members 
were edentulous. Some 54 Study members either declined to have an oral examination or 
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could not attend for one, or they had a history of cardiac valvular abnormalities or rheumatic 
fever. The remaining 900 participants had a full-mouth periodontal examination in which 
the clinical procedures were exactly the same as at age 32.   
  
2.2.1.4 Periodontal prevalence case definition, extent and severity 
At each age, three different case definitions for the prevalence of periodontal disease were 
determined by identifying Study members with 1+ sites with 4+mm AL, with 2+ sites with 
4+mm AL, and with 1+ sites with 5+mm AL (Thomson et al., 2007). Two different 
measures of the extent of periodontal disease were obtained by computing the percentage of 
sites with 4+mm AL, or 5+mm AL, for each participant. Finally, severity of periodontal 
disease was estimated by calculating mean AL.  Half-mouth data was used at all ages for 
analyses to enable longitudinal comparisons. 
 
2.2.1.5 Periodontal examiner reliability 
Replicate examinations were not carried out at age 26 due to time constraints (participants 
undergo a very busy assessment day with the dental examinations being carried out at the 
end of the day) so examiner reliability data were not available for the age 26 assessment.  
 
Replicate examinations were conducted on a separate sample of 16 adults on four occasions 
during the age 32 data collection phase, giving data for 1,423 measured sites (Thomson et 
al., 2006). Intra-examiner reliability coefficients for absolute agreement of the site-level 
periodontal measurements pooled for the two examiners (with individual examiner intra-
examiner reliability coefficients in parentheses) were 0.93 (0.94, 0.89) for mean GR, 0.68 
(0.46, 0.83) for mean PD, and 0.69 (0.66, 0.86) for mean AL. Cohen's kappa coefficient (a 
measure of inter-examiner agreement) for the prevalence of 1+ sites with 4+ mm AL was 
0.5 (0.7, 0.8). Of the 1,423 replicated pairs of measurements for AL, only 0.4% differed by 
3+ mm (99.6% were within ±2 mm). Accordingly, intra- and inter-examiner reliability at 
age 32 was acceptable (Goodson, 1986). 
 
As at age 32, replicate examinations were conducted on a separate sample of adults during 
the age-38 assessment; these gave data for 672 periodontal sites measured by the three 
examiners twice each. Intra-examiner reliability coefficients for absolute agreement of the 
site-level periodontal measurements were pooled for the three examiners (with individual 
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examiner intra-examiner reliability coefficients in parentheses). These were found to be 0.95 
(0.99, 0.92, 0.94) for GR; 0.73 (0.73, 0.69, 0.80) for PD; and 0.71 (0.71, 0.68, 0.79) for AL; 
and 0.75 (0.99, 0.74, 0.97) for the prevalence of 1+ sites with 4+mm AL (Zeng et al., 2014). 
When intra-examiner reliability was pooled for all three examiners, only 2.6% of 
measurements differed by >1 mm, and no measurements differed by >2 mm.  This indicates 
high intra-examiner reliability as 1 mm within and among examiners is considered to be 
normal measurement error for GR, PD, and AL (Goodson, 1986). In a similar manner, inter-
examiner reliability at age-38 was also high. Of all the sites assessed for AL, each of the 
examiners differed from the other examiners by 1+mm in no more than 5.4% of 
measurements, and by 2+mm in no more than 0.8% of measurements (Zeng et al., 2014). 
Thus intra- and interexaminer reliability was high, and was similar to that reported in other 
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2.2.2 Glycated haemoglobin  
Glycated haemoglobin (HbA1c) was measured during assessments at ages 26, 32, and 38 in 
order to quantify chronic glycaemia. Not all Study members consented to venepuncture. To 
ensure the validity of the data, HbA1c assays were not carried out on pregnant women (33 
women at age 26, 31 at age 32 and 9 at age 38); HbA1c levels vary significantly during 
pregnancy (Nielsen et al., 2004). In addition, there were four individuals with Type 1 
diabetes in the cohort; these individuals were excluded from all analyses. In total, HbA1c 
data was available for 836 Study members at age 26, 858 at age 32 and 891 at age 38.  
 
Venepuncture was conducted by a registered nurse between 16:15 and 16.45 at each 
assessment. The blood samples collected at age 26 were processed and aliquoted, then 
stored at -80º Celsius controlled temperature. Age 26 HbA1c was then assayed in 2002 
using ion-exchange high performance liquid chromatography (HPLC) on a BioRad Variant 
II (Bio-Rad, Hercules, California). HbA1c was measured at 32 and 38 using ion-exchange 
HPLC on a BioRad Variant II and a BioRad Variant II Turbo (Bio-Rad, Hercules, 
California) respectively.  
 
HbA1c is presently reported in two different units: the older National Glycohemoglobin 
Standardization Program (NGSP) units, whereby HbA1c is expressed as a % of total 
haemoglobin; and the International Federation of Clinical Chemistry (IFCC) reference 
system, where it is expressed in SI (Sisteme Internationale) units (mmol/mol). The age 38 
data were reported in both units at the time of measurement; the age 26 and 32 data were 
converted to the IFCC SI units using the master equation IFCC-HbA1c (mmol/mol) = 
[NGSP-HbA1c (%) - 2.15]*10.929.  
 
The prevalence of diabetes and prediabetes was defined according to the American Diabetes 
Association (ADA) guidelines, whereby prediabetes was defined as 39 to 47 mmol/mol 
HbA1c, and diabetes as ≥48 mmol/mol  HbA1c (American Diabetes Association, 2011). 
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2.3 Measurement of risk variables 
A range of potential risk and confounding factors were assessed at each assessment age. 
These include sociodemographic factors, health- and oral health-related behaviours, and 
anthropometric factors. 
2.3.1 Socioeconomic status  
Measures of socioeconomic status (SES) were obtained for each Study member. Childhood 
SES is an established risk factor for poorer health outcomes in adulthood (Poulton et al., 
2002; Thomson et al., 2004). In the DMHDS childhood SES was measured on the basis of 
the parents’ occupational status (the average of the highest SES level of either parent) 
assessed repeatedly from Study members’ birth to age 15. SES at ages 26, 32 and 38 was 
obtained from each Study member according to their own occupation. The childhood and 
age 26 measures used the Elley-Irving 1985 scale which applied a six-category grouping of 
occupations (Elley and Irving, 1985; Poulton et al., 2002). However, this scale did not 
classify students, the unemployed, retired people or homemakers. The age 32 measure used 
the New Zealand Socio-Economic Index (NZSEI) which was developed to replace the 
Elley-Irving scale. This scale applies a six-interval, occupationally-based classification of 
socioeconomic status which also allowed classification of those individuals outside the 
labour market (Davis et al., 1997; Davis et al., 2003). As an example, a doctor scores “1” 
and a labourer scores “6” on both scales. Study members with a score of “1” or “2” were 
allocated to the “High” SES group; those with a score of “3” or “4” were assigned to the 
“Medium” SES group; and those with a score of “5” or “6” were assigned to the “Low” SES 
group. An updated version of the scale (NZSEI-06) was similarly used to categorise Study 
members in “High”, “Medium” and “Low” SES groups at age 38 (Milne et al., 2013). A 
comparison between NZSEI-06 and the earlier NZSEI showed that both scales classified 
individuals from the 2006 Census similarly, but not identically (Milne et al., 2013). 
2.3.2 Smoking 
Associations between tobacco smoking and periodontal disease are well documented 
(Gelskey, 1999; Thomson et al., 2007; Zeng et al., 2014); links between cannabis use and 
periodontal disease have been found more recently (Thomson et al., 2008; Zeng et al., 
2014). Study members were questioned on their smoking history at ages 26, 32 and 38.  
Current smokers were those who gave a positive response to the question “Have you 
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smoked every day for one month or more of the previous 12 months?”. Current and ex-
smokers were also asked about the number of cigarettes smoked per day and the number of 
years at this level of consumption. These data were used to compute “pack-years to age 26”, 
“pack-years to age 32” and “pack-years to age 38” for each individual; this represents the 
number of packs of cigarettes smoked per day multiplied by the number of years smoked at 
that rate.  Pack-years may be regarded as a measure of cumulative smoking risk, and “10 
pack-years” could be interpreted variously as a pack a day for 10 years, or half a pack a day 
for 20 years, or two packs a day for five years. 
2.3.3 Cannabis use 
Cannabis smoking was assessed at all three ages. Frequency of cannabis use was determined 
by asking participants how many times in the previous year they had smoked cannabis. 
Those who reported no cannabis use in the previous year were assigned to the “no cannabis 
use group”; the remainder were categorised as “less than weekly” or “weekly or more” 
according to their answer to the frequency question. A further category of “regular users” 
comprised those who typically used cannabis 4+ times weekly in the previous year.  
2.3.4 Alcohol use 
Research suggests a U-shaped dose-response relationship between alcohol consumption and 
type 2 diabetes; moderate consumption may be protective for type 2 diabetes but the 
opposite is true for heavier consumption (Baliunas et al., 2009). Study members were asked 
the following at ages 26, 32 and 38: 1) how many weeks in the past year they’d used 
alcohol; 2) how many drinks (standard units) they’d usually have Monday to Thursday; and 
3) how many drinks (standard units) they’d usually have Friday to Sunday. The latter two 
questions were used to calculate the total number of alcohol units consumed per week at 
each of the three ages. 
2.3.5 Physical activity 
There is convincing evidence of a reduced risk of Type 2 diabetes associated with regular 
physical activity (World Health Organization, 2003). In the DMHDS, exercise frequency 
was assessed at ages 32 and 38; comparable data were not available for exercise at age 26. 
Exercise activities included occupational and household tasks, and sport/leisure activities. 
The mean number of hours during weekdays and weekends for all forms of exercise – 
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moderate, hard and extreme – was recorded at ages 32 and 38. Moderate exercise involved 
activities such as gardening, brisk walking and golf. Hard exercise comprised building, 
chopping wood and running ≥8 km/hour. Extreme exercise included firefighting, karate and 
cross-country skiing at a vigorous pace. These exercise data were converted to Metabolic 
Equivalent Hours (MET) whereby one hour of moderate activity was equivalent to four 
MET, one hour of hard activity was equivalent to seven MET and one hour of extreme 
activity was equivalent to 10 MET (Ainsworth et al., 2011). The total MET hours per week 
was computed by summing MET hours from each activity type. A MET is defined as the 
ratio of the energy expenditure of a given activity to the energy expenditure at rest (Moore 
et al., 2012). Thus the greater the energy expenditure of the activity, and the longer its 
duration, the higher the MET will be. It provides a mechanism for quantifying exercise 
activity across different individuals with different levels and durations of activity.   
2.3.6 Use of dental services  
Non-routine use of dental services is a known risk factor for poorer oral health (Thomson et 
al., 2010). Data on use of dental services was collected at ages 26, 32 and 38. Study 
members were asked whether they usually visited the dentist for a check-up or visited only 
to have a problem addressed (episodic attender), and the length of time since their previous 
visit was recorded (Thomson et al., 2010). A routine attender was determined to be one who 
(1) usually visited for a check-up, and (2) had attended within the previous year.  
2.3.7 Anthropometric measures 
Anthropometric parameters assessed at ages 26, 32, and 38 included height, weight, waist 
circumference (WC) and hip girth. These were assessed by anthropometrist-trained health 
professionals, with participants in the standing position, head and eyes directed forward and 
arms hanging by the sides. Height was measured on a portable stadiometer in bare feet to 
the nearest 1 mm, with feet together and standing as tall as possible. Body weight was 
recorded using calibrated scales in light clothing to the nearest 0.1 of a kilogram. Individual 
body mass index (BMI) was computed using the formula: BMI = weight in kg/(height in 
meters)2. WC was recorded by measuring girth to the nearest 1 mm at the skin, using a steel 
tape calibrated in centimetres with millimetre gradations. It was taken at the level of the 
noticeable waist narrowing located approximately halfway between the costal border and 
the iliac crest; it was measured at the time of greatest expiration, and with instructions to 
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relax the diaphragm. Hip girth was taken as the perimeter at the level of the greatest 
protuberance and at about the symphysion pubic level anteriorly. Measurements were taken 
twice and the mean of two readings calculated. Waist-hip ratio and waist-height ratio were 
recorded as the ratio of the WC to that of the hips, and to that of the person's height 
respectively. 
 
In addition to these outcome covariates being used as continuous variables, BMI, WC, 
waist-hip ratio and waist-height ratio were also dichotomised according to established 
guidelines for greater risk of cardiometabolic complications. The WHO classifies BMI 30+ 
as obese (National Health and Medical Research Council, 2013; National Institutes of 
Health, 1998; World Health Organisation, 2006). Guidelines for waist circumference differ 
according to sex, ethnicity, country and the organisation proposing the guideline, but 
women and men are generally considered to be at much higher risk at 880+mm and 
1020+mm respectively (National Health and Medical Research Council, 2013; National 
Institutes of Health, 1998). Abdominal obesity is defined as a waist-hip ratio of more than 
0.85 for females, and more than 0.90 for males (World Health Organisation., 2008). A 
waist-height ratio of 0.50+ is generally regarded as being of higher risk for both sexes 
(Ashwell et al., 2012; Browning et al., 2010; Hsieh et al., 2003). Thus, the covariates were 
dichotomised as per the table below (Table 2.1). 
 
 
Table 2.1. Cut-off points for high risk anthropometric covariates and high risk group by sex. 
 
High risk group Cut-off point 
Covariate 
BMI High BMI group 30+ 
Waist circumference High WC group 880+mm (women) 
1020+mm (men) 
Waist-Hip ratio High waist-hip group 0.85+ (women) 
0.90+ (men) 
Waist-Height ratio High waist-height group 0.50+ 
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2.4 Statistical analysis 
2.4.1 Descriptive and bivariate analyses 
Analyses began with an attrition analysis followed by a description of the cohort at ages 26, 
32 and 38. This was followed by both cross-sectional bivariate analyses at each age, and 
longitudinal bivariate analyses for data at 26 and 32; 26 and 38; and 32 and 38. Chi-square 
tests and Fisher’s exact tests were used to examine the statistical significance of associations 
observed between categorical variables. Mann-Whitney U tests and Kruskal-Wallis tests 
were used to test the statistical significance of associations between independent variables 
and continuous dependent variables. Spearman’s rho correlations were used to explore 
relationships between continuous independent and dependent variables. Statistical tests were 
two-tailed and the threshold for statistical significance was set at p<0.05. All descriptive and 
bivariate analyses were conducted using either SPSS version 20 (SPSS Inc. Chicago, 
Illinois) or Stata IC 12.0 for Windows (StataCorp 2011, Stata Statistical Software: Release 
12, College Station, Tx, USA). 
2.4.2 Longitudinal analyses 
The defining feature of longitudinal studies such as the DMHDS (that involve repeated 
measurements of the same variables for each participant over a period of time) is precisely 
what makes their analyses so complex. While there have been extensive methodological 
developments for the analysis of such data in recent years it remains a challenging 
undertaking. There is no “perfect” method of carrying out analyses with each of the various 
statistical methods available having their limitations (Tu et al., 2013). Problems that may be 
encountered include large variations in the response profile among individuals (some are 
intrinsically high responders, others are low responders); missing data; lack of statistical 
independence between observations on the same individuals at different times; non-
homogeneity of variance; and measurement error (Diggle et al., 2002). Ignoring these 
matters will generally result in biased estimates, and may result in inaccurate conclusions 
(Fitzmaurice et al., 2004). Since different methods have different strengths and weaknesses, 
a combination of diverse techniques may be a valid approach to unravel the complexities 
observed in longitudinal research and draw more reliable conclusions from the information-
rich data (Tu et al., 2013). 
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First, group based trajectory modeling (GBTM) was used to describe the natural history of 
the outcomes of interest, to explore the impact of risk factors on them and investigate their 
influence on each other. A second analysis of the longitudinal data was carried out using 
linear mixed effect modeling which integrates both fixed and random effects. The aim of 
this was to provide a methodological complement to the GBTM analysis, to provide 
analytical triangulation and so give the thesis findings more rigour. Thus, the complex 
relationship between periodontal disease and glycaemia was investigated in two different 
ways. 
 
2.4.2.1 Group based trajectory modeling (GBTM) 
A primary aim of this research was to describe the natural history of two outcomes: 
periodontal condition (as measured by extent of 4+mm AL); and glycaemia (as measured by 
HbA1c) over 12 years. The evolution of an outcome over time is its developmental 
trajectory, and it was hypothesised that there were groups of individuals within the cohort 
that follow distinctive developmental trajectories that were not identifiable prior to analysis 
(Nagin, 1999). GBTM was used to identify latent trajectory groups for both periodontal 
experience and HbA1c levels from age 26 to 38 (Nagin, 2005).  
 
GBTM is a specialised application of finite mixture modeling and involves a procedure 
which gathers individuals into meaningful subgroups that show statistically similar 
trajectories. It provides a statistical method to identify (rather than assuming a priori) groups 
of distinctive trajectories which are summarised by a finite set of different polynomial 
functions of age or time, as determined by maximum likelihood estimation (Nagin, 1999; 
2005). The maximisation is performed using a general quasi-Newton procedure (Jones and 
Nagin, 2012). Rather than prescribing the existence of trajectories of a specific form ex ante 
on the basis of an individual trait or traits, the method allows the trajectories to emerge from 
the data itself. This offers an alternative to the limitations of using assignment rules based 
on inherently subjective categorisation criteria; it determines the form and number of groups 
that best fit the data; and it provides a metric for evaluating the precision of group 
assignments (Nagin, 1999). GBTM predicts the trajectory of each group, the form of each 
trajectory, estimates the probability for each individual of group membership and assigns 
them to the group for which they have the highest probability.  
 
                                                                                                                                                        Dara Shearer 
51 
 
GBTM handles missing data by fitting the model using maximum likelihood estimation. 
This will generate asymptotically unbiased parameter estimates assuming the data are 
missing at random (Nagin and Odgers, 2010). Data are considered to be missing at random 
(MAR) if the “missingness” is not related to the measured outcome. For both the 
periodontal and HbA1c GBTM, there were potentially three data points for each participant 
– at 26, 32 and 38. It was decided to include those who had data collected at two or more 
ages, and exclude those with fewer than two. 
 
Trajectory groups are latent strata; that is, they are groups of individuals following 
approximately the same developmental course. Individuals do not actually belong to 
trajectory groups; rather, they are assigned a probability of group membership. Groups 
should not be reified (that is, should not be regarded as concrete or real). The cohort 
naturally follows a continuous rather than a discrete distribution; the model should then be 
regarded as a convenient statistical device, rather than a state of being, for summarizing 
trajectories in distinctive regions of the distribution (Nagin and Odgers, 2010). The number 
of trajectory groups is not immutable, and individuals do not follow the group-level 
trajectory in lock step (Nagin and Tremblay, 2005). 
 
Generalisations of the GBTM model were used to (1) link baseline characteristics to the 
probability of group membership, and (2) to identify effect modifiers associated with 
deviations from the group trajectory (Nagin, 2005; Nagin and Odgers, 2010). GBTM 
analyses were undertaken using Stata IC 12.0 for Windows (StataCorp 2011, Stata 
Statistical Software: Release 12, College Station, Tx, USA). 
 
While GBTM has been used extensively in delinquency trajectory research, it has only 
recently been used in oral health research (Broadbent et al., 2008; Thomson et al., 2013). 
Several developmental trajectory modeling techniques—including linear modeling, latent 
class growth analysis, linear mixed modeling and group-based trajectory modeling 
(Gebregziabher et al., 2010; Heianza et al., 2012; Helgeson et al., 2010; Hilliard et al., 2013; 
Luyckx and Seiffge-Krenke, 2009; Wang et al., 2011)—have been used to track HbA1c 
over time. However, that research has focused on either populations with type 1 diabetes 
(Helgeson et al., 2010; Hilliard et al., 2013; Luyckx and Seiffge-Krenke, 2009; Wang et al., 
2011), or on older populations with type 2 diabetes (Gebregziabher et al., 2010; Heianza et 
al., 2012). To date, GBTM has not been used to track HbA1c in initially healthy populations 
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from young adulthood onwards into early middle age, a potentially important time for 
intervention aimed at preventing progression to type 2 diabetes.    
 
The GBTM was undertaken using a Stata Plugin for estimating group-based trajectory 
models (Jones and Nagin, 2013; Jones and Nagin, 2012). The Plugin generates parameter 
estimates which allow the calculation of a) the probability of group membership8; b) the 
predicted trajectory for each group9; and c) the posterior probabilities of group 
membership10. 
 
Mean HbA1c was modelled using the censored normal distribution (Jones and Nagin, 
2013). Censors were set at values that were well beyond the range of any data values 
(minimum HbA1c = 10mmol/mol and maximum HbA1c = 150mmol/mol). Periodontal 
experience (as measured by the extent of 4+mm AL) was modelled using the zero-inflated 
Poisson distribution. We used the Bayesian information criterion (BIC)11 as the criterion for 
model selection. However, this was moderated by (a) a preference for a useful parsimonious 
model which fitted the data well; (b) close correspondence between each group’s estimated 
probability and the proportion of Study members classified to that group according to the 
maximum posterior probability assignment rule; (c) an average posterior probability 
(AvePP) value >0.7 for each group; (d) adequate sample numbers in each group; (e) 
reasonably narrow confidence intervals; and (f) the odds of correct classification based on 
the posterior probabilities of group membership >5 for each group (Nagin and Odgers, 
2010). There is more information on these criteria and diagnostics, and how they were 
computed and interpreted, in the Results chapter (Section 3.5). Wald tests were used to test 
whether the model parameter estimates (intercepts and slopes) differed between trajectory 
groups. 
 
Once GBTM groups were determined, bivariate associations between trajectory groups and 
covariates were tested for statistical significance using Chi-square tests for proportions, and 
                                                 
8 The proportion of the population that belongs to each group. 
9 The capture of the essential features of a complex reality by a finite number of trajectory groups, each of a 
specific form, whether zero-order, linear, quadratic, cubic or higher. 
10 The collective measurement of each individual’s probability of belonging to each trajectory group. 
11 The BIC (Bayesian information criterion) was introduced as an alternative to the Akaike information 
criterion (AIC) in 1978 (Schwarz, 1978). The two criteria are closely related, are both model selection criteria, 
and feature the same goodness-of-fit term. Generally the BIC penalises free parameters more strongly than 
does the AIC, so the BIC favours more parsimonious models. The model with the highest (least negative) 
value of BIC and AIC is preferred. 
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Kruskal-Wallis tests for means. Statistical tests were two-tailed and the threshold for 
statistical significance was set at p<0.05.  
 
Two generalisations of the GBTM model were applied (Fig 2.1). The first was used to link 
baseline (at age 26 or earlier) or time-invariant individual characteristics and risk factors to 
the probability of group membership (Nagin, 2005; Nagin and Odgers, 2010). The 
association between each of these baseline characteristics and the probability of group 
membership was estimated simultaneously with the estimation of the trajectories themselves 
(Nagin, 2005). In GBTM, where there are more than two trajectory groups, associations are 
examined by specifying the probability of trajectory group membership to follow a 
multinomial logit model. The coefficients produced can be interpreted in terms of odds ratio 
(obtained by exponentiating the multinomial logit coefficients). Wald tests were used to test 
the equality of the time-invariant factors estimates across the trajectories. 
 
The second generalisation applied added effect modifiers or time-varying covariates to the 
trajectories themselves (Fig 2.1). This examined whether events that occurred during the 
course of the trajectory altered its course (Nagin, 2005; Nagin and Odgers, 2010). For this 
generalisation the coefficients produced are interpreted in terms of how much higher or 
















                                                                                                                                                        Dara Shearer 
54 
 
Fig 2.1. GBTM generalisations 
 
 
                                                                                       (Adapted from (Nagin, 2005))
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2.4.2.2 Linear Mixed Modelling  
Linear mixed effects models (LMM) account for two common features of longitudinal data: 
non-independence of the observations and non-homogeneity of variance. First, longitudinal 
observations in the same participant over time are correlated. A response on one occasion 
predicts the likely value of the response on the next occasion, so the repeated measures 
cannot be regarded as independent from each other. Second, the variance of the response 
often changes over time. The lack of statistical independence and non-homogeneity of 
variance violate the assumptions of generalised linear modeling and other standard 
analytical techniques. LMM provides a technique for the analysis of longitudinal continuous 
data in which the residuals are normally distributed but may not have constant variance or 
be independent (West et al., 2014). LMM adjusts for the non-independence of the repeated 
observations within one individual by estimating the differences among all the individuals. 
The term “mixed” indicates that the model contains both (a) fixed effects (population 
characteristics assumed to be common to all individuals) and (b) random effects 
(characteristics that are specific to a particular individual). An added advantage is that cases 
with some missing values can be included in LMM analyses, thus minimising selection bias. 
In this thesis, LMM was used to quantify associations between continuous dependent 
variables (mean HbA1c and mean AL) and predictor variables while estimating covariance 
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Naïve regression model 
Assume that we are interested in the relationship between response variable Y and time-
dependent variable X (could be age, years or hours etc). Consider first the simple ‘standard’ 
or ‘naïve’ regression model which ignores correlations between observations (Fig 2.2).  
Yit = β0 + β1Xit + εit                                                                                                                   
where Yit = response variable for individual i at time t; β0 = intercept (value of Y when time 
= 0); β1 = regression coefficient (slope) for X; Xit = time-dependent variable for individual i 
at time t; and ε = error or residual for individual i at time t. 
 
The intercept β0 and the regression coefficient β1 form the “fixed” part of the model, and the 
difference between the observed response and the fixed part is the residual or “random” part 
of the model ε. 
 
 









                                                                                                                                                        Dara Shearer 
57 
 
Random intercepts models 
Some individuals will have higher values than the mean response profile in the population 
(marginal mean) and some will have lower (Fig 2.3). The solid line denotes the marginal 
mean, and the broken lines denote the conditional (or subject-specific) response trajectories 
of two individuals, say 1 and 2. The intercept for individual 1 is higher than the marginal 
mean, and the intercept for individual 2 is lower than the marginal mean. 
 
 





The model could incorporate a correction using dummy variables for these two individuals 
whereby different intercepts are estimated for each. 
Yit = β0 + β1Xit  + β2(individual1) + β3(individual2) + εit                                        
where Yit = response variable for individual i at time t; β0 = intercept (value of Y when time 
= 0); β1 = regression coefficient (slope) for X; Xit = time-dependent variable for individual i 
at time t; β2 = regression coefficient for dummy variable for individual 1; individual1 = 
dummy variable representing individual 1; β3 = regression coefficient for dummy variable 
for individual 2; individual2 = dummy variable representing individual 2; and εit = error or 
residual for individual i at time t. 
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Estimating individual intercepts in this way for larger sample sizes is obviously impractical 
as the greater the number of individuals, the greater the number of dummy variables and 
consequent complexity involved. Instead, the random intercepts model provides an efficient, 
elegant and parsimonious method to incorporate individual intercepts into the model by 
estimating the variance of the intercepts, rather than estimating the separate intercepts 
themselves. The model assumes that there is a normal distribution of individual intercepts, 
and the variance of that distribution is estimated (Twisk, 2006). One variance parameter 
replaces all the parameters required for each individual. This random intercepts model is the 
simplest form of a LMM (Fig 2.4).  
Yit = β0i + β1Xit + εit                                                                                                                 
where Yit = response variable for individual i at time t; β0i  = random intercept; β1 = 
regression coefficient (slope) for X; Xit = time-dependent variable for individual i at time t; 
and εit = error or residual for individual i at time t. 
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Random intercepts and slope models 
Random intercepts and slope models expand on the random intercepts models by allowing 
each individual’s value of the outcome variable to follow a unique trajectory over time. 
While the random intercepts model allows the intercepts to differ between individuals, their 
regression coefficients (slopes) are all the same. Different individual regression coefficients 
as well as intercepts are a common characteristic of longitudinal studies; in other words, 
there is an interaction between the individual and the time-dependent covariate X (Fig 2.5). 
 
 




The model could correct for the different regression coefficients for these two individuals by 
incorporating dummy variables with interaction terms into the model.  
Yit = β0i + β1Xit + β2(individual1*X) + β3(individual2*X) + εit                          
where Yit = response variable for individual i at time t; β0i  = random intercept; β1 = 
regression coefficient (slope) for X; Xit = time-dependent variable for individual i at time t; 
β2 = regression coefficient for the interaction between the dummy variable for individual 1 
and X; β3 = regression coefficient for the interaction between the dummy variable for 
individual 2 and X; and εit = error or residual for individual i at time t. 
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As for the random intercepts model, this method becomes impractical for larger sample 
sizes and the parsimonious solution is as for the random intercepts model. A normal 
distribution is drawn around the regression coefficients, the variance of that distribution is 
estimated, and this variance parameter is added to the model (Fig 2.6) 
Yit = β0i + β1iXit + εit                                                                                                                
where Yit = response variable for individual i at time t; β0i  = random intercept; β1i = random 
regression coefficient (slope) for X; Xit = time-dependent variable for individual i at time t; 
and εit = error or residual for individual i at time t. 
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Essentially, a LMM can control for the effect of individual variation. It gives structure to the 
residual or “random” part of the model by dividing it into (a) variance due to the random 
intercept component, (b) variance due to the random regression coefficients component, and 













3.1 Attrition analysis 
A total of 980, 972 and 961 individuals participated in the age 26, age 32 and age 38 
assessments respectively (Fig 3.1). These represented 96.2%, 95.8% and 95.8% respectively 
of the surviving cohorts at each age. There were three Study members with Type 1 diabetes 
in the cohort at the age 26 and age 32 assessments. By the age 38 assessment, one of these 
people was deceased, but another person had been diagnosed with Type 1 diabetes between 
the age 32 and age 38 assessments. Thus, there was a total of three excluded from analyses 
at each of the three ages, resulting in 977, 969 and 958 participants respectively being 




Fig 3.1. Attrition flowchart 
 
                                                                                                                                                             Dara Shearer 
63 
 
Of these, 915 (93.7%) had a periodontal examination at age 26, 915 (94.4%) at age 32 and 898 
(93.7%) at age 38. A further 33 (3.4%) at 26, 31 (3.2%) at 32 and 9 (0.9%) at 38 were 
excluded from HbA1c assays and anthropometric measurements due to pregnancy. Of the 
remaining participants, 836 (85.6%), 858 (88.5%) and 891 (93.0%) had HbA1c assays at ages 
26, 32 and 38 respectively. 
 
With respect to the GBTM, there were potentially three data points for each study member – at 
26, 32 and 38. It was decided to include those who had data collected at two or more ages, and 
exclude those with less than two (Figs 3.2 and 3.3). In total, 924 and 893 Study members were 
included in the periodontal and HbA1c GBTM analysis respectively. 
 
While those excluded from the GBTM represent a small proportion of the original cohort, it is 
important to determine whether they differ from those included. The two groups were 
compared on the basis of sex, childhood SES, SES at 26, 32 and 38, and smoking. There were 
proportionately fewer individuals of low childhood SES, low SES at 26 and 32, and smokers 
at 32 included in the periodontal GBTM (Table 3.1). No differences were found between those 
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Fig 3.3. Inclusion in the HbA1c GBTM 
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Table 3.1. Attrition analyses. 
 Periodontal GBTM  HbA1c GBTM 
 Included  Not included  Included Not included 
 N = 924 N = 113  N = 893 N = 144 
Male (N=535, 51.6%) 469 (50.8) 66 (58.4)  457 (51.2) 78 (54.2) 
Maori (N=73, 7.5%) 68 (7.4) 5 (8.6)  67 (7.5) 5 (6.8) 
Low childhood SES group (N=215, 20.9%) 181 (19.7) 34 (30.4)a  178 (20.0) 37 (25.9) 
Low SES group at age 26 (N=258, 27.6%) 228 (26.0) 30 (50.0)b  228 (26.9) 30 (34.5) 
Low SES group at age 32 (N=301, 31.0%) 278 (30.2) 23 (46.0)c  272 (30.5) 29 (36.3) 
Low SES group at age 38 (N=187, 19.6%) 175 (19.4) 12 (24.5)  169 (19.3) 18 (23.1) 
Smoker at 26 (N=392, 39.5%) 364 (39.5) 28 (48.3)  356 (40.0) 36 (40.4) 
Smoker at 32 (N=327, 33.6%) 303 (32.9) 24 (48.0)c  300 (33.6) 27 (33.8) 
Smoker at 38 (N=253, 26.4%) 234 (25.8) 19 (37.3)  232 (26.4) 21 (26.6) 
ap<0.01; chi-square test.   bp<0.001; chi-square test.  cp<0.01; chi-square test.    
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3.2 Description of the sample at ages 26, 32 and 38 
 
The DMHDS cohort at age three consisted of 535 (51.6%) boys and 502 (48.4%) girls. The 
prevalence of males had dropped slightly by ages 26 and 32, and again by 38 (Table 3.2). The 
percentage of Study members self-identifying as Maori remained constant over the 12 years. A 
similar proportion of female Study members were pregnant at 26 and 32 with the proportion 
dropping sharply by age 38.   
 
A total of 1031 Study members had childhood SES – based on the mean of parents’ 
occupational status – recorded over the years between birth and age 15 (Table 3.2). SES was 
also assessed at ages 26, 32 and 38. Different prevalences of low, medium and high SES were 
seen as the cohort aged, and became more affluent (these disparities also reflected the use of 
different measurement scales).  
 
The prevalence of smoking declined from four out of ten of the sample reporting smoking 
every day for a month or more in the previous year at 26 to just over a quarter at 38 (Table 
3.2). The mean number of cumulative pack years doubled between these ages. Marijuana use 
declined from half of the sample at age 26 to a quarter at 38 while the proportion of regular 
users (four or more times per week) dropped by almost a third.  
 
As the cohort aged, there was an increase in the mean number of alcoholic drinks consumed 
during the week, and a decrease in the mean number during the weekend (Table 3.2).  
However, the mean total number of drinks per week remained the same over the twelve years. 
The mean number of hours for all forms of exercise – moderate, hard and extreme – increased 
between ages 32 and 38. The mean number of MET hours per week increased markedly 
between ages 32 and 38. Comparable data were not available for exercise at age 26.  
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Table 3.2. Demographic characteristics, socio-economic status, smoking status, marijuana and 
alcohol use, and exercise frequency at ages 26, 32 and 38. 
 Age 26 
N = 977 
Age 32 
N = 968 
Age 38 
N = 958 
Male (%) 498 (51.0) 493 (50.9) 483 (50.4) 
Maori1 (%) 72 (7.4) 71 (7.4) 70 (7.4) 
Pregnant (%) 33 (3.4) 31 (3.2) 9 (0.9) 

































Current smoker4 (%) 










Frequency of marijuana use6 (%) 
None 
Less than weekly 
Weekly or more 














  99 (10.5) 
58 (6.1) 
Alcohol use7 (SD) 
Mean number of weeks had alcohol 
Mean number of drinks Monday-Thursday 
Mean number of drinks Friday-Sunday 

















Mean hours moderate – weekdays 
Mean hours moderate – weekends 
Mean total hours moderate 
Mean hours hard – weekdays 
Mean hours hard – weekends 
Mean total hours hard 
Mean hours extreme – weekdays 
Mean hours extreme – weekends 
Mean total hours extreme 


































Percentages may not total 100% due to rounding.  Not all participants responded to all items. 
1N = 975 at 26, 959 at 32, and 946 at 38.  
2N = 972 at 26, 963 at 32, and 953 at 38. 
3N = 933 at 26, 967 at 32, and 950 at 38.  
4N = 976 at 26, and 954 at 38 
5N = 976 at 26, 967 at 32, and 950 at 38.  
6N = 973 at 26 (958 at 26 for ‘Regular Users’ variable), 964 at 32, and 945 at 38. 
7N = 973 at 26, 960 at 32, and 947 at 38. 
8N = 959 at 32, and 955 at 38.                               
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Periodontal status worsened with age (Table 3.3). Half-mouth measures were available for all 
three ages 26, 32 and 38 with full-mouth measures for ages 32 and 38 only. The mean number 
of periodontally-examined sites decreased with age, prevalence and extent increased, and a 
clear gradient was seen in these parameters across the ages. No such clear pattern was seen 
with severity of disease, although mean AL was higher at age 38 than at 26 or 32. Looking at 
the half-mouth measures, prevalence increased by almost half, almost three-fold and  over 
four-fold for 1+ sites with 4+mm AL, 2+ sites with 4+mm AL and 1+ sites with 5+mm AL 
respectively between ages 26 and 38. Mean extent showed a similar striking increase. 
Generally, the greatest deterioration in periodontal status was between the ages 32 and 38. 
Conversely, other periodontal measures improved. The mean % of sites showing BOP reduced 
by a quarter, the mean plaque score reduced by a third, and the proportion of Study members 
in the “moderate” or “high” plaque score groups decreased markedly over the twelve years. 
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Table 3.3.  Prevalence, extent and severity of periodontal disease, bleeding on probing, plaque 
score and plaque score group, and dental attendance patterns, at ages 26, 32 and 38.   
 Age 26 N = 915 
Age 32 
N = 915 
Age 38 
N =898 
Full-mouth     
Mean number of sites assessed (SD) - 79.8 (6.3) 78.4 (8.5) 
Prevalence of periodontitis 
1+ sites with 4+mm AL (%)  
2+ sites with 4+mm AL (%)  














Mean % of sites with 4+mm AL (SD) 
















Mean % of sites with BOP (SD) - 8.5 (7.2) 7.4 (7.5) 
Mean plaque score1 (SD) - 0.8 (0.5) 0.6 (0.5) 
Half-mouth     
Mean number of sites assessed (SD) 40.4 (2.6) 39.8 (3.3) 39.2 (4.4) 
Prevalence of periodontitis 
1+ sites with 4+mm AL (%)  
2+ sites with 4+mm AL (%)  














Mean % of sites with 4+mm AL (SD) 


















Mean % of sites with BOP (SD) 9.9 (8.6) 8.3 (7.7) 7.4 (8.0) 
Mean plaque score1 (SD) 0.9 (0.5) 0.8 (0.5) 0.6 (0.5) 
Plaque score group 



















Dental attendance patterns    
Routine attender2 (%) 286 (31.3) 295 (32.4) 306 (34.1) 
Episodic attender3 (%) 492 (53.8) 486 (53.2) 505 (56.2) 
SD; Standard Deviation.  AL; Combined Attachment Loss, BOP; Bleeding on probing     
1N = 923 at 26, 926 at 32 and 907 at 38 (some participants who were excluded from a full periodontal 
examination agreed to have their plaque scores recorded). 
2N = 913 at 26, 910 at 32 and 897 at 38. 
3N = 914 at 32. 
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Mean HbA1c increased with age, as did the prevalence of prediabetes, type 2 diabetes and 
dysglycaemia (Table 3.4). There was an overall relative increase of 16.0% in mean HbA1c 
between 26 and 38, with the greatest increase between ages 26 and 32 (11.1% between ages 26 
and 32 and 4.4% between 32 and 38). Of those who had HbA1c levels assayed at both 26 and 
38, some 724 (93.2%) experienced a rise in HbA1c between these ages, and 54 (6.8%) 
experienced a drop. Of those 54 individuals whose HbA1c dropped, the mean drop was 1.3 
mmol/mol (SD = 1.3) between 26 and 38, the median was 1.3 mmol/mol and the range was 0.1 
mmol/mol – 6.6 mmol/mol. Of those 724 individuals whose HbA1c rose, the mean rise was 
5.4 mmol/mol (SD = 5.1), the median was 4.9 mmol/mol and the range was 0.1 mmol/mol – 
92.9 mmol/mol. 
 
The anthropometric measures all increased between ages 26 and 38; there were increases of 
9.0%, 8.8%, 7.9%, 7.5% and 6.4% (respectively) for mean weight, mean BMI, mean WC, 
mean waist-hip ratio and mean waist-height ratio between ages 26 and 38 (Table 3.4). 
Generally, the greatest increases were between ages 26 and 32, with smaller increases between 
ages 32 and 38. Likewise, the proportion of Study members in the high risk anthropometric 
groups increased steadily over the twelve years, more than doubling in the case of the high 
BMI group and high waist-height groups, almost tripling in the case of the high WC group, 
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Table 3.4. Mean HbA1c levels, prevalence of prediabetes, type 2 diabetes and dysglycaemia, 
mean anthropometric measures, and anthropometric high risk groups  at ages 26, 32 and 38. 
 Age 26 N = 944 
Age 32 
N = 937 
Age 38 
N =949 
Mean HbA1c in mmol (SD)1 30.7 (3.1) 34.0 (3.6) 35.5 (5.5) 
Prediabetes (%)1 2 (0.2) 31 (3.6) 155 (17.4) 
Diabetes (%)1 0 (0.0) 1 (0.1) 6 (0.6) 
Dysglycaemia (%)1 2 (0.2) 32 (3.7) 161 (18.1) 
Anthropometric measures (SD)    
Mean weight in kg2 (SD) 74.1 (14.8) 78.2 (16.6) 80.8 (17.4) 
Mean BMI3 (SD) 25.0 (4.4) 26.2 (5.0) 27.2 (5.3) 
Mean waist circumference in mm4 (SD) 801.4 (99.6) 844.5 (114.0) 864.1 (126.4) 
Mean waist-hip ratio5 (SD) 0.80 (0.07) 0.83 (0.07) 0.85 (0.08) 
Mean waist-height ratio4 (SD) 0.47 (0.06) 0.49 (0.06) 0.50 (0.07) 
High BMI group3 (%)  110 (11.8) 164 (15.9) 227 (24.4) 
High WC group4 (%)   63 (6.8) 144 (15.5) 191 (18.5) 
High waist-hip group5 (%)   60 (6.5) 198 (21.4) 316 (34.1) 
High waist-height group4 (%)   208 (20.1) 346 (37.3) 422 (45.3) 
SD; Standard Deviation.      
Prediabetes; 39mmol/mol – 47mmol/mol.  Diabetes; 48+mmol/mol).  Dysglycaemia; 39+mmol/mol 
1N = 836 at 26, 858 at 32, and 891 at 38.  
2N = 936 at 26, 926 at 32, and 936 at 38.  
3N = 936 at 26, 926 at 32, and 931 at 38.  
4N = 924 at 26, 927 at 32, and 932 at 38.  
5N = 924 at 26, 927 at 32, and 928 at 38. 
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3.3 Cross-sectional associations at ages 26, 32 and 38 
3.3.1 Periodontal experience – covariate associations 
The cross-sectional bivariate associations between periodontal experience and periodontal 
covariates were explored using chi-square tests for categorical variables, Mann-Whitney U 
tests for categorical and continuous variables, and Spearman’s correlation coefficient for 
continuous variables.  
 
3.3.1.1 Age 26 
Statistically significant associations were found between all three periodontal disease 
prevalence case definitions and low childhood SES, smoking status, mean pack years, regular 
marijuana use and mean plaque score (Table 3.5). While an association was found between 
low SES at age 26 and 1+ sites with 4+mm AL, no associations were found with the more 
severe prevalence case definitions. Those with 1+ or 2+ sites with 4+mm AL were more likely 
to be in the “high” plaque score group; the opposite was the case for those in “very low” 
plaque score group. Those with 1+ sites with 4+mm AL or 1+ sites with 5+mm AL were more 
likely to be episodic attenders while those with 1+ or 2+ sites with 4+mm AL were less likely 
to be routine attenders. 
 
Statistically significant associations were found between extent of periodontal disease (as 
measured by the mean % of sites with 4+mm AL) and low childhood SES, SES at 26, smoking 
status, mean pack years, regular marijuana use, mean plaque score, plaque score group and use 
of dental services (Table 3.6). More extensive disease (as measured by the mean % of sites 
with 5+mm AL) was associated with low childhood SES, smoking status, mean pack years, 
weekly+ and regular marijuana use, mean plaque score and episodic use of dental services. 
The severity of periodontal disease was associated with all the demographic, smoking and oral 
health care covariates. The correlations between continuous variables were all positive; both 
extent and severity of disease at age 26 were positively associated with mean pack years and 
with mean plaque score. The correlations ranged in value from 0.072 to 0.362 (representing 
shared variances of 0.5% and 13.1% respectively). 
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Table 3.5. Age 26 periodontitis prevalence (half-mouth measures) by demographic, smoking and oral health care variables. Column percentages or 
standard deviation in parentheses. N = 915. 
 Periodontitis prevalence (half-mouth) at 26 
 1+ sites with 4+mm AL 2+ sites with 4+mm AL 1+ sites with 5+mm AL 












Demographic characteristics       
Male (N=466, 50.9%) 368 (49.6) 98 (56.6) 425 (50.7) 41 (53.2) 443 (50.3) 23 (65.7) 
Low childhood SES1 (N=180, 19.8%) 124 (16.8) 56 (32.7)a 154 (18.4) 26 (34.7)b 164 (18.7) 16 (47.1)a 
Low SES at age 26 (N=233, 26.8%) 181 (25.3) 52 (33.5)c 210 (26.0) 23 (35.9) 221 (26.2) 12 (42.9) 
Smoking at age 26       
Current smoker (N=363, 39.7%) 274 (36.9) 89 (51.4)b 315 (37.6) 48 (62.3)a 342 (38.9) 21 (60.0)c 
Mean pack years (SD) 2.7 (4.1) 4.6 (5.0)d 2.8 (4.1) 6.0 (5.4)d 2.9 (4.2) 6.6 (5.5)d 
Marijuana weekly or more (N=158, 17.3%) 123 (16.6) 35 (20.2) 138 (16.5) 20 (26.0) 145 (16.5) 13 (37.1)b 
Regular Marijuana user2 (N=82, 9.1%) 59 (8.0) 23 (13.5)c 69 (8.3) 13 (17.1)c 72 (8.3) 10 (28.6)a 
Oral health care at age 26       
Mean plaque score (SD) 0.8 (0.5) 1.1 (0.6)d 0.8 (0.5) 1.1 (0.6)d 0.9 (0.5) 1.1 (0.6)e 
Plaque score group 
Very low (N=305, 33.5%) 
Low (N=333, 36.6%) 
Moderate (N=185, 20.3%) 































Routine attender (N=286, 31.3%) 248 (33.5) 38 (22.1)f 271 (32.4) 15 (19.7)c 280 (31.9) 6 (17.1) 
Episodic attender (N=492, 53.8%) 383 (51.6) 109 (63.0)f 442 (52.7) 50 (64.9) 466 (53.0) 26 (74.3)c 
ap<0.001; chi-square test.  bp<0.005; chi-square test.   cp<0.05; chi-square test.  dp<0.001; Mann-Whitney U test.   ep<0.05; Mann-Whitney U test.  fp<0.01; chi-square test.   SES; 
Socioeconomic status.     1Low SES birth to age 15.   2Uses marijuana 4+ times a week. 
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Table 3.6. Age 26 periodontitis extent and severity (half-mouth measures) by demographic, 
smoking and oral health care variables, and correlations with mean pack years. Standard 
deviation in parentheses. N = 918. 
 Periodontitis extent and severity (half-
mouth) at 26 (SD) 
 Mean % of 
sites with 
4+mm AL 




Demographic characteristics    
Male  
No (N=449, 49.1%) 










Low childhood SES  
No (N=731, 80.2%) 










Low SES at age 26  
No (N=638, 73.2%) 










Smoking at age 26    
Current smoker  
No (N=552, 60.3%) 










Mean pack years*  0.173e  0.140e 0.219e 
Marijuana weekly or more  
No (N=754, 82.7%) 










Regular Marijuana user  
No (N=821, 90.9%) 










Oral health care at age 26    
Mean plaque score*  0.173e 0.072f 0.362e 
Plaque score group 
Very low (N=305, 33.5%) 
Low (N=333, 36.6%) 
Moderate (N=185, 20.3%) 
















Routine attender  
No (N=627, 68.7%) 










Episodic attender  
No (N=423, 46.2%) 










*Spearman correlation coefficient.  ap<0.001; Mann-Whitney U test.  bp<0.01; Mann-Whitney U test.   cp<0.05; 
Mann-Whitney U test. dp<0.005; Mann-Whitney U test.   ep<0.001; Spearman’s rho correlation.  fp<0.05; 
Spearman’s rho correlation. gp<0.001; Kruskal Wallis test.   
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3.3.1.2 Age 32 
Statistically significant associations were found between all three periodontal disease 
prevalence case definitions and low childhood SES, low SES at 32, smoking status, mean pack 
years, marijuana use weekly or more, regular marijuana use, and mean plaque score (Table 
3.7). Those with any of the three prevalence case definitions were more likely to be in the 
“high” plaque score group and to be episodic attenders, and less likely to be in the “low” 
plaque score group and to be routine attenders. 
 
Statistically significant associations were found between extent of periodontal disease (as 
measured by the mean % of sites with 4+mm or 5+mm AL) and low childhood SES, low SES 
at 32, smoking status, mean pack years, marijuana use weekly or more, regular marijuana use, 
mean plaque score, plaque score group and use of dental services (Table 3.8). Severity of 
periodontal disease was associated with all the demographic, smoking and oral health care 
covariates. The correlations between continuous variables were all positive; both the extent 
and severity of disease at age 32 were positively associated with mean pack years and with 
mean plaque score. The correlations ranged in value from 0.073 to 0.349 (representing shared 
variances of 0.5% and 12.2% respectively). 
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Table 3.7. Age 32 periodontitis prevalence (half-mouth measures) by demographic, smoking and oral health care variables. Column percentages or 
standard deviation in parentheses. N = 915. 
 Periodontitis prevalence (half-mouth) at 32 
 1+ sites with 4+mm AL 2+ sites with 4+mm AL 1+ sites with 5+mm AL 












Demographic characteristics       
Male (N=468, 51.1%) 353 (49.8) 115 (55.8) 405 (50.9) 63 (52.9) 425 (50.7) 43 (55.8) 
Low childhood SES1 (N=180, 19.8%) 116 (16.5) 64 (31.1)a 135 (17.1) 45 (37.8)a 153 (18.4) 27 (35.1)b 
Low SES at age 32 (N=277, 30.3%) 182 (25.7) 95 (46.3)a 221 (27.8) 56 (47.1)a 238 (28.4) 39 (50.6)a 
Smoking at age 32       
Current smoker (N=305, 33.3%) 182 (25.7) 123 (59.7)a 220 (27.6) 85 (71.4)a 252 (30.1) 53 (68.8)a 
Mean pack years (SD) 3.6 (5.5) 9.0 (7.8)c 3.9 (5.9) 10.5 (7.6)c 4.3 (6.3) 10.1 (7.0)c 
Marijuana weekly or more (N=133, 14.6%) 72 (10.2) 61 (29.8)a 95 (12.0) 38 (31.9)a 108 (12.9) 25 (32.5)a 
Regular Marijuana user2 (N=81, 8.9%) 42 (5.9) 39 (19.0)a 60 (7.6) 21 (17.6)b 67 (8.0) 14 (18.2)d 
Oral health care at age 32       
Mean plaque score (SD) 0.7 (0.5) 1.0 (0.7)c 0.7 (0.5) 1.0 (0.7)c 0.7 (0.5) 1.0 (0.7)e 
Plaque score group 
Very low (N=403, 44.2%) 
Low (N=287, 31.5%) 
Moderate (N=134, 14.7%) 































Routine attender (N=295, 32.4%) 252 (35.7) 43 (21.0)a 275 (34.7) 20 (16.9)a 281 (33.7) 14 (18.2)d 
Episodic attender (N=486, 53.1%) 349 (49.2) 137 (66.8)a 397 (49.9) 89 (75.4)a 429 (51.3) 57 (74.0)a 
ap<0.001; chi-square test.  bp<0.005; chi-square test.  cp<0.001; Mann-Whitney U test.  dp<0.01; chi-square test.  ep<0.05; Mann-Whitney U test.   
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Table 3.8. Age 32 periodontitis extent and severity (half-mouth measures) by demographic, 
smoking and oral health care variables, and correlations with mean pack years. Standard 
deviation in parentheses. N = 915. 
 Periodontitis extent and severity (half-
mouth) at 32 (SD) 
 Mean % of 
sites with 
4+mm AL 




Demographic characteristics    
Male  
No (N=447, 48.9%) 










Low childhood SES1  
No (N=730, 80.2%) 










Low SES at age 32  
No (N=637, 69.7%) 










Smoking at age 32    
Current smoker  
No (N=610, 66.7%) 










Mean pack years*  0.349b 0.248b 0.306b 
Marijuana weekly or more  
No (N=780, 85.4%) 










Regular Marijuana user2  
No (N=832, 91.1%) 










Oral health care at age 32    
Mean plaque score*  0.177b 0.073d 0.333b 
Plaque score group 
Very low (N=403, 44.2%) 
Low (N=287, 31.5%) 
Moderate (N=134, 14.7%) 
















Routine attender  
No (N=615, 67.6%) 










Episodic attender  
No (N=428, 46.8%) 










*Spearman correlation coefficient.  ap<0.001; Mann-Whitney U test.  bp<0.001; Spearman’s rho correlation.   
cp<0.005; Mann-Whitney U test.  dp<0.05; Spearman’s rho correlation. ep<0.001; Kruskal Wallis test.  fp<0.001; 
Kruskal Wallis test.    gp<0.01; Mann-Whitney U test.   
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3.3.1.3 Age 38 
The association between sex and periodontal disease prevalence became apparent by age 38 
whereby Study members with any of the three prevalence case definitions were more likely to 
be male (Table 3.9). Statistically significant associations were also found between all three 
periodontal disease prevalence case definitions and low childhood SES, low SES at 38, 
smoking status, mean pack years, marijuana use weekly or more, regular marijuana use, and 
mean plaque score. Those with any of the three prevalence case definitions were more likely 
to be in the “high” plaque score group and to be episodic attenders, and less likely to be in the 
“low” plaque score group and to be routine attenders. 
 
Statistically significant associations were found between extent of periodontal disease (as 
measured by the mean % of sites with 4+mm or 5+mm AL) and all the demographic, smoking 
and oral health care covariates (Table 3.10). Severity of periodontal disease was also 
associated with all covariates. By age 38, correlations between continuous variables were 
stronger than in previous years; both extent and severity of disease at age 38 were positively 
associated with mean pack years and mean plaque score. The correlations ranged in value 
from 0.224 to 0.425 (representing shared variances of 5.0% and 18.0% respectively). 
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Table 3.9. Age 38 periodontitis prevalence (half-mouth measures) by demographic, smoking and oral health care variables. Column percentages or 
standard deviation in parentheses. N = 898. 
 Periodontitis prevalence (half-mouth) at 38 
 1+ sites with 4+mm AL 2+ sites with 4+mm AL 1+ sites with 5+mm AL 












Demographic characteristics       
Male (N=452, 50.3%) 265 (45.3) 187 (59.7)a 325 (47.0) 127 (61.4)a 356 (48.2) 96 (60.0)b 
Low childhood SES1 (N=171, 19.1%) 83 (14.3) 88 (28.2)a 105 (15.3) 66 (32.0)a 121 (16.5) 50 (31.2)a 
Low SES at age 38 (N=166, 18.5%) 62 (10.6) 104 (33.4)a 86 (12.5) 80 (38.8)a 105 (14.3) 61 (38.4)a 
Smoking at age 38       
Current smoker (N=230, 25.7%) 92 (15.8) 138 (44.1)a 120 (17.4) 110 (53.1)a 148 (20.1) 82 (51.2)a 
Mean pack years (SD) 3.6 (6.3) 10.2 (10.2)c 3.9 (6.6) 12.5 (10.6)c 4.5 (7.3) 12.4 (10.6)c 
Marijuana weekly or more (N=92, 10.3%) 35 (6.0) 57 (18.3)a 42 (6.1) 50 (24.3)a 52 (7.1) 40 (25.2)a 
Regular Marijuana user2 (N=52, 5.8%) 18 (3.1) 34 (10.9)a 22 (3.2) 30 (14.6)a 26 (3.5) 26 (16.4)a 
Oral health care at age 38       
Mean plaque score (SD) 0.5 (0.4) 0.8 (0.6)c 0.6 (0.4) 0.9 (0.7)c 0.6 (0.5) 0.9 (0.7)c 
Plaque score group 
Very low (N=496, 55.7%) 
Low (N=239, 26.9%) 
Moderate (N=90, 10.1%) 































Routine attender (N=306, 34.1%) 232 (39.7) 75 (23.6)a 263 (38.1) 44 (20.8)a 274 (37.2) 32 (20.0)a 
Episodic attender (N=505, 56.2%) 283 (48.4) 222 (70.9)a 352 (50.9) 153 (73.9)a 382 (51.8) 123 (76.9)a 
ap<0.001; chi-square test.  bp<0.01; chi-square test.  cp<0.001; Mann-Whitney U test.    
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Table 3.10. Age 38 periodontitis extent and severity (half-mouth measures) by demographic, 
smoking and oral health care variables, and correlations with mean pack years. Standard 
deviation in parentheses. N = 898. 
 Periodontitis extent and severity (half-
mouth) at 38 (SD) 
 Mean % of 
sites with 
4+mm AL 




Demographic characteristics    
Male  
No (N=446, 49.7%) 










Low childhood SES1 
No (N=722, 80.9%) 










Low SES at age 38 
No (N=729, 81.5%) 










Smoking at age 38    
Current smoker 
No (N=666, 74.3%) 










Mean pack years* 0.391b 0.325c 0.425c 
Marijuana weekly or more 
No (N=803, 89.7%) 










Regular Marijuana user2 
No (N=848, 94.2%) 










Oral health care at age 38    
Mean plaque score* 0.274c 0.224c 0.339c 
Plaque score group 
Very low (N=496, 55.7%) 
Low (N=239, 26.9%) 
Moderate (N=90, 10.1%) 

















No (N=591, 65.9%) 











No (N=393, 43.8%) 










*Spearman correlation coefficient. ap<0.001; Mann-Whitney U test.  bp<0.01; Mann-Whitney U test.  cp<0.001; 
Spearman’s rho correlation.  dp<0.001; Kruskal Wallis test.    
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3.3.2 Glycated haemoglobin – covariate associations 
The cross-sectional bivariate associations between the prevalence of prediabetes, diabetes or 
dysglycaemia and mean HbA1c and their covariates were explored using chi-square tests for 
categorical variables (or Fisher’s exact test where sample sizes were small); Mann-Whitney U 
tests for categorical and continuous variables; and Spearman’s correlation coefficient for 
continuous variables.  
 
3.3.2.1 Prediabetes, diabetes or dysglycaemia at ages 26, 32 and 38 
As there were only two individuals with dysglycaemia at age 26 (both had prediabetes, none 
had diabetes) it was not appropriate to conduct statistical testing on associations between the 
prevalence of prediabetes, diabetes or dysglycaemia at 26 and demographic covariates, alcohol 
use or anthropometric covariates (Table 3.11). 
 
By age 32, only one Study member had diabetes and 31 had prediabetes (Table 3.12). 
Statistical testing was not conducted for associations between diabetes at 32 and demographic 
covariates, alcohol use or anthropometric covariates due to insufficient sample size in the 
category for diabetes at age 32. Associations were seen between prediabetes/dysglycaemia and 
the mean number of weeks alcohol was consumed. Study members with prediabetes or 
dysglycaemia were more likely to have higher scores on most anthropometric measures as 
well as being in the high risk groups for these measures. 
 
Statistically significant associations were found between prediabetes/dysglycaemia and sex, 
low SES at 38, smoking, mean scores and high score groups for anthropometric measures 
(Table 3.13). Those with diabetes at 38 reported significantly lower consumption of alcohol 
than healthy participants (whether measured by the mean number of weeks alcohol was 
consumed or the mean number of drinks a week). Those with dysglycaemia reported a lower 
mean number of weeks in which alcohol was consumed than normoglycaemic participants. 
Those with prediabetes, diabetes or dysglycaemia were more likely to have higher mean 
scores on all anthropometric measures as well as being in the high risk groups for these 
measures (with the exception of waist-hip ratio in those with diabetes). 
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Table 3.11. Prevalence of prediabetes, diabetes and dysglycaemia by demographic characteristics, alcohol use and anthropological measures at 26. 
Percentages or standard deviation in parentheses. N = 836.  
 Prevalence at 26 
 Prediabetes*  Diabetes* Dysglycaemia* 












Demographic characteristics       
Male (N=447, 53.5%) 446 (53.5) 1 (50.0) 447 (53.5) 0 (0.0) 446 (53.5) 1 (50.0) 
Low childhood SES1 (N=163, 19.6%) 162 (19.5) 1 (50.0) 163 (19.6) 0 (0.0) 162 (19.5) 1 (50.0) 
Low SES at age 26 (N=217, 27.1%) 216 (27.1) 1 (50.0) 217 (27.1) 0 (0.0) 216 (27.1) 1 (50.0) 
Smoking       
Smoker at 26 (N=327, 39.1%) 326 (39.1) 1 (50.0) 327 (39.1) 0 (0.0) 326 (39.1) 1 (50.0) 
Alcohol use       
Mean number of weeks had alcohol (SD) 34.1 (18.7) 27.0 (35.4) 34.1 (18.8) - 34.1 (18.7) 27.0 (35.4) 
Mean number of drinks a week (SD) 12.6 (15.1) 8.5 (5.0) 12.6 (15.1) - 12.6 (15.1) 8.5 (5.0) 
Anthropometric measures        
Mean weight kg (SD) 74.5 (14.7) 88.9 (1.9) 74.5 (14.7) - 74.5 (14.7) 88.9 (1.9) 
Mean BMI (SD) 25.1 (4.4) 30.7 (3.8) 25.1 (4.4) - 25.1 (4.4) 30.7 (3.8) 
Mean waist circumference mm (SD) 803.3 (99.7) 913.0 (4.2) 803.6 (99.7) - 803.3 (99.7) 913.0 (4.2) 
Mean waist-hip ratio (SD) 0.80 (0.07) 0.82 (0.12) 0.80 (0.07) - 0.80 (0.07) 0.82 (0.12) 
Mean waist-height ratio (SD) 0.47 (0.05) 0.54 (0.04) 0.47 (0.05) - 0.47 (0.05) 0.54 (0.04) 
High BMI group (N=98, 11.8%) 97 (11.7) 1 (50.0) 98 (11.8) 0 (0.0) 97 (11.7) 1 (50.0) 
High WC group (N=58, 7.0%) 57 (6.9) 1 (50.0) 58 (7.0) 0 (0.0) 57 (6.9) 1 (50.0) 
High waist-hip group (N=55, 6.7%) 54 (6.5) 1 (50.0) 55 (6.7) 0 (0.0) 54 (6.5) 1 (50.0) 
High waist-height group (N=190, 23.0%) 188 (22.8) 2 (100.0) 190 (23.0) 0 (0.0) 188 (22.8) 2 (100.0) 
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Table 3.12. Prevalence of prediabetes, diabetes and dysglycaemia by demographic characteristics, alcohol use, exercise (MET hours) and 
anthropological measures at 32. Percentages or standard deviation in parentheses. N = 858.  
 Prevalence at 32 
 Prediabetes  Diabetes* Dysglycaemia 












Demographic characteristics       
Male (N=453, 52.8%) 434 (52.5) 19 (61.3) 452 (52.7) 1 (100.0) 433 (52.4) 20 (62.5) 
Low childhood SES1 (N=170, 19.9%) 162 (19.7) 8 (25.8) 170 (20.0) 0 (0.0) 162 (19.7) 8 (25.0) 
Low SES at age 32 (N=267, 31.2%) 256 (31.0) 11 (35.5) 267 (31.2) 0 (0.0) 256 (31.0) 11 (34.4) 
Smoking       
Smoker at 32 (N=294, 34.3%) 282 (34.1) 12 (38.7) 294 (34.3) 0 (0.0) 282 (34.1) 12 (37.5) 
Alcohol use       
Mean number of weeks had alcohol (SD) 34.0 (19.6) 24.5 (21.0)a 33.7 (19.7) 8.0 (0.0) 34.0 (19.6) 24.0 (20.9)b 
Mean number of drinks a week (SD) 11.7 (15.2) 9.9 (15.1) 11.6 (15.2) 6.0 (0.0) 11.7 (15.2) 9.8 (14.8) 
Exercise        
Mean hours moderate weekly (SD) 6.8 (9.6) 6.2 (6.8) 6.8 (9.5) 1.5 (0.0) 6.9 (9.6) 6.0 (6.7) 
Mean hours hard weekly (SD) 1.6 (5.3) 0.9 (2.3) 1.5 (5.3) 0.0 (0.0) 1.6 (5.3) 0.9 (2.3) 
Mean MET hours weekly (SD) 38.7 (53.6) 31.4 (29.7) 38.5 (52.9) 6.0 (0.0) 38.8 (53.6) 30.6 (29.6) 
Anthropometric measures        
Mean weight kg (SD) 77.6 (16.0) 90.5 (25.3)b 78.0 (16.5) 120.0 (0.0) 77.5 (15.9) 91.4 (25.5)c 
Mean BMI (SD) 26.0 (4.7) 30.2 (8.0)c 26.1 (4.9) 35.0 (0.0) 26.0 (4.7) 30.3 (7.9)c 
Mean waist circumference mm (SD) 840.8 (109.7) 924.9 (165.7)b 843.5 (112.9) 1097.5 (0.0) 840.5 (109.4) 930.3 (165.8)c 
Mean waist-hip ratio (SD) 0.83 (0.07) 0.86 (0.08) 0.83 (0.07) 0.95 (0.0) 0.83 (0.07) 0.86 (0.08)a 
Mean waist-height ratio (SD) 0.49 (0.06) 0.53 (0.09)b 0.49 (0.06) 0.59 (0.0) 0.49 (0.06) 0.54 (0.09)c 
High BMI group (N=147, 17.2%) 135 (16.3) 12 (38.7)d 146 (17.1) 1 (100.0) 134 (16.2) 13 (40.6)e 
High WC group (N=130, 15.2%) 119 (14.4) 11 (35.5)e 129 (15.1) 1 (100.0) 118 (14.3) 12 (37.5)e 
High waist-hip group (N=179, 20.9%) 168 (20.3) 11 (35.5)f 179 (20.8) 1 (100.0) 167 (20.2) 12 (37.5)f 
High waist-height group (N=320, 37.3%) 303 (36.7) 17 (54.8)f 319 (37.3) 1 (100.0) 302 (36.6) 18 (56.3)f 
*Statistical testing not conducted due to insufficient sample size in the category for diabetes at age 32.  ap<0.05; Mann-Whitney U test.  bp<0.01; Mann-Whitney U test.  cp<0.005; 
Mann-Whitney U test.  dp<0.005; chi-square test.  ep<0.005; Fisher’s exact test.  fp<0.05; chi-square test.   
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Table 3.13. Prevalence of prediabetes, diabetes and dysglycaemia by demographics, alcohol use, exercise (MET hours) and anthropological 
measures at 38. Percentages or standard deviation in parentheses. N = 891. 
 Prevalence at 38 
 Prediabetes  Diabetes Dysglycaemia 












Demographic characteristics       
Male (N=449, 50.4%) 350 (47.6) 99 (63.9)a 445 (50.3) 4 (66.7) 346 (47.4) 103 (64.0)a 
Low childhood SES1 (N=173, 19.5%) 138 (18.8) 35 (22.9) 171 (19.4) 2 (33.3) 136 (18.7) 37 (23.3) 
Low SES at age 38 (N=170, 19.2%) 121 (16.5) 49 (31.8)a 169 (19.2) 1 (16.7) 120 (16.5) 50 (31.2)a 
Smoking       
Smoker at 38 (N=237, 26.6%) 176 (23.9) 61 (39.4)a 236 (26.7) 1 (16.7) 175 (24.0) 62 (38.5)a 
Alcohol use       
Mean number of weeks had alcohol (SD) 34.6 (19.9) 31.4 (21.0) 34.3 (20.0) 4.3 (5.3)b 34.9 (19.7) 30.4 (21.2)c 
Mean number of drinks a week (SD) 11.8 (15.6) 14.2 (22.0) 12.3 (16.9) 2.7 (3.2)c 11.9 (15.6) 13.8 (21.7) 
Exercise        
Mean hours moderate weekly (SD) 6.9 (9.9) 8.4 (11.2) 7.2 (10.1) 3.8 (5.4) 6.9 (9.9) 8.2 (11.1) 
Mean hours hard weekly (SD) 3.2 (7.7) 4.9 (11.1) 3.5 (8.4) 0.3 (0.8) 3.3 (7.7) 4.7 (10.9) 
Mean MET hours weekly (SD) 54.3 (70.6) 70.2 (91.4) 57.3 (75.0) 17.7 (26.9)c 54.6 (70.7) 68.3 (90.3) 
Anthropometric measures        
Mean weight kg (SD) 79.6 (16.6) 85.8 (19.1)d 80.5 (16.9) 113.7 (22.2)b 79.4 (16.2) 86.9 (19.8)d 
Mean BMI (SD) 26.9 (5.1) 28.5 (5.7)b 27.1 (5.2) 38.0 (8.5)b 26.8 (5.0) 28.9 (6.1)d 
Mean waist circumference mm (SD) 854.8 (120.3) 905.6 (138.3)d 861.8 (122.9) 1130.9 (162.1)d 852.5 (117.4) 914.1 (145.2)d 
Mean waist-hip ratio (SD) 0.85 (0.08) 0.88 (0.08)d 0.85 (0.08) 0.95 (0.11)c 0.85 (0.08) 0.89 (0.08)d 
Mean waist-height ratio (SD) 0.50 (0.07) 0.52 (0.08)d 0.50 (0.07) 0.65 (0.10)b 0.50 (0.07) 0.53 (0.08)d 
High BMI group (N=214, 24.1%) 161 (21.9) 53 (34.4)e 209 (23.7) 5 (83.3)f 156 (21.4) 58 (36.3)a 
High WC group (N=179, 20.2%) 134 (18.3) 45 (29.2)e 174 (19.7) 5 (83.3)f 129 (17.7) 50 (31.3)a 
High waist-hip group (N=304, 34.4%) 227 (31.1) 77 (50.0)a 301 (34.2) 3 (60.0) 224 (30.9) 80 (50.3)a 
High waist-height group (N=403, 45.4%) 319 (43.5) 84 (54.5)g 397 (45.0) 6 (100.0)h 313 (43.0) 90 (56.3)e 
ap<0.001; chi-square test.  bp<0.005; Mann-Whitney U test.  cp<0.05; Mann-Whitney U test.  dp<0.001; Mann-Whitney U test.  ep<0.005; chi-square test. 
  fp<0.005; Fisher’s exact test.  gp<0.05; chi-square test.   hp<0.01; Fisher’s exact test.   
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3.3.2.2 Mean HbA1c at ages 26, 32 and 38 
Statistically significant associations were found between HbA1c and sex and mean waist 
circumference at ages 32 and 38 (Table 3.14). Associations between HbA1c and smoking, 
mean waist-hip ratio, high BMI risk group, high WC risk group and high waist-height risk 
group were seen at all three ages while associations between HbA1c and the mean number of 
weeks alcohol was consumed, mean weight, mean BMI and mean waist-height ratio were 
found at age 38 only. The mean number of weeks alcohol was consumed at age 38 was 
negatively correlated with mean HbA1c at this age. Correlations with anthropological 
measures were positive. The correlations ranged in value from -0.102 to 0.216 (representing 
shared variances of 1.0% and 4.7% respectively). Low childhood SES was associated with 
mean HbA1c at age 26 only while there were cross-sectional associations between mean 
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Table 3.14. Mean HbA1c by demographic characteristics, smoking and anthropological high 
risk groups, and correlations between mean HbA1c and alcohol use, exercise (MET hours) 
and anthropological measures. Standard deviation in parentheses. N = 836. 
 Mean HbA1c (SD) 
 Age 26 
N = 836 
Age 32 
N = 858 
Age 38 
N = 891 





































Smoking    












Alcohol use    
Mean number of weeks had alcohol*  -0.047 -0.022 -0.102e 
Mean number of drinks a week*  -0.028 -0.001 -0.030 
Exercise     
Mean hours moderate weekly*  - 0.061 0.038 
Mean hours hard weekly*  - -0.023 -0.018 
Mean MET hours weekly*  - 0.049 0.033 
Anthropometric measures     
Mean weight*  0.043 0.064 0.173f 
Mean BMI*  0.012 0.031 0.128f 
Mean waist circumference*  0.053 0.071g 0.183f 
Mean waist-hip ratio*  0.083g 0.098e 0.216f 
Mean waist-height ratio*  0.027 0.048 0.148f 
















































*Spearman correlation coefficient.  ap<0.01; Mann-Whitney U test.  bp<0.001; Mann-Whitney U test.  cp<0.005; 
Mann-Whitney U test.   dp<0.05; Mann-Whitney U test.  ep<0.005; Spearman’s rho correlation.   fp<0.001; 
Spearman’s rho correlation.  gp<0.05; Spearman’s rho correlation. 
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3.3.3 Glycated haemoglobin – Periodontal associations 
The cross-sectional bivariate associations between periodontal experience (prevalence, extent 
and severity of periodontitis) and the prevalence of prediabetes, diabetes or dysglycaemia and 
mean HbA1c were explored using chi-square tests for categorical variables (or Fisher’s exact 
test where sample sizes were small); Mann-Whitney U tests for categorical and continuous 
variables; and Spearman’s correlation coefficient for continuous variables.  
 
3.3.3.1 Age 26 
Statistical testing was not conducted for associations between the prevalence of prediabetes, 
diabetes, and dysglycaemia at age 26 and periodontal experience at 26 due to insufficient 
sample sizes in the categories for prediabetes, diabetes, and dysglycaemia at age 26 (Table 
3.15). Statistically significant associations were found between mean HbA1c and the 
prevalence of all three periodontal case definitions (Tables 3.15). Those with 1+ or 2+ sites 
with 4+mm AL or 1+ sites with 5+mm AL had a higher mean HbA1c at 26 than those without. 
The extent of periodontal disease at age 26 was positively associated with mean HbA1c (Table 
3.16). The correlations ranged in value from 0.097 to 0.120 (representing shared variances of 
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Table 3.15. Mean HbA1c, and prevalence of prediabetes, diabetes and dysglycaemia at 26 by 
periodontitis prevalence (half-mouth measures) at 26. Column percentages or standard 
deviation in parentheses. N = 802. 
 Periodontitis prevalence (half-mouth) at 26 
 1+ sites  
with 4+mm AL 
2+ sites  
with 4+mm AL 
1+ sites  
with 5+mm AL 












HbA1c at 26       
Mean HbA1c (SD) 30.6 (3.1) 31.3 (3.3)a 30.6 (3.1) 31.5 (3.5)b 30.6 (3.1) 32.6 (3.2)c 
Prediabetes (N=2, 0.2%)* 2 (0.3) 0 (0.0) 2 (0.3) 0 (0.0) 2 (0.3) 0 (0.0) 
Diabetes (N=0, 0.0%)* 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Dysglycaemia (N=2, 0.2%)* 2 (0.3) 0 (0.0) 2 (0.3) 0 (0.0) 2 (0.3) 0 (0.0) 
*Statistical testing not conducted due to insufficient sample sizes in the categories for prediabetes, diabetes, and 
dysglycaemia at age 26. 
ap<0.01; Mann-Whitney U test.   bp<0.05; Mann-Whitney U test.   cp<0.005; Mann-Whitney U test.  
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Table 3.16. Correlations between mean HbA1c at 26 and periodontitis extent and severity 
(half-mouth measures) at 26, and prevalence of prediabetes, diabetes and dysglycaemia at 26 
by periodontitis extent and severity (half-mouth measures) at 26. Standard deviation in 
parentheses. N = 802. 
 Periodontitis extent and severity (half-mouth) at 26 
 
Mean % of sites  
with 4+mm AL (SD) 
Mean % of sites  
with 5+mm AL (SD) 
Mean AL  
(SD) 
HbA1c at 26    
Mean HbA1c§ 0.097a 0.120b 0.065 
Prediabetes*  
No (N=800, 99.8%) 











No (N=802, 100.0%) 











No (N=800, 99.8%) 










§Spearman correlation coefficient.  ap<0.01; Spearman’s rho correlation.  bp<0.005; Spearman’s rho correlation.  
*Statistical testing not conducted due to insufficient sample sizes in the categories for prediabetes, diabetes, and 
dysglycaemia at age 26. 
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3.3.3.2 Age 32 
By age 32, one Study member had type 2 diabetes, 30 had prediabetes, and 31 had 
dysglycaemia (Table 3.17). Statistical testing was not conducted for associations between the 
prevalence diabetes at age 32 and periodontal experience at 32 due to insufficient sample sizes 
in the category for diabetes at age 32. Statistically significant associations were found between 
mean HbA1c and the prevalence of all three periodontal case definitions at age 32 (Table 
3.17). Those with 1+ or 2+ sites with 4+mm AL or 1+ sites with 5+mm AL had a higher mean 
HbA1c at this age than those without. The extent of periodontal disease at 32 was positively 
associated with mean HbA1c (Table 3.18). The correlations ranged in value from 0.080 to 
0.113 (representing shared variances of 0.6% and 1.3% respectively). The extent of 
periodontal disease at 32 (as defined by the mean % of sites with 4+mm AL) was associated 
with prediabetes whereby those with prediabetes experienced more extensive disease than 




Table 3.17. Mean HbA1c, and prevalence of prediabetes, diabetes and dysglycaemia at 32 by 
periodontitis prevalence (half-mouth measures) at 32. Column percentages or standard 
deviation in parentheses. N = 824. 
 Periodontitis prevalence (half-mouth) at 32 
 1+ sites  
with 4+mm AL 
2+ sites  
with 4+mm AL 
1+ sites  
with 5+mm AL 












HbA1c at 32       
Mean HbA1c (SD) 33.8 (3.5) 34.7 (3.3)a 33.9 (3.5) 34.8 (3.2)b 33.9 (3.5) 34.9 (3.4)c 
Prediabetes (N=30, 3.6%) 19 (3.0) 11 (5.9) 23 (3.2) 7 (6.7) 25 (3.3) 5 (7.0) 
Diabetes (N=1, 0.1%)* 1 (0.2) 0 (0.0) 1 (0.2) 0 (0.0) 1 (0.1) 0 (0.0) 
Dysglycaemia (N=31, 3.8%) 20 (3.1) 11 (5.9) 24 (3.3) 7 (6.7) 26 (3.5) 5 (7.0) 
ap<0.005; Mann-Whitney U test.   bp<0.01; Mann-Whitney U test.   cp<0.05; Mann-Whitney U test. 
*Statistical testing not conducted due to insufficient sample size in the category for diabetes at age 32. 
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Table 3.18. Correlations between mean HbA1c at 32 and periodontitis extent and severity 
(half-mouth measures) at 32, and prevalence of prediabetes, diabetes and dysglycaemia at 32 
by periodontitis extent and severity (half-mouth measures) at 32. Standard deviation in 
parentheses. N = 824. 
 Periodontitis extent and severity (half-mouth) at 32 
 Mean % of sites  
with 4+mm AL (SD) 
Mean % of sites  
with 5+mm AL (SD) 
Mean AL  
(SD) 
HbA1c at 32    
Mean HbA1c§  0.113a 0.080b 0.051 
Prediabetes  
No (N=794, 96.4%) 











No (N=823, 99.9%) 











No (N=793, 96.2%) 










§Spearman correlation coefficient.  ap<0.005; Spearman’s rho correlation.  bp<0.05; Spearman’s rho correlation.  
cp<0.05; Mann-Whitney U test. 
*Statistical testing not conducted due to insufficient sample size in the category for diabetes at age 32.       
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3.3.3.3 Age 38 
Although there were six individuals with Type 2 diabetes by age 38, only four of them had a 
periodontal examination (Table 3.19). Statistically significant associations were found 
between the prevalence of periodontal disease at 38 and the prevalence of prediabetes and 
dysglycaemia whereby those with 2+ sites with 4+mm AL had a greater prevalence of both 
prediabetes and dysglycaemia (Table 3.19). The extent of periodontal disease at 32 (as defined 
by the mean % of sites with 4+mm AL) and mean AL were positively associated with mean 
HbA1c. The correlations ranged in value from 0.070 to 0.071 (representing shared variances 
of 0.5% and 0.5% respectively). Study members with prediabetes had a higher extent of 4+mm 
AL, and higher a mean AL, than those without diabetes; and those with dysglycaemia had a 




Table 3.19. Mean HbA1c, and prevalence of prediabetes, diabetes and dysglycaemia at 38 by 
periodontitis prevalence (half-mouth measures) at 38. Column percentages or standard 
deviation in parentheses. N = 849. 
 Periodontitis prevalence (half-mouth) at 38 
 1+ sites  
with 4+mm AL 
2+ sites  
with 4+mm AL 
1+ sites  
with 5+mm AL 












HbA1c at 38       
Mean HbA1c (SD) 35.1 (4.3) 35.9 (6.3) 35.2 (4.1) 36.1 (7.4) 35.3 (4.2) 36.0 (8.0) 
Prediabetes (N=148, 17.4%) 88 (15.9) 60 (20.3) 104 (15.9) 44 (22.4)a 116 (16.7) 32 (20.9) 
Diabetes (N=4, 0.5%) 3 (0.5) 1 (0.3) 3 (0.5) 1 (0.5) 3 (0.4) 1 (0.7) 
Dysglycaemia (N=152, 17.9%) 91 (16.5) 61 (20.6) 107 (16.4) 45 (23.0)a 119 (17.1) 33 (21.6) 
ap<0.05; chi-square test 
 
.  
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Table 3.20. Correlations between mean HbA1c at 38 and periodontitis extent and severity 
(half-mouth measures) at 38, and prevalence of prediabetes, diabetes and dysglycaemia at 38 
by periodontitis extent and severity (half-mouth measures) at 38. Standard deviation in 
parentheses. N = 849. 
 Periodontitis extent and severity (half-mouth) at 38 
 Mean % of sites  
with 4+mm AL  
(SD) 
Mean % of sites  
with 5+mm AL  
(SD) 
Mean AL  
(SD) 
HbA1c at 38    
Mean HbA1c*  0.070a 0.026 0.071a 
Prediabetes  
No (N=701, 82.6%) 











No (N=845, 99.5%) 











No (N=697, 82.1%) 










*Spearman correlation coefficient. ap<0.05; Spearman’s rho correlation.  bp<0.05; Mann-Whitney U test.  
cp<0.005; Mann-Whitney U test.    
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3.4 Longitudinal bivariate associations  
3.4.1 Periodontal - Glycated haemoglobin associations 
 
3.4.1.1 Periodontal experience at 26 - Glycated haemoglobin at 32  
Due to there being no individuals in the category for diabetes at age 32 statistical testing was 
not carried out for associations between diabetes at age 32 and periodontal experience at 26. 
No associations were found between periodontitis prevalence, extent or severity at age 26 and 




Table 3.21. Mean HbA1c, and prevalence of prediabetes, diabetes and dysglycaemia at 32 by 
periodontitis prevalence (half-mouth measures) at 26. Column percentages or standard 
deviation in parentheses. N = 811. 
 Periodontitis prevalence (half-mouth) at 26 
 1+ sites  
with 4+mm AL 
2+ sites  
with 4+mm AL 
1+ sites  
with 5+mm AL 












HbA1c at 32       
Mean HbA1c (SD) 33.9 (3.4) 34.1 (3.0) 33.9 (3.3) 34.3 (2.8) 33.9 (3.3) 34.8 (2.9) 
Prediabetes (N=29, 3.6%) 25 (3.8) 4 (2.6) 27 (3.6) 2 (3.0) 7 (3.5) 2 (6.5) 
Diabetes (N=0, 0.0%)* 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Dysglycaemia (N=29, 3.6%) 25 (3.8) 4 (2.6) 27 (3.6) 2 (3.0) 7 (3.5) 2 (6.5) 
*Statistical testing not conducted due to no individuals in the category for diabetes at age 26.        
 
 
                                                                                                                                                             Dara Shearer 
95 
 
Table 3.22. Correlations between mean HbA1c at 32 and periodontitis extent and severity 
(half-mouth measures) at 26, and prevalence of prediabetes, diabetes and dysglycaemia at 32 
by periodontitis extent and severity (half-mouth measures) at 26. Standard deviation in 
parentheses. N = 811. 
 Periodontitis extent and severity (half-mouth) at 26 
 Mean % of sites  
with 4+mm AL  
(SD) 
Mean % of sites  
with 5+mm AL  
(SD) 
Mean AL  
(SD) 
HbA1c at 32    
Mean HbA1c§  0.028 0.053 0.043 
Prediabetes  
No (N=782, 96.4%) 











No (N=811, 100.0%) 











No (N=782, 96.4%) 










§Spearman correlation coefficient.   










3.4.1.2 Periodontal experience at 26 - Glycated haemoglobin at 38 
Statistically significant associations were found between the prevalence of periodontal disease 
at 26 and mean HbA1c at 38 whereby those with 1+ sites with 5+mm AL at 26 had a higher 
mean HbA1c at 38 than those without 1+ sites with 5+mm AL (Table 3.23). The extent of 
periodontal disease at 26 (as defined by the mean % of sites with 5+mm AL) was positively 
associated with mean HbA1c at 38 (Table 3.24). The correlation 0.080 represented a shared 
variance of 0.6%. Study members who had prediabetes at 38 had a higher mean AL at 26 than 
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Table 3.23. Mean HbA1c, and prevalence of prediabetes, diabetes and dysglycaemia at 38 by 
periodontitis prevalence (half-mouth measures) at 26. Column percentages or standard deviation in 
parentheses. N = 839. 
 Periodontitis prevalence (half-mouth) at 26 
 1+ sites  
with 4+mm AL 
2+ sites  
with 4+mm AL 
1+ sites  
with 5+mm AL 












HbA1c at 38       
Mean HbA1c (SD) 35.5 (6.0) 35.6 (3.3) 35.5 (5.7) 36.0 (3.5) 35.5 (5.7) 36.8 (3.1)a 
Prediabetes (N=145, 17.3%) 116 (16.9) 29 (18.8) 132 (17.1) 13 (19.1) 139 (17.2) 6 (20.0) 
Diabetes (N=6, 0.7%) 6 (0.9) 0 (0.0) 6 (0.8) 0 (0.0) 6 (0.7) 0 (0.0) 
Dysglycaemia (N=151, 18.0%) 122 (17.8) 29 (18.8) 138 (17.9) 13 (19.1) 145 (17.9) 6 (20.0) 






Table 3.24. Correlations between mean HbA1c at 38 and periodontitis extent and severity 
(half-mouth measures) at 26, and prevalence of prediabetes, diabetes and dysglycaemia at 38 
by periodontitis extent and severity (half-mouth measures) at 26. Standard deviation in 
parentheses. N = 839. 
 Periodontitis extent and severity (half-mouth) at 26 
 Mean % of sites  
with 4+mm AL  
(SD) 
Mean % of sites  
with 5+mm AL  
(SD) 
Mean AL  
(SD) 
HbA1c at 38    
Mean HbA1c*  0.052 0.080a 0.057 
Prediabetes  
No (N=694, 82.7%) 











No (N=833, 99.3%) 











No (N=688, 82.0%) 










*Spearman correlation coefficient.  ap<0.05; Spearman’s rho correlation.  bp<0.05; Mann-Whitney U test. 
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3.4.1.3 Periodontal experience at 32 - Glycated haemoglobin at 38 
Statistically significant associations were found between the prevalence of periodontal disease 
at 32 and mean HbA1c at 38, whereby those with 1+ sites with 4+mm AL at 32 had a higher 
mean HbA1c at 38 than those without 1+ sites with 4+mm AL (Table 3.25). In addition, those 
with 1+ sites with 4+mm AL at 32 had a greater prevalence of dysglycaemia at 38 than those 
who were periodontally healthy at 32. The extent of periodontal disease (as defined by the 
mean % of sites with 4+mm AL) and mean AL at 32 were positively associated with mean 
HbA1c at 38 (Table 3.26). The correlations ranged in value from 0.072 to 0.080 (representing 
shared variances of 0.5% and 0.6% respectively). Participants with prediabetes or 
dysglycaemia at 38 had a higher mean % of sites with 4+mm AL and a higher mean AL at 32 





Table 3.25. Mean HbA1c, and prevalence of prediabetes, diabetes and dysglycaemia at 38 by 
periodontitis prevalence (half-mouth measures) at 32. Column percentages or standard 
deviation in parentheses. N = 844. 
 Periodontitis prevalence (half-mouth) at 32 
 1+ sites  
with 4+mm AL 
2+ sites  
with 4+mm AL 
1+ sites  
with 5+mm AL 












HbA1c at 38       
Mean HbA1c (SD) 35.1 (3.9) 36.8 (9.3)a 35.4 (5.6) 36.1 (5.5) 35.4 (4.8) 36.6 (11.0) 
Prediabetes (N=145, 17.2%) 104 (15.8) 41 (21.9) 121 (16.5) 24 (21.8) 133 (17.2) 12 (16.7) 
Diabetes (N=6, 0.7%) 3 (0.5) 3 (1.6) 5 (0.7) 1 (0.9) 5 (0.6) 1 (1.4) 
Dysglycaemia (N=151, 17.9%) 107 (16.3) 44 (23.5)b 126 (17.2) 25 (22.7) 138 (17.9) 13 (18.1) 
ap<0.05; Mann-Whitney U test.   bp<0.05; chi-square test.   
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Table 3.26. Correlations between mean HbA1c at 38 and periodontitis extent and severity 
(half-mouth measures) at 32, and prevalence of prediabetes, diabetes and dysglycaemia at 38 
by periodontitis extent and severity (half-mouth measures) at 32. Standard deviation in 
parentheses. N = 844. 
 Periodontitis extent and severity (half-mouth) at 32 
 Mean % of sites  
with 4+mm AL  
(SD) 
Mean % of sites  
with 5+mm AL  
(SD) 
Mean AL  
(SD) 
HbA1c at 38    
Mean HbA1c*  0.080a 0.014 0.072a 
Prediabetes  
No (N=699, 82.8%) 











No (N=838, 99.3%) 











No (N=693, 82.1%) 










*Spearman correlation coefficient.   ap<0.05; Spearman’s rho correlation.  bp<0.05; Mann-Whitney U test.    
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3.4.2 Glycated haemoglobin – Periodontal experience associations 
3.4.2.1 Glycated haemoglobin at 26 - Periodontal experience at 32  
Statistically significant associations were found between the prevalence of periodontal disease 
at 32 and mean HbA1c at 26 whereby those with 1+ or 2+ sites with 4+mm AL at 32 had a 
higher mean HbA1c at 26 than those without (Table 3.27). In addition, positive correlations 
were found between mean HbA1c at 26 and the extent of periodontal disease (as defined by 
the mean % of sites with 4+mm AL) and mean AL at 32. The correlations ranged in value 
from 0.041 to 0.141 (representing shared variances of 0.2% and 2.0% respectively). Statistical 
testing was not conducted for associations between the prevalence of diabetes at 26 and 
periodontal experience at 32 due to insufficient sample size in the category for diabetes at age 
26 (Table 3.28). No associations were seen between the prevalence of prediabetes or 





Table 3.27. Periodontitis prevalence (half-mouth measures) at 32 by mean HbA1c at 26, 
and correlations between mean HbA1c at 26 and periodontitis extent and severity (half-
mouth measures) at 32. Standard deviation in parentheses. N =788. 
 Mean HbA1c at 26 (SD) 
Periodontitis prevalence at 32  
1+ sites with 4+mm AL  
No (N = 620, 78.7%) 




2+ sites with 4+mm AL  
No (N = 692, 87.8%) 




1+ sites with 5+mm AL  
No (N=725, 92.0%) 




Periodontitis extent at 32  
Mean % of sites with 4+mm AL*  0.141c 
Mean % of sites with 5+mm AL*  0.041 
Periodontitis severity at 32  
Mean AL*  0.109d 
*Spearman correlation coefficient.  ap<0.001; Mann-Whitney U test.   bp<0.005; Mann-Whitney U test.   
cp<0.001; Spearman’s rho correlation.  cp<0.001; Spearman’s rho correlation. 
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Table 3.28. Periodontitis prevalence, extent and severity at 32 (half-mouth measures) by prevalence of prediabetes, diabetes and dysglycaemia at 26. 
Column percentages or standard deviation in parentheses. N = 788. 
 Prediabetes at 26* Diabetes at 26* Dysglycaemia at 26* 












Periodontitis prevalence at 32       
1+ sites with 4+mm AL (N=168, 21.3%) 167 (21.2) 1 (50.0) 168 (21.3) - 167 (21.2) 1 (50.0) 
2+ sites with 4+mm AL (N=96, 12.2%) 96 (12.2) 0 (0.0) 96 (12.2) - 96 (12.2) 0 (0.0) 
1+ sites with 5+mm AL (N=63, 8.0%) 63 (8.0) 0 (0.0) 63 (8.0) - 63 (8.0) 0 (0.0) 
Periodontitis extent at 32       
Mean % of sites with 4+mm AL (SD) 1.9 (5.8) 1.3 (1.8) 1.8 (5.8) - 1.9 (5.8) 1.3 (1.8) 
Mean % of sites with 5+mm AL (SD) 0.5 (2.8) 0 (0.0) 0.5 (2.8) - 0.5 (2.8) 0 (0.0) 
Periodontitis severity at 32       
Mean AL (SD) 1.41 (0.43) 1.47 (0.09) 1.41 (0.43) - 1.41 (0.43) 1.47 (0.09) 
*Statistical testing not conducted due to insufficient sample sizes in the categories for prediabetes, diabetes, and dysglycaemia at age 26.    
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3.4.2.2 Glycated haemoglobin at 26 - Periodontal experience at 38 
Statistically significant associations were found between the prevalence of periodontal disease 
at 38 and mean HbA1c at 26 whereby those with 2+ sites with 4+mm AL at 38 had a higher 
mean HbA1c at 26 than those without (Table 3.29). In addition, positive correlations were 
found between mean HbA1c at 26 and the extent of periodontal disease (as defined by the 
mean % of sites with 4+mm AL) and mean AL at 38. The correlations ranged in value from 
0.062 to 0.093 (representing shared variances of 0.4% and 0.9% respectively). 
 
Statistical testing was not conducted for the prevalence of prediabetes, diabetes or 
dysglycaemia at 26 and periodontal experience at 38 due to insufficient sample sizes in the 





Table 3.29. Periodontitis prevalence (half-mouth measures) at 38 by mean HbA1c at 26, and 
correlations between mean HbA1c at 26 and periodontitis extent and severity (half-mouth 
measures) at 38. Standard deviation in parentheses. N = 773. 
 Mean HbA1c at 26 (SD) 
Periodontitis prevalence at 38  
1+ sites with 4+mm AL  
No (N = 506, 65.5%) 




2+ sites with 4+mm AL  
No (N = 597, 77.2%) 




1+ sites with 5+mm AL  
No (N=640, 82.8%) 




Periodontitis extent at 38  
Mean % of sites with 4+mm AL*  0.092b 
Mean % of sites with 5+mm AL*  0.062 
Periodontitis severity at 38  
Mean AL*  0.093c 
*Spearman correlation coefficient.  ap<0.01; Mann-Whitney U test.   bp<0.05; Spearman’s rho correlation.  
cp<0.01; Spearman’s rho correlation 
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Table 3.30. Periodontitis prevalence, extent and severity at 38 (half-mouth measures) by prevalence of prediabetes, diabetes and dysglycaemia at 26. 
Column percentages or standard deviation in parentheses. N = 773. 
 Prediabetes at 26* Diabetes at 26* Dysglycaemia at 26* 












Periodontitis prevalence at 38       
1+ sites with 4+mm AL (N=267, 34.5%) 266 (34.5) 1 (50.0) 267 (34.5) - 266 (34.5) 1 (50.0) 
2+ sites with 4+mm AL (N=176, 22.8%) 175 (22.7) 1 (50.0) 176 (22.8) - 175 (22.7) 1 (50.0) 
1+ sites with 5+mm AL (N=133, 17.2%) 133 (17.3) 0 (0.0) 133 (17.2) - 133 (17.3) 0 (0.0) 
Periodontitis extent at 38       
Mean % of sites with 4+mm AL (SD) 5.0 (13.3) 3.8 (5.4) 5.0 (13.3) - 5.0 (13.3) 3.8 (5.4) 
Mean % of sites with 5+mm AL (SD) 2.3 (9.6) 0 (0.0) 2.3 (9.6) - 2.3 (9.6) 0 (0.0) 
Periodontitis severity at 38       
Mean AL (SD) 1.60 (0.74) 1.47 (0.43) 1.60 (0.74) - 1.60 (0.74) 1.47 (0.43) 
*Statistical testing not conducted due to insufficient sample sizes in the categories for prediabetes, diabetes, and dysglycaemia at age 26.   
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3.4.2.3 Glycated haemoglobin at 32 - Periodontal experience at 38  
No associations were seen between periodontal experience at 38 and mean HbA1c at 32 
(Table 3.31). Statistical testing was not conducted for associations between periodontal 
experience at 38 and the prevalence of diabetes at 32 due to insufficient sample size in the 
category for diabetes at age 32 (Table 3.32). No associations were seen between periodontal 




Table 3.31. Periodontitis prevalence (half-mouth measures) at 38 by mean HbA1c at 32, and 
correlations between mean HbA1c at 32 and periodontitis extent and severity (half-mouth 
measures) at 38. Standard deviation in parentheses. N = 799. 
 Mean HbA1c at 32 (SD) 
Periodontitis prevalence at 38  
1+ sites with 4+mm AL  
No (N = 521, 65.2%) 




2+ sites with 4+mm AL  
No (N = 614, 76.8%) 




1+ sites with 5+mm AL  
No (N=657, 82.2%) 




Periodontitis extent at 38  
Mean % of sites with 4+mm AL*  0.054 
Mean % of sites with 5+mm AL*  0.044 
Periodontitis severity at 38  
Mean AL*  0.038 
*Spearman correlation coefficient. 
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Table 3.32. Periodontitis prevalence, extent and severity (half-mouth measures) at 38 by prevalence of prediabetes, diabetes and dysglycaemia at 32. 
Column percentages or standard deviation in parentheses. N = 799. 
 Prediabetes at 32 Diabetes at 32* Dysglycaemia at 32 












Periodontitis prevalence at 38       
1+ sites with 4+mm AL (N=278, 34.8%) 267 (34.5) 11 (42.3) 277 (34.7) 1 (100.0) 266 (34.5) 12 (44.4) 
2+ sites with 4+mm AL (N=185, 23.2%) 176 (22.8) 9 (34.6) 184 (23.1) 1 (100.0) 175 (22.7) 10 (37.0) 
1+ sites with 5+mm AL (N=142, 17.8%) 135 (17.5) 7 (26.9) 142 (17.8) 0 (0.0) 135 (17.5) 7 (25.9) 
Periodontitis extent at 32       
Mean % of sites with 4+mm AL (SD) 5.0 (13.1) 8.5 (20.3) 5.1 (13.4) 4.8 (0.0) 5.0 (13.1) 8.4 (19.9) 
Mean % of sites with 5+mm AL (SD) 2.2 (8.9) 5.7 (19.8) 2.3 (9.5) 0 (0.0) 2.2 (8.9) 5.5 (19.5) 
Periodontitis severity at 32       
Mean AL (SD) 1.60 (0.71) 1.89 (1.46) 1.61 (0.75) 1.60 (0.0) 1.60 (0.71) 1.88 (1.43) 
*Statistical testing not conducted due to insufficient sample size in the category for diabetes at age 32. 
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3.5 Group based trajectory modeling analyses 
3.5.1 Identification of periodontal GBTM groups 
The identification of periodontal GBTM groups included 924 Study members who had two or 
more periodontal assessments over the 12 years. The zero-inflated Poisson (ZIP) model was 
used to model the extent of periodontal disease (as measured by the mean % sites with 4+mm 
AL).  
 
GBTM began with the choice of the number of groups to include in the model. There were a 
large number of participants with zero % sites with 4+mm AL at each of the three ages. To 
accommodate this group, the models in the search included one group that was specified to 
follow a zero-order trajectory (that is, constant over the twelve years). It was hypothesised the 
other groups would follow a quadratic trajectory (although lower order trajectories were also 
tested). 
 
GBTM analyses using the mean % sites with 4+mm AL measures at ages 26, 32 and 38 started 
with 2-group models, testing zero-order, linear and quadratic specifications for the trajectory 
shapes (Table 3.33). Extra groups were added (3-, 4- and 5-groups) until the best fitting model 
was established. Some of the 5-group models had an insufficient number of people in one 
group, and would not allow the calculation of standard errors for the coefficients due to the 
variance matrix being non-symmetric or highly singular. A 5-group model with one zero-order 
and four quadratic trajectories (0 2 2 2 2) was found to have the highest (least negative) BIC 
whether calculated for the total number of participants or total number of observations (Table 
3.33). However, the 4-group model with one zero-order and three quadratic trajectories (0 2 2 
2) was found to capture the essential features of the data in a more parsimonious, 
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(N = 924) 
BIC3 
(N = 2685) 
2 0 0 -8309.26 -8310.86 
2 0 1 -6971.86 -6974.00 
2 0 2 -6975.05 -6977.71 
3 0 0 0 -7195.13 -7197.80 
3 0 1 1 -5728.34 -5732.07 
3 0 1 2 -5731.19 -5735.46 
3 0 2 1 -5680.38 -5684.65 
3 0 2 2 -5680.44 -5685.24 
4 0 0 0 0 -7201.96 -5205.70 
4 0 1 1 1 -4992.66 -4997.99 
4 0 1 1 2 -4994.76 -5000.63 
4 0 1 2 2 -4991.18 -4997.58 
4 0 2 2 2 -4968.20 -4975.13 
5 0 1 1 1 1* -5002.90 -5009.83 
5 0 1 1 1 2* -5005.01 -5012.47 
5 0 1 1 2 2* -5072.31 -5080.31 
5 0 1 2 2 2 -4978.44 -4986.98 
5 0 2 2 2 2 -4698.66 -4707.73 
1Trajectory shapes; 0 = zero-order; 1 = linear; 2 = quadratic. 
2BIC = Bayesian information criterion (for the total number of participants) 
3BIC = Bayesian information criterion (for the total number of observations) 
*Variance matrix is nonsymmetric or highly singular. The regression results display coefficient estimates but no 
standard errors for any of the coefficients. It is generally due to one or more of the groups having a very small 
proportion of the observations. 
 
The model had an adequate proportion and sample number in each group: “Very low” 54.0%, 
“Low” 31.3%, “Medium” 11.3%, and “High” 3.5% (Figure 3.4). The matrix of the observed 
and predicted values showed that the model fitted the data well and confidence intervals were 
narrow for each group (Table 3.34). The average posterior probability (AvePP) value was 0.98 
or more for each group, well above the recommended minimum AvePP value of 0.70 (Table 
3.35). The odds of correct classification based on the posterior probabilities of group 
membership were well over 5.0 for all four groups, indicating the model had good assignment 
accuracy (Table 3.35). Finally, there was very close correspondence between each group’s 
estimated probability and the proportion of Study members assigned to it according to the 
maximum posterior probability assignment rule (Table 3.36) 
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Fig 3.4. Periodontal trajectory groups 
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Table 3.34. Matrix of the observed and predicted values for periodontal (mean % sites with 4+mm AL) GBTM groups 
 Periodontal trajectory group 
 Very low Low Medium High 
Age 26 
Observed values 
Predicted values (95% CI) 
 
0.00 
0.00 (0.00, 0.00) 
 
1.30  
1.30 (1.15, 1.45) 
 
3.18 
3.18 (2.78, 3.59) 
 
8.15 
8.15 (7.06, 9.23) 
Age 32 
Observed values 
Predicted values (95% CI) 
 
0.00 
0.00 (0.00, 0.00) 
 
1.23 
1.23 (1.10, 1.37) 
 
6.54 
6.54 (5.94, 7.14) 
 
25.92 
25.92 (23.87, 27.96) 
Age 38 
Observed values 
Predicted values (95% CI) 
 
0.00 
0.00 (0.00, 0.00) 
 
2.89  
2.89 (2.66, 3.13) 
 
19.56 
19.56 (18.35, 20.77) 
 
64.39 
64.39 (60.45, 68.33) 
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Table 3.35. Average posterior probability (AvePP) value and odds of correct classification for 
periodontal (mean % sites with 4+mm AL) GBTM groups 
 
Mean % sites with 4+mm AL 
 Trajectory group 
 Very 
low Low Medium High 
 
Average posterior probability value  





















Table 3.36. Periodontal trajectory groups’ estimated probability and the proportion of Study 





Proportion assigned to group 
according to the maximum posterior 
probability assignment rule 
Very low 53.8 54.0 
Low 31.5 31.3 
Medium 11.3 11.3 
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3.5.2 Natural history of periodontal disease 
The “Very low” group experienced no disease (at least as measured by the extent of sites with 
4+mm AL). The “Low” group experienced minimal disease over the 12 years going from a 
mean % of 1.3 sites with 4+mm AL at 26, dropping slightly to a mean % of 1.2 sites at 32 
before rising to a mean % of 2.9 sites at 38 (Figure 3.4). The “Medium” group showed a rise 
between 26 and 32 going from a mean % of 3.2 sites to a mean % of 6.5 sites before rising 
sharply to a mean % of 19.6 sites with 4+mm AL at 38. The “High” group showed the greatest 
increase of all, going from a mean % of 8.2 sites with 4+mm AL to a mean % of 25.9 at 32 
followed by a very marked increase to a mean % of 64.4 sites with 4+mm AL at 38. The four 
trajectory groups had statistically significantly different mean % sites with 4+mm AL at all 
ages (Table 3.34). The “Very low” group included participants with zero % sites with 4+mm 
AL at all three ages, and thus had no changes over the twelve years. The “Low” group had no 
difference in the mean % sites with 4+mm AL between ages 26 and 32, but a significant 
difference was seen between ages 32 and 38. Both the “Medium” and “High” groups had 
different mean % sites with 4+mm AL between 26 and 32, and between 32 and 38. 
 
Wald tests found the intercepts of all four groups to be significantly different from one other 
(χ² = 49.0, p < 0.001). This was also true of the three groups with linear functions (χ² = 57.9, p 
< 0.001), and quadratic functions (χ² = 50.2, p < 0.001). The “Very low” group had neither 
linear nor quadratic functions, and therefore had no slope. 
 
The prevalence of low SES, prevalence of periodontal disease, current smoking, regular 
marijuana use, high plaque score and episodic use of dental services at all three ages showed a 
clear upward gradient across the four groups from “Very low” to “High” (Tables 3.37 and 
3.38). The gradient for male sex was less clear across the groups although the prevalence for 
the “High” group was one-third higher again than for the “Very low” group. A very clear 
upward gradient was seen across the groups from “Very low” to “High” for the mean % sites 
with 1+ sites AL at 26, 32 and 38. At all three ages, Study members in the “High” periodontal 
trajectory group had a higher mean HbA1c than those in the “Very low” and “Low” groups 
with a clear upward gradient across the groups at ages 26 and 32, and a less clear gradient at 
38. The prevalence of dysglycaemia at 32 and 38 showed a clear upward gradient across the 
four groups from “Very low” to “High” (although the association at 32 did not reach statistical 
significance). 
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Table 3.37. Periodontal trajectory group by demographic characteristics, periodontal and HbA1c variables. Percentages or standard deviation in 
parentheses. N = 924. 
 Periodontal trajectory group 
 Very low (N=499) Low (N=289) Medium (N=104) High (N=32) 
Demographic characteristics     
Male (N=469, 50.8%) 223 (44.7) 169 (58.5) 58 (55.8) 19 (59.4)a 
Low SES at 26 (N=228, 26.0%) 96 (19.7) 81 (30.0) 37 (40.7) 14 (51.9)b 
Low SES at 32 (N=278, 30.2%) 117 (23.5) 95 (33.1) 47 (45.2) 19 (61.3)b 
Low SES at 38 (N=175, 19.4%) 51 (10.4) 62 (22.2) 44 (43.1) 18 (56.3)b 
Periodontal measures     
1+ sites with 4+mm AL at 26 (N=168, 18.7%) 0 (0.0) 97 (34.3) 51 (53.7) 20 (62.5)c 
1+ sites with 4+mm AL at 32 (N=200, 22.1%) 0 (0.0) 96 (33.8) 74 (72.6) 30 (96.8)c 
1+ sites with 4+mm AL at 38 (N=307, 34.9%) 0 (0.0) 182 (66.7) 98 (98.0) 27 (100.0)c 
2+ sites with 4+mm AL at 26 (N=73, 8.1%) 0 (0.0) 27 (9.5) 33 (34.7) 13 (40.6)c 
2+ sites with 4+mm AL at 32 (N=114, 12.6%) 0 (0.0) 31 (10.9) 53 (52.0) 30 (96.8)c 
2+ sites with 4+mm AL at 38 (N=203, 23.1%) 0 (0.0) 80 (29.3) 96 (96.0) 27 (100.0)c 
Mean % sites with 1+ sites with 4+mm AL at 26 (SD) 0 (0.0) 1.3 (2.3) 3.3 (4.4) 8.0 (10.8)d 
Mean % sites with 1+ sites with 4+mm AL at 32 (SD) 0 (0.0) 1.3 (2.0) 6.5 (7.1) 26.0 (17.6)d 
Mean % sites with 1+ sites with 4+mm AL at 38 (SD) 0 (0.0) 2.9 (2.9) 19.5 (10.3) 63.9 (23.2)d 
HbA1c measures     
HbA1c at 26 (SD) 30.4 (3.1) 30.7 (3.1) 31.7 (3.0) 31.9 (3.0)d 
HbA1c at 32 (SD) 33.7 (3.6) 34.2 (3.9) 34.5 (3.2) 35.6 (2.7)e 
HbA1c at 38 (SD) 35.0 (4.1) 35.9 (5.9) 36.6 (9.8) 36.1 (3.9)f 
Dysglycaemia at 26 (N=2, 0.3%) 1 (0.2) 1 (0.4) 0 (0.0) 0 (0.0) 
Dysglycaemia at 32 (N=30, 3.6%) 14 (3.2) 9 (3.5) 5 (5.4) 2 (7.1) 
Dysglycaemia at 38 (N=153, 17.9%) 73 (15.7) 47 (17.7) 23 (24.0) 10 (33.3)g 
ap<0.005; chi-square test.   bp<0.001; chi-square test.   cp<0.001; Fisher’s exact test.   dp<0.001; Kruskal–Wallis test.   ep<0.01; Kruskal–Wallis test.  fp<0.05; Kruskal–Wallis test.   
gp<0.05; chi-square test.    
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Table 3.38. Periodontal trajectory group by smoking and oral health care and variables. Percentages in parentheses. N = 924. 
 Periodontal trajectory group 
 Very low (N=499) Low (N=289) Medium (N=104) High (N=32) 
Smoking      
Current smoker at 26 (N=364, 39.5%) 139 (27.9) 123 (42.6) 75 (73.5) 27 (84.4)a 
Current smoker at 32 (N=303, 32.9%) 100 (20.0) 107 (37.2) 70 (67.3) 26 (83.9)a 
Current smoker at 38 (N=234, 25.8%) 66 (13.5) 85 (30.3) 62 (60.2) 21 (65.6)a 
Regular Marijuana user1 at 26 (N=75, 8.3%) 18 (3.7) 27 (9.5) 20 (19.6) 10 (31.3)a 
Regular Marijuana user1 at 32 (N=80, 8.7%) 21 (4.2) 26 (9.1) 23 (22.1) 10 (32.3)a 
Regular Marijuana user1 at 38 (N=53, 5.9%) 15 (3.1) 11 (3.9) 16 (15.5) 11 (34.4)a 
Oral health care      
High plaque score group at 26 (N=83, 9.2%) 25 (5.1) 36 (12.7) 13 (13.7) 9 (29.0)a 
High plaque score group at 32 (N=84, 9.3%) 22 (4.5) 27 (9.5) 20 (19.8) 15 (50.0)a 
High plaque score group at 38 (N=62, 7.1%) 17 (3.5) 21 (7.7) 15 (15.3) 9 (36.0)a 
Episodic attender at 26 (N=484, 53.1%) 235 (47.7) 152 (53.2) 69 (69.7) 28 (87.5)a 
Episodic attender at 32 (N=484, 52.7%) 225 (45.3) 158 (55.1) 73 (70.9) 28 (90.3)a 
Episodic attender at 38 (N=512, 56.5%) 233 (47.5) 173 (61.6) 77 (74.8) 29 (90.6)a 
ap<0.001; chi-square test.   
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3.5.2.1 Time-invariant predictors of periodontal group membership 
The first generalisation of the GBTM model linked time-invariant (baseline) individual 
characteristics and risk factors to the probability of periodontal group membership with the 
associations between each of these baseline characteristics and the probability of group 
membership being estimated simultaneously with the estimation of the trajectories themselves 
(Table 3.39).  
 
Model 1 examined associations with the baseline demographic factors sex and SES at 26. 
Being male, and being of low SES at 26, increased the odds ratio (OR) of being in a trajectory 
group other than the “Very low” reference group (Table 3.39). The addition of these factors to 
the model raised the BIC from -4968.20 for the ‘empty’ model to -4444.39. 
 
Model 2 added tobacco smoking and regular marijuana use at 26 to Model 1 (Table 3.39).  The 
OR for males of being in the “High” trajectory group was reduced slightly and was no longer 
statistically significant. The OR for those of low SES at 26 of being in a trajectory group other 
than the “Very low” was reduced, and the OR for the “Low” group was no longer statistically 
significant. Strong associations were seen between smoking at 26 and the OR of being in the 
“Low”, “Medium” and “High” groups, and a very clear upward gradient was seen across the 
groups from “Very low” to “High”. Associations were also seen for being a regular marijuana 
user at 26 and RR of Medium” and “High” group membership. The addition of the baseline 
smoking factors again raised the BIC. 
 
Model 3 added oral health care factors, high plaque score group and episodic attendance, to 
Model 2 (Table 3.39). In this model, the OR for those of low SES at 26 of being in the 
“Medium” group, and the OR for regular marijuana users of being in the “High” group, were 
no longer statistically significant. However, strong associations were still seen between 
smoking at 26 and the odds of being in the “Low”, “Medium” and “High” groups, with a very 
clear upward gradient seen across the groups. Study members in the high plaque score group 
had a higher OR of being in the “Low” and “Medium” groups while those who were episodic 
attenders had a higher OR of being in the “High” group only. It is worth noting that, in the 
“High” trajectory group, there were only seven individuals who were regular marijuana users 
and six who were in the high plaque score group, so a lack of statistical power may have led to 
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a Type 2 error for this group. The addition of the baseline oral health care factors raised the 
BIC to -4277.73. 
 
Wald tests were conducted to test the equality of the time-invariant factors’ estimates across 
the trajectories. Only smoking showed a differential effect on the trajectory groups (χ² = 18.6, 
p < 0.001). The “Low” and “Medium” groups differed from each other (χ² = 13.5, p < 0.001) 
as did the “Low” and “High” groups (χ² = 6.9, p < 0.01). The effect of smoking at 26 on the 
“Medium” and “High” groups did not differ.   
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Table 3.39. Adjusted odds ratios for periodontal trajectory group membership 
 
Periodontal trajectory group membership OR (CI) 
 
 Very Low Low Medium High BIC  
Model 1  
Male 





1.88 (1.38, 2.56) 
1.63 (1.14, 2.32) 
 
1.78 (1.10, 2.87) 
2.67 (1.64, 4.37) 
 
2.53 (1.07, 5.98) 
4.46 (2.02, 9.86) 
-4444.39 
Model 2  
Male 
Low SES at 26 
Current smoker at 26 







1.83 (1.33, 2.52) 
1.40 (0.97, 2.03) 
1.71 (1.22, 2.41) 
1.78 (0.91, 3.49) 
 
1.78 (1.07, 2.96) 
1.78 (1.06, 3.00) 
5.62 (3.32, 9.54) 
2.88 (1.33, 6.25) 
 
2.30 (0.94, 5.64) 
2.70 (1.18, 6.18) 
9.39 (3.27, 26.95) 




Low SES at 26 
Current smoker at 26 
Regular Marijuana user1 at 26 
High plaque score group at 26 









1.67 (1.21, 2.32) 
1.40 (0.96, 2.04) 
1.66 (1.17, 2.36) 
1.75 (0.88, 3.48) 
2.04 (1.13, 3.66) 
0.96 (0.69, 1.33) 
 
1.72 (1.00, 2.94) 
1.67 (0.97, 2.87) 
4.89 (2.82, 8.49) 
2.86 (1.30, 6.28) 
2.24 (1.01, 4.96) 
1.27 (0.74, 2.18) 
 
2.26 (0.85, 6.00) 
2.86 (1.23, 6.69) 
7.29 (2.43, 21.82) 
2.62 (0.90, 7.67) 
2.34 (0.78, 7.00) 
5.03 (1.24, 20.37) 
-4277.73 
CI; confidence intervals.  BIC; Bayesian information criterion (for the total number of participants).   
Reference categories: female (for male); high SES at 26 (for low SES at 26); not current smoker at 26 (for current smoker at 26); not regular marijuana user at 26 (for regular 
marijuana user at 26); low plaque score group at 26 (for high plaque score group at 26); and non-episodic attender at 26 (for episodic attender at 26). 
Statistically significant associations in bold type. 
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3.5.2.2 Effect of time-varying covariates (effect modifiers) 
The second generalisation of the GBTM model added the time-varying covariate 
dysglycaemia to the trajectories themselves, in order to examine whether dysglycaemia at 32 
and 38 altered the course of the “Low”, “Medium” and “High” trajectories (Table 3.40). It was 
not appropriate to generate coefficients and confidence intervals for the “Very low” trajectory 
due to its very large negative intercept (as a result of this trajectory being made up of 
participants with zero % sites with 4+mm AL). All the coefficients were positive, indicating 
that having dysglycaemia at 32 and 38 was associated with an upward shift of the trajectories. 
However, these associations were statistically significant for the “High” trajectory only. The 
addition of dysglycaemia case status to the model raised the BIC to -3939.61. This represented 
an improvement of 26.1% over the unadjusted model. 
 
A detailed examination of the predicted values for each of the trajectories confirmed this 
upward shift associated with dysglycaemia for the “Low”, “Medium” and “High” trajectories 
at ages 32 and 38 (Table 3.41). However, overlapping confidence intervals for most of the 
parameters demonstrated that the associations were statistically significant for the “High” 
trajectory at age 38 only. The marked upward shift in the “High” trajectory at age 38 (fully 
adjusted model) can be seen graphically (Fig 3.5.).  
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Table 3.40. Coefficients for shift in periodontal trajectory per unit change for dysglycaemia at 32 and 38 
 Periodontal trajectory group 
 Low Medium High BIC 
Shift in trajectory      
Unadjusted model1 0.116 (-0.086, 0.319) 0.080 (-0.062, 0.222) 0.178 (0.073, 0.283) -4532.52 
Model 32 0.052 (-0.195, 0.230) 0.128 (-0.035, 0.291) 0.195 (0.089, 0.300) -3939.61 
1Unadjusted model includes time-varying covariates only. 
2Model 3 includes both time-invariant covariates (sex, SES at 26, smoking at 26, marijuana use at 26, high plaque score group membership at 26, and use of dental 
services at 26) and time-varying covariates. 
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Table 3.41. Predicted values for periodontal (mean % sites with 4+mm AL) GBTM groups with and without dysglycaemia at 32 and 38.  
Confidence intervals in parentheses.  
 Periodontal trajectory group 
 Very low Low Medium High 
Age 26 
Fully adjusted model (Model 3) 
No dysglycaemia at 32 and 38 




0.00 (0.00, 0.00) 




1.16 (1.01, 1.31) 




3.40 (2.87, 3.93) 




8.52 (7.27, 9.77) 
8.52 (7.27, 9.77) 
Age 32 
Fully adjusted model (Model 3) 
No dysglycaemia at 32 and 38 
Dysglycaemia at 32 and 38 
 
 
0.00 (0.00, 0.00) 
0.00 (0.00, 0.00) 
 
 
1.27 (1.11, 1.44) 
1.34 (0.97, 1.71) 
 
 
6.47 (5.77, 7.17) 
7.35 (5.99, 8.71) 
 
 
23.79 (21.52, 26.05) 
28.89 (24.81, 32.98) 
Age 38 
Fully adjusted model (Model 3) 
No dysglycaemia at 32 and 38 
Dysglycaemia at 32 and 38 
 
 
0.00 (0.00, 0.00) 
0.00 (0.00, 0.00) 
 
 
2.74 (2.43, 3.06) 
2.89 (2.19, 3.59) 
 
 
17.09 (15.64, 18.53) 
19.41 (16.37, 22.45) 
 
 
56.23 (52.29, 60.17) 
68.30 (62.35, 74.26) 
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Fig 3.5. Periodontal GBTM trajectories for (a) no prevalence of and (b) prevalence of dysglycaemia at 32 and 38. 
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3.5.3 Identification of HbA1c GBTM groups 
Identification of HbA1c GBTM groups began with 897 Study members who had two or more 
HbA1c assays over the 12 years. The four most extreme outliers were also removed because 
they gave rise to an analytically intractable 4-person group. The censored normal model was 
used to model mean HbA1c, with censors set at minimum 10mmol/mol and maximum 
150mmol/mol. 
 
The HbA1c GBTM proceeded in a similar way to the periodontal GBTM, beginning with the 
choice of the number of groups to include in the model (Table 3.42). Although the (1 2 2) 
model had a slightly higher BIC than the (2 2 2) model, the latter fitted the data better. Both 
the 4-group and the 5-group models gave rise to one or more groups with a very small 
proportion of the observations (ten or less individuals). Thus the 3-group model with three 
quadratic trajectories (2 2 2) was chosen. 
 
Table 3.42. BIC for HbA1c GBTM according to number of groups and trajectory shapes.  
Number of groups Trajectory shapes1 BIC2 (N = 896) BIC3 (N = 2520) 
2 0 0 -7205.68 -7207.75 
2 0 1 -6912.80 -6915.38 
2 0 2 -6898.46 -6901.56 
2 1 1  -6781.01 -6784.11 
2 1 2 -6839.65 -6843.26 
2 2 2 -6828.91 -6833.05 
3 0 0 0 -6879.95 -6883.05 
3 0 1 1 -6371.67 -6375.80 
3 0 1 2 -6360.70 -6365.34 
3 0 2 2 -6335.71 -6340.88 
3 1 1 1 -6346.80 -6351.45 
3 1 1 2 -6338.70 -6343.86 
3 1 2 1 -6314.04 -6319.21 
3 1 2 2 -6311.06 -6316.74 
3 2 1 0 -6382.19 -6386.84 
3 2 1 1 -6342.69 -6347.85 
3 2 1 2 -6337.07 -6342.75 
3 2 2 1 -6313.65 -6319.33 
3 2 2 2 -6311.47 -6317.67 
4 0 0 0 0*  -6882.62 -6878.49 
5 0 0 0 0 0* -6890.45 -6885.29 
1Trajectory shapes; 0 = zero-order; 1 = linear; 2 = quadratic. 
2BIC = Bayesian information criterion (for the total number of participants) 
3BIC = Bayesian information criterion (for the total number of observations) 
*One or more of the groups had a very small proportion of the observations. 
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The model had an adequate proportion and sample number in each group: “Low” 11.0%, 
“Medium” 54.0%, and “High” 35.0% (Figure 3.6). The matrix of the observed and predicted 
values showed that the model fitted the data well and confidence intervals were narrow for 
each group (Table 3.43). The average posterior probability (AvePP) value was 0.84 or more 
for each group; well above the recommended minimum AvePP value of 0.70 (Table 3.44). The 
odds of correct classification based on the posterior probabilities of group membership were 
over 5.0 for all three groups, indicating the model had good assignment accuracy (Table 3.44). 
Finally, there was very close correspondence between each group’s estimated probability and 
the proportion of Study members assigned to it according to the maximum posterior 
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Fig 3.6. HbA1c trajectory groups 
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Table 3.43. Matrix of the observed and predicted values for mean HbA1c GBTM groups 
 
HbA1c trajectory group 
 Low Medium High 
Age 26 
Observed values 
Predicted values (95% CI) 
 
26.13 
26.13 (25.37, 26.89) 
 
29.91 
29.91 (29.45, 30.36) 
 
33.14 
33.14 (32.73, 33.55) 
Age 32 
Observed values 
Predicted values (95% CI) 
 
28.90 
28.90 (28.06, 29.74) 
 
33.20 
33.20 (32.73, 33.66) 
 
36.45 
36.45 (36.04, 36.87) 
Age 38 
Observed values 
Predicted values (95% CI) 
 
29.89 
29.89 (29.14, 30.63) 
 
34.15 
34.15 (33.59, 34.70) 
 
38.49 
38.49 (37.98, 38.99) 
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Table 3.44. Average posterior probability (AvePP) value and odds of correct classification for 
HbA1c GBTM groups 
 
HbA1c trajectory group 
 
Low Medium High 
 
Average posterior probability value  

















Table 3.45. HbA1c trajectory groups’ estimated probability and the proportion of 
Study members classified to each group according to the maximum posterior 




Proportion assigned to group 
according to the maximum 
posterior probability assignment 
rule 
Low 11.3 11.0 
Medium 52.5 54.0 
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3.5.4 Natural history of glycated haemoglobin 
The three groups had statistically significantly different mean HbA1c at age 26 (as evidenced 
by non-overlapping confidence intervals at age 26), and followed similar rising trajectories to 
age 32, with increases in mean HbA1c of 2.8 mmol/mol, 3.3 mmol/mol and 3.3 mmol/mol for 
the “Low”, “Medium”, and “High” groups respectively over the six years (Table matrix and 
Fig). While the trajectories for all three groups rose less steeply between ages 32 and 38, the 
“High” group followed a steeper trajectory than the other two groups with increases in mean 
HbA1c of 1.0 mmol/mol, 1.0 mmol/mol and 2.0 mmol/mol for the “Low”, “Medium”, and 
“High” groups respectively.  Overall, the “Low” group had a 4.4% increase, the “Medium” 
group had a 4.2% increase and the “High” group had a 6.1% increase over the twelve years 
from 26 to 38. While the differences between the mean HbA1c values at 26 and 32 were 
statistically significant for all three groups, the differences between 32 and 38 were significant 
for the “High” group only.  
 
Wald tests found that the intercepts (χ² = 4.8, p < 0.05) and the quadratic functions (χ² = 4.4, p 
< 0.05) of the “Medium” and “High” trajectory groups differed from each other. No 
differences were found between the intercepts or the slopes of the “Low” and “Medium” 
groups or the “Low” and “High” groups.   
 
Low SES at 26 and 38, mean HbA1c at all three ages, dysglycaemia at 32 and 38, and having 
1+ sites with 4+mm AL at 32 showed a clear upward gradient across the three groups from 
“Low” to “High” (Table). The gradient for males was less clear across the groups, although 
there were a higher proportion of males in the “High” group than in the “Low” group. Mean 
weight, mean WC, mean waist-hip ratio and mean waist-height ratio (at age 38 only) followed 
a similar pattern, with those in “High” group experiencing higher mean values at all three ages 
than those in the “Low” group (Table). The change over time was similar for the high risk 
anthropometric groups, although statistical significance was not reached at all ages. 
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Table 3.46. HbA1c trajectory group by demographic, HbA1c and periodontal variables. Percentages or standard deviation in parentheses. N = 893 
 HbA1c trajectory group 
 Low (N=98) Medium (N=482) High (N=313) 
Demographic characteristics    
Male (N=457, 51.2%) 47 (48.0) 226 (46.9) 184 (58.8)a 
Low SES at 26 (N=228, 26.9%) 20 (20.8) 110 (24.4) 98 (32.5)b 
Low SES at 32 (N=272, 30.5%) 24 (24.5) 155 (32.2) 93 (29.9) 
Low SES at 38 (N=169, 19.3%) 8 (8.2) 85 (18.0) 76 (24.9)a 
HbA1c measures    
HbA1c at 26 (SD) 25.9 (1.9) 29.9 (2.1) 33.4 (2.1)c 
HbA1c at 32 (SD) 28.6 (2.2) 33.2 (2.1) 36.7 (2.2)c 
HbA1c at 38 (SD) 29.6 (2.1) 34.1 (2.3) 38.7 (2.7)c 
Dysglycaemia at 26 (N=2, 0.3%) 0 (0.0) 0 (0.0) 2 (0.7) 
Dysglycaemia at 32 (N=27, 3.2%) 0 (0.0) 1 (0.2) 26 (8.9)d 
Dysglycaemia at 38 (N=149, 17.5%) 0 (0.0) 5 (1.1) 144 (48.3)d 
Periodontal measures    
1+ sites with 4+mm AL at 26 (N=157, 18.5%) 11 (12.0) 82 (17.8) 64 (21.6) 
1+ sites with 4+mm AL at 32 (N=187, 21.9%) 12 (13.6) 97 (20.8) 78 (26.1)b 
1+ sites with 4+mm AL at 38 (N=291, 34.6%) 28 (29.8) 156 (34.5) 107 (36.3) 
2+ sites with 4+mm AL at 26 (N=69, 8.1%) 3 (3.3) 36 (7.8) 30 (10.1) 
2+ sites with 4+mm AL at 32 (N=107, 12.5%) 6 (6.8) 57 (12.2) 44 (14.7) 
2+ sites with 4+mm AL at 38 (N=192, 22.8%) 17 (18.1) 100 (22.1) 75 (25.4) 
Mean % sites with 4+mm AL at 26 (SD) 0.5 (2.0) 1.0 (3.1) 1.3 (3.9) 
Mean % sites with 4+mm AL at 32 (SD) 0.9 (2.7) 1.9 (6.4) 2.5 (7.0)e 
Mean % sites with 4+mm AL at 38 (SD) 2.6 (6.4) 4.7 (12.5) 6.4 (16.0) 
Smoking    
Smoker at 26 (N=356, 40.0%) 23 (23.7) 189 (39.3) 144 (46.2)f 
Smoker at 32 (N=300, 33.6%) 22 (22.5)  157 (32.6) 121 (38.8)g 
Smoker at 38 (N=232, 26.4%) 11 (11.2) 117 (24.7) 104 (34.0)f 
ap<0.005; chi-square test.  bp<0.05; chi-square test.  cp<0.001; Kruskal–Wallis test.  dp<0.001; Fisher’s exact test.  ep<0.05; Kruskal–Wallis test.  fp<0.001; chi-square test. 
 gp<0.01; chi-square test. 
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Table 3.47. HbA1c trajectory group by anthropometric variables. Percentages or standard deviation in parentheses. N = 893. 
 HbA1c trajectory group 
 Low (N=98) Medium (N=482) High (N=313) 
Anthropometric measures    
Mean weight in kg at 26 (SD) 73.7 (11.3) 72.8 (13.5) 76.2 (16.1)a 
Mean weight in kg at 32 (SD) 77.2 (13.6) 76.4 (15.2) 81.0 (18.6)b 
Mean weight in kg at 38 (SD) 79.7 (13.8) 78.9 (16.1) 83.7 (19.2)b 
Mean BMI at 26 (SD) 24.8 (3.4) 24.7 (3.9) 25.5 (4.9) 
Mean BMI at 32 (SD) 25.6 (4.0) 25.8 (4.5) 26.8 (5.5) 
Mean BMI at 38 (SD) 26.7 (4.4) 26.7 (4.9) 27.9 (5.9) 
Mean WC in mm at 26 (SD) 795.6 (81.6) 792.0 (91.6) 817.7 (106.4)b 
Mean WC in mm at 32 (SD) 833.9 (99.8) 834.4 (105.8) 863.0 (123.1)b 
Mean WC in mm at 38 (SD) 851.8 (103.6) 850.7 (118.2) 885.8 (140.0)c 
Mean waist-hip ratio at 26 (SD)  0.79 (0.07) 0.79 (0.07) 0.81 (0.07)d 
Mean waist-hip ratio at 32 (SD) 0.82 (0.08) 0.83 (0.07) 0.84 (0.07)a 
Mean waist-hip ratio at 38 (SD) 0.84 (0.08) 0.85 (0.08) 0.87 (0.08)d 
Mean waist-height ratio at 26 (SD) 0.46 (0.05) 0.46 (0.05) 0.47 (0.06) 
Mean waist-height ratio at 32 (SD) 0.48 (0.05) 0.49 (0.06) 0.50 (0.07) 
Mean waist-height ratio at 38 (SD) 0.49 (0.06) 0.50 (0.07) 0.51 (0.08)a 
High BMI group at 26 (N=98, 11.4%) 9 (9.6) 47 (10.0) 42 (14.0) 
High BMI group at 32 (N=151, 17.5%) 10 (10.8) 70 (14.9) 71 (23.4)e 
High BMI group at 38 (N=207, 23.9%) 18 (18.4) 95 (20.5) 94 (30.9)e 
High WC group at 26 (N=56, 6.6%) 3 (3.2) 24 (5.2) 29 (9.9)f 
High WC group at 32 (N=132, 15.3%) 7 (7.5) 66 (14.0) 59 (19.5)g 
High WC group at 38 (N=176, 20.3%) 17 (17.4) 82 (17.7) 77 (25.3)h 
High waist-hip group at 26 (N=54, 6.3%) 5 (5.3) 22 (4.7) 27 (9.18) 
High waist-hip group at 32 (N=183, 21.2%) 19 (20.4) 93 (19.8) 71 (23.5) 
High waist-hip group at 38 (N=294, 34.1%) 28 (28.9) 145 (31.4) 121 (39.8)h 
High waist-height group at 26 (N=190, 22.3%) 14 (14.9) 91 (19.5) 85 (28.9)e 
High waist-height group at 32 (N=327, 37.8%) 30 (32.3) 169 (35.9) 128 (42.4) 
High waist-height group at 38 (N=391, 45.2%) 41 (41.8) 196 (42.2) 154 (50.7) 
ap<0.05; Kruskal–Wallis test.   bp<0.01; Kruskal–Wallis test.   cp<0.005; Kruskal–Wallis test.   dp<0.001; Kruskal–Wallis test. ep<0.005; chi-square test.  fp<0.05; Fisher’s exact 
test.    gp<0.001; Fisher’s exact test.   hp<0.05; chi-square test.   
High BMI group; 30+.  High WC group; women 880+mm, men 1020+mm.  High waist-hip ratio group; women 0.85+, men 0.90+.  High waist-height ratio group; 0.50+. 
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3.5.4.1 Time-invariant predictors of HbA1c group membership 
As previously described, a generalisation of the GBTM model linked time-invariant (baseline) 
individual characteristics and risk factors to the probability of periodontal group membership 
with the associations between each of these baseline characteristics and the probability of 
group membership being estimated simultaneously with the estimation of the trajectories 
themselves (Table 3.48).  
 
Model 1 examined associations between baseline demographic factors sex and SES at 26, and 
smoking at 26. Being a smoker at 26 increased the odds of being in the “Medium” or “High” 
trajectory group (Table 3.48). Being male increased the odds of being in the “High” trajectory 
group. The addition of these factors to the model raised the BIC from -6317.67 for the ‘empty’ 
model to -6025.06.  
 
To examine the individual effects of anthropometric risk factors, Models 2 (a), 2(b), 2(c) and 
2(d) added high BMI group, high WC group, high waist-hip group and high waist-height 
group membership (respectively) to Model 1 (Table 3.48). Both high WC group and high 
waist-height membership increased the odds of being in the “High” trajectory, and the 
inclusion of either of these two high risk groups increased the BIC (to -5852.70 and -5853.31 
respectively). Smoking at 26 continued to increase the odds of belonging to the “Medium” or 
“High” trajectory group, whereas being male was associated with being in the “High” group 
only. Wald tests were conducted to test the equality of the time-invariant factors estimates 
across the trajectories. The effect of sex, smoking, and high WC group membership differed 
for the “Medium” and “High” trajectories in the high WC group model (χ² = 12.0, p < 0.001 
for sex; χ² = 6.5, p < 0.05 for smoking; and χ² = 7.1, p < 0.01 for high WC group membership). 
The effect of sex, smoking and high waist-height group membership differed for the 
“Medium” and “High” trajectories in the high waist-height group model (χ² = 9.7, p < 0.005 
for sex; χ² = 7.7, p < 0.01 for smoking; and χ² = 7.5, p < 0.01 for high waist-height group 
membership).  
 
Finally, it was considered whether the addition of high BMI group membership improved the 
model. Models 3(a) and 3(b) added high BMI group membership to the high WC group and 
high waist-height group models (Table 3.49). This addition did not improve the models. 
Instead, it lowered the BIC to -5856.89 and -5856.54 respectively. This may have been due to 
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the BIC generally favouring more parsimonious models. However, the AIC (which does not 
penalise as much as the BIC for more complex models) also showed deterioration with the 
addition of high BMI group membership (from -5803.32 to -5805.13 for the high WC group 
model, and from -5803.00 to -5804.78 for the waist-height group model).   
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Table 3.48. Adjusted odds ratio (OR) for HbA1c trajectory group membership 
 HbA1c trajectory group membership OR (CI)  
 Low Medium High BIC  
Model 1  
Male 
Low SES at 26 






0.99 (0.57, 1.75) 
1.00 (0.52, 1.92) 
1.95 (1.03, 3.69) 
 
1.78 (1.02, 3.12) 
1.22 (0.65, 2.30) 
3.21 (1.73, 5.96) 
-6025.06 
Model 2 (a)  
Male 
Low SES at 26 
Smoker at 26 







0.99 (0.56, 1.76) 
1.13 (0.57, 2.24) 
1.91 (1.02, 3.60) 
1.05 (0.41, 2.68) 
 
1.91 (1.08, 3.38) 
1.33 (0.70, 2.55) 
3.25 (1.76, 6.01) 
1.91 (0.79, 4.58) 
-5906.20 
Model 2 (b)  
Male 
Low SES at 26 
Smoker at 26 







1.07 (0.61, 1.86) 
1.11 (0.57, 2.17) 
1.90 (1.03, 3.49) 
1.80 (0.37, 8.72) 
 
2.27 (1.27, 4.03) 
1.30 (0.69, 2.47) 
3.25 (1.78, 5.94) 
5.32 (1.21, 23.34) 
-5850.38 
Model 2 (c)  
Male 
Low SES at 26 
Smoker at 26 







1.03 (0.58, 1.81) 
1.15 (0.58, 2.28) 
1.89 (1.00, 3.56) 
0.77 (0.22, 2.62) 
 
1.80 (1.02, 3.18) 
1.34 (0.70, 2.57) 
3.20 (1.73, 5.93) 
1.80 (0.60, 5.34) 
-5853.48 
Model 2 (d)  
Male 
Low SES at 26 
Smoker at 26 







1.00 (0.57, 1.75) 
1.12 (0.57, 2.20) 
1.93 (1.03, 3.60) 
1.31 (0.63, 2.72) 
 
1.92 (1.09, 3.40) 
1.26 (0.66, 3.42) 
3.46 (1.87, 6.40) 
2.51 (1.26, 5.01) 
-5850.06 
CI; confidence intervals.  BIC; Bayesian information criterion (for the total number of participants).   
Reference categories: female (for male); high SES at 26 (for low SES at 26); non-smoker at 26 (for smoker at 26); not in high BMI group at 26 (for high BMI group at 26); not in 
high WC group at 26 (for high WC group at 26); not in high waist-hip group at 26 (for high waist-hip group at 26); and not in high waist-height group at 26 (for high waist-height 
group at 26).   Statistically significant associations in bold type. 
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Table 3.49. Adjusted odds ratio (OR) for HbA1c trajectory group membership 
 HbA1c trajectory group membership OR (CI)  
 Low Medium High BIC  
Model 3 (a)  
Male 
Low SES at 26 
Smoker at 26 
High WC group at 26 








1.07 (0.62, 1.87) 
1.11 (0.57, 2.17) 
1.89 (1.03, 3.48) 
2.23 (0.37, 13.54) 
0.77 (0.28, 2.12) 
 
2.27 (1.28, 4.04) 
1.29 (0.68, 2.45) 
3.24 (1.78, 5.92) 
5.53 (1.01, 30.25) 
0.96 (0.35, 2.58) 
-5856.89 
Model 3 (b)  
Male 
Low SES at 26 
Smoker at 26 
High waist-height group at 26 








0.98 (0.56, 1.73) 
1.11 (0.57, 2.19) 
1.93 (1.03, 3.60) 
1.58 (0.60, 4.14) 
0.69 (0.20, 2.30) 
 
1.90 (1.07, 3.39) 
1.26 (0.66, 2.41) 
3.44 (1.86, 6.37) 
2.76 (1.10, 6.93) 
0.83 (0.26, 2.61) 
-5856.54 
CI; confidence intervals.  BIC; Bayesian information criterion (for the total number of participants).   
Reference categories: female (for male); high SES at 26 (for low SES at 26); non-smoker at 26 (for smoker at 26); not in high BMI group at 26 (for high BMI group at 26); not in 
high WC group at 26 (for high WC group at 26); not in high waist-hip group at 26 (for high waist-hip group at 26); and not in high waist-height group at 26 (for high waist-height 
group at 26).   Statistically significant associations in bold type. 
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3.5.4.2 Effect of time-varying covariates (effect modifiers) 
The second generalisation of the GBTM model added the time-varying covariate periodontitis 
(as measured by prevalence of 1+ sites with 4+mm AL) to the trajectories themselves to 
examine whether periodontitis at 32 and 38 altered the course of the “Low”, “Medium” and 
“High” trajectories (Table 3.50). This was carried out for Model 2(d), the high waist-height 
group model. All of the coefficients were positive, indicating that having periodontitis at 32 
and 38 was associated with an upward shift of the trajectories. However, these associations 
were statistically significant for the “High” trajectory only. The addition of periodontitis case 
status to the model raised the BIC to -5628.83. These values represented an improvement of 
12.2% over the completely unadjusted (no time-invariant or time-varying covariates) model. 
 
A detailed examination of the predicted values for each of the trajectories confirmed this 
upward shift associated with periodontitis for the “Low”, “Medium” and “High” trajectories at 
ages 32 and 38 (Table 3.51). However, overlapping confidence intervals were seen for all of 
the parameters, indicating that none of the associations were statistically significant. While the 
upward shift in the trajectories (fully adjusted model) can be seen graphically, the overlapping 
confidence intervals are also evident (Fig 3.7). 
 
As a sensitivity analysis, this generalisation was also carried out for a more rigorous 
periodontitis case definition, 2+ sites with 4+mm AL. The findings were almost identical to 
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Table 3.50. Coefficients for shift in HbA1c  trajectory per unit change for prevalence of 1+ sites with 4+mm AL at 32 and 38  
 HbA1c trajectory group 
 Low Medium High BIC 
Shift in trajectory      
Unadjusted model1 0.787 (-0.253, 1.827) 0.245 (-0.146, 0.636) 0.596 (0.211, 0.982) -6055.00 
High waist-height group model2 0.495 (-0.577, 1.568) 0.238 (-0.178, 0.653) 0.562 (0.152, 0.971) -5628.83 
1Unadjusted model includes time-varying covariates only. 
2The high waist-height group model includes both time-invariant covariates (sex, SES at 26, smoking at 26 and membership of the high waist-height group at 26) 
and time-varying covariates. 
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Table 3.51. Predicted values for HbA1c GBTM groups with and without periodontitis at 32 and 38.  Confidence intervals in parentheses.  
 HbA1c trajectory group 
 Low Medium High 
Age 26 
Fully adjusted model  
No periodontitis at 32 and 38 
Periodontitis at 32 and 38 
 
 
25.62 (24.62, 26.61) 
25.62 (24.62, 26.61) 
 
 
29.58 (29.09, 30.07) 
29.58 (29.09, 30.07) 
 
 
32.84 (32.44, 33.24) 
32.84 (32.44, 33.24) 
Age 32 
Fully adjusted model  
No periodontitis at 32 and 38 
Periodontitis at 32 and 38 
 
 
28.25 (27.05, 29.44) 
28.74 (27.30, 30.18) 
 
 
32.85 (32.34, 33.36) 
33.08 (32.48, 33.69) 
 
 
36.15 (35.75, 36.55) 
36.71 (36.22, 37.20) 
Age 38 
Fully adjusted model  
No periodontitis at 32 and 38 
Periodontitis at 32 and 38 
 
 
29.52 (28.52, 30.51) 
30.01 (28.84, 31.18) 
 
 
33.64 (33.04, 34.24) 
33.88 (33.24, 34.52) 
 
 
38.17 (37.68, 38.67) 
38.73 (38.20, 39.27) 
Fully adjusted model includes time-invariant covariates sex, SES at 26, smoking at 26 and membership of the high waist-height group, and time-varying covariate prevalence of 
periodontitis (as measured by prevalence of 1+ sites with 4+mm AL) at 32 and 38. 
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Fig 3.7. HbA1c GBTM trajectories for (a) no periodontitis and (b) periodontitis at 32 and 38. 
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3.6 Linear Mixed Models 
A linear mixed model (LMM) was used to model (a) the HbA1c trajectory over time and (b) the 
mean AL trajectory over time, with age considered as the time variable. Analysis began with a 
closer examination of these two variables using boxplots and random draw scatterplots.  
The boxplots graphically depict information about the distributions of HbA1c and mean AL at 
ages 26, 32 and 38 (Figure 3.8). The median value (the solid line across the inside of each box) 
for HbA1c increased over the twelve years, with the greatest increase between ages 26 and 32. 
The boxes represent the interquartile range (values from the 25th to the 75th percentile) and 
contain 50% of participants. The whiskers (the lines extending vertically from the boxes) indicate 
the upper and lower quartiles. The whiskers end at the most extreme values that are within 1.5 
box lengths from the edge of the box, with outliers lying beyond that. There are outliers at both 
low and high values at each age, with extreme high value outliers at ages 32 and 38. 
 
Figure 3.8. Boxplots for HbA1c and mean AL at ages 26, 32 and 38. 
 
 
The median value for mean AL decreased between ages 26 and 32, rising slightly again between 
32 and 38 (Figure 3.8). There were one and two low value outliers at ages 26 and 38 respectively, 
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no low value outliers at age 32, many high value outliers at all three ages, and extreme high value 
outliers at ages 32 and 38.  
 
Random draw scatter plots of HbA1c and mean AL over time provide a quick glance into how 
the variables developed over the twelve years from 26 to 38 (Figure 3.9). These indicate that 
there are indeed different intercepts and slopes for different participants.   
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3.6.1 Linear Mixed Model for mean AL 
The results of a simple ‘standard’ or ‘naïve’ regression model for associations between mean AL 
and covariates mean HbA1c and age are shown in Table 3.53. The fixed effects part of the model 
gives estimates for β0 (the intercept for AL when HbA1c = 0 and age = 26) and coefficients for 
mean HbA1c and age 32 and 38, along with their associated standard errors. Mean AL and ages 
32 and 38 had statistically significant coefficients of 0.01, -0.11 and 0.06, respectively. The 
coefficient 0.01 represents the increase in the predicted value of AL for each 1 mmol/mol 
increase in mean HbA1c, if age remains constant; the coefficient -0.11 represents the decrease in 
the predicted value of AL for the six-year difference in age from 26 to 32, if HbA1c remains 
constant; and the coefficient 0.06 represents the increase in the predicted value of AL for the 
twelve-year difference in age from 26 to 38, if HbA1c remains constant. The random effects part 
of the model gives estimates for the total variance in HbA1c not explained by explanatory 
variables AL and age, that is, the Variance (Residual) estimate and its standard error. However, 
this model does not account for correlations between observations; it does not have a random 
intercept and therefore essentially ignores the longitudinal nature of the data. The table also 
shows the model information criteria: the log-likelihood of model, the AIC and the BIC. 
 
Model 2 shows the results of a LMM analysis which adds a random intercept to the model (Table 
3.53). The -xtmixed- default maximum likelihood (ML) estimation approach was used to estimate 
both fixed effects and random effects. The coefficient for mean HbA1c was unchanged. The 
variance component has now been divided into two parts: one part is related to the random 
variance around the intercept (0.16); the other is the remaining variance (0.14) not explained by 
the explanatory variables or the intercept variance. The model information criteria indicated that 
this model is a better fit than Model 1. The log-likelihood, AIC and BIC were all improved by 
adding a random intercept to the model. 
  
In Model 3, a random slope was added to the random intercept model (Table 3.53). The 
coefficient for mean HbA1c was further reduced, and was no longer statistically significant.  The 
variance component has been given more structure. It is now made up of four parts: the variance 
of the slope 0.00; the variance around the intercept 0.04; the covariance between the random 
intercept and the random slope 0.01; and the remaining variance 0.06 not explained by the 
explanatory variables or the other variances. The estimate for the covariance between the random 
intercept and the random slope gives information about the relationship between random intercept 
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and slope. It is positive, which indicates that the participants with a high intercept also have a 
high slope. The log-likelihood, AIC and BIC for Model 3 showed an improvement over those of 
Model 2. 
 
The fully adjusted LMM with random intercept and slope models (Model 4) is presented in Table 
3.54. This model added the covariates smoking, sex, SES, plaque score group, and use of dental 
services to the model. In addition, a range of interactions between age and other predictors were 
included. In this fully adjusted model, the coefficient for mean HbA1c was unchanged, and was 
not statistically significant. The coefficients for age, male sex, plaque score group, and use of 
dental services were all significant as were interactions between age and use of marijuana weekly 
or more, age and smoking, age and male, age 32 and routine use of dental services, and age 38 
and SES. The variance component part of the model was similar to the unadjusted Model 3, but 
the values for the model information criteria all showed an improvement, indicating the fully 













Table 3.53. Linear mixed models for mean AL without explanatory variables other than mean HbA1c and age.  
 Model 1 
Naïve Model 
Model 2 
Random Intercept model 
Model 3 
Random Intercept & slope 
model 
Fixed effect parameters Estimate SE 95% CI Estimate SE 95% CI Estimate SE 95% CI 
β0 (Intercept) 1.15 0.08 (0.99, 1.32) 1.30 0.09 (1.13, 1.47) 1.41 0.07 (1.27, 1.55) 































Random effect parameters Estimate SE 95% CI Estimate SE 95% CI Estimate SE 95% CI 
Variance (Age) - - - - - - 0.00 0.00 (0.00, 0.00) 
Variance (Intercept) - - - 0.16 0.02 (0.12, 0.21) 0.04 0.01 (0.03, 0.06) 
Covariance (Age, Intercept) - - - - - - 0.01 0.00 (0.00, 0.01) 
Variance (Residual) 0.29 0.01 (0.27, 0.30) 0.14 0.02 (0.10, 0.18) 0.06 0.01 (0.05, 0.07) 
Model Information Criteria Estimate Estimate Estimate 
Log-likelihood of model -1959.54 -1669.28 -1231.03 
AIC 3929.09 3350.57 2478.06 
BIC 3958.16 3385.45 2524.57 
Statistically significant parameters in bold type.  SE; standard error of the estimate. CI; confidence interval.  
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Table 3.54. Adjusted Linear mixed model for mean AL 
 Model 4 Random Intercept & slope model 
Fixed effect parameters Estimate SE 95% CI 
β0 (Intercept) 1.38 0.07 (1.23, 1.52) 
Mean HbA1c 0.00 0.00 (-0.00, 0.01) 
Age 321 -0.15 0.03 (-0.21, -0.08) 
Age 381 0.14 0.06 (0.01, 0.26) 
Smoker2 0.02 0.02 (-0.02, 0.06) 
Male3 0.07 0.02 (0.03, 0.11) 
Marijuana Use4 
Less than weekly 





































(0.15, 0.27)  
Routine attender7 -0.09 0.02 (-0.13, -0.05) 
Interactions    
Age 32* Marijuana less than weekly8 -0.01 0.03 (-0.07, 0.05) 
Age 32* Marijuana weekly or more 8 0.15 0.04 (0.07, 0.23) 
Age 38* Marijuana less than weekly8 0.01 0.05 (-0.08, 0.10) 
Age 38* Marijuana weekly or more 8 0.27 0.09 (0.08, 0.45) 
Age 32*Smoker9 0.10 0.03 (0.04, 0.16) 
Age 38*Smoker9 0.31 0.05 (0.21, 0.42) 
Age 32*Male10 0.05 0.02 (0.00, 0.09) 
Age 38*Male10 0.09 0.03 (0.02, 0.16) 
Age 32*Routine11 0.07 0.03 (0.02, 0.12) 
Age 38*Routine11 -0.02 0.03 (-0.08, 0.04) 
Age 32*Medium SES12 -0.03 0.03 (-0.09, 0.03) 
Age 32*High SES12 0.03 0.04 (-0.10, 0.05) 
Age 38*Medium SES12 -0.18 0.06 (-0.30, -0.06) 
Age 38*High SES12 -0.18 0.06 (-0.31, -0.05) 
Random effect parameters Estimate SE 95% CI 
Variance (Age) 0.00 0.00 (0.00, 0.00) 
Variance (Intercept) 0.03 0.01 (0.02, 0.05) 
Covariance (Age, Intercept) 0.00 0.00 (0.00, 0.00) 
Variance (Residual) 0.06 0.00 (0.05, 0.07) 
Model Information Criteria Estimate 
Log-likelihood of model -922.32 
AIC 1908.63 
BIC 2093.83 
SE; standard error of the estimate. CI; confidence interval. Statistically significant coefficients in bold type. 
Reference categories: 1Age 26, 2Non-smoker, 3Female, 4No marijuana use, 5Low SES, 6Very low plaque score 
group, 7Non-routine attender, 8Age 26 + No marijuana use, 9Age 26 + non-smoker, 10Age 26 + female, 11Age 26 + 
Non-routine attender, 12Age 26 + low SES.   
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3.6.2 Linear Mixed Model for mean HbA1c 
Results of a simple ‘standard’ or ‘naïve’ regression model for associations between mean 
HbA1c and covariates mean AL and age are shown  in Table 3.51. The fixed effects part of the 
model gives estimates for β0 (the intercept for HbA1c when AL = 0 and age = 26) and 
coefficients for mean AL and age 32 and 38, along with their associated standard errors. Mean 
AL and age 32 and 38 had statistically significant coefficients of 0.63, 3.40 and 4.65 
respectively. The coefficient 0.63 represents the increase in the predicted value of HbA1c for 
each 1% point increase in AL, if age remains constant; the coefficient 3.40 represents the 
increase in the predicted value of HbA1c for the six-year difference in age from 26 to 32, if 
AL remains constant; and the coefficient 4.65 represents the increase in the predicted value of 
HbA1c for the twelve-year difference in age from 26 to 38, if AL remains constant. The 
random effects part of the model gives estimates for the total variance in mean HbA1c not 
explained by explanatory variables mean AL and age, that is, the Variance (Residual) estimate 
and its standard error. However, this model does not account for correlations between 
observations; it does not have a random intercept and therefore essentially ignores the 
longitudinal nature of the data. 
 
The Table also shows the model information criteria: the log-likelihood of model, the AIC and 
the BIC (Table 3.51). As outlined in the Methods section, these criteria in themselves are not 
meaningful. Rather, they are used to compare competing nested models with the model, with 
the lowest (or least negative in the case of negative values) AIC or BIC being the “best” model 
among all models specified for the data at hand. 
 
Model 2 shows the results of a LMM analysis which adds a random intercept to the model 
(Table 3.51). The -xtmixed- default maximum likelihood (ML) estimation approach was used 
to estimate both fixed effects and random effects. The coefficient for mean AL was reduced. 
The variance component has been divided into two parts: one part is related to the random 
variance around the intercept, the other is the remaining variance not explained by the 
explanatory variables or the intercept variance. The model information criteria indicated this 
model is a better fit than Model 1. The log-likelihood, AIC and BIC were all improved by 
adding a random intercept to the model.  
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In Model 3, a random slope was added to the random intercept model (Table 3.51). The 
coefficient for mean AL was further reduced and was no longer statistically significant.  The 
variance component has been given more structure. It is now made up of four parts: the 
variance of the slope 0.07; the variance around the intercept 4.76; the covariance between the 
random intercept and the random slope 0.08; and the remaining variance 5.78 not explained by 
the explanatory variables or the other variances. The estimate for the covariance between the 
random intercept and the random slope gives information about the relationship between 
random intercept and slope. It is positive which indicates the participants with a high intercept 
also have a high slope. The log-likelihood, AIC and BIC for Model 3 showed an improvement 
over those for Model 2. 
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Table 3.51. Linear mixed models for Mean HbA1c without explanatory variables other than mean AL and age. 
 Model 1 
Naïve Model 
Model 2 
Random Intercept model 
Model 3 
Random Intercept & 
 slope model 
Fixed effect parameters Estimate SE 95% CI Estimate SE 95% CI Estimate SE 95% CI 
β0 (Intercept) 29.74 0.26 (29.22, 30.26) 30.07 0.31 (29.46, 30.68) 30.18 0.29 (29.61, 30.75) 































Random effect parameters Estimate SE 95% CI Estimate SE 95% CI Estimate SE 95% CI 
Variance (Age) - - - - - - 0.07 0.05 (0.02, 0.31) 
Variance (Intercept) - - - 7.47 0.63 (6.33, 8.81) 4.76 0.98 (3.18, 7.12) 
Covariance (Age, Intercept) - - - - - - 0.08 0.06 (-0.05, 0.20) 
Variance (Residual) 15.97 0.45 (15.12, 16.89) 8.42 3.00 (4.19, 16.94) 5.78 1.23 (3.82, 8.79) 
Model Information Criteria Estimate Estimate Estimate 
Log-likelihood of model -6940.69 -6706.83 -6592.36 
AIC 13891.39 13425.65 13200.71 
BIC 13920.39 13460.54 13247.22 
Statistically significant parameters in bold type.  SE; standard error of the estimate. CI; confidence interval.  
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The fully adjusted LMM with random intercept and slope models (Model 4) is presented in 
Table 3.52. This model added smoking, BMI, SES and sex covariates to the model. In 
addition, sex*age interactions were included. The presence of a significant interaction 
indicates that the effect of one predictor variable (such as age) on the response variable (mean 
HbA1c) is different at different values of the other predictor variable (such as sex). 
 
In this fully adjusted model, the coefficient for mean AL was further reduced and was not 
statistically significant (Table 3.52). The coefficients for smoking, marijuana use weekly or 
more, BMI, and age 32 and 38 were all statistically significant. In addition, the male*age-38 
interaction indicated that the association between mean HbA1c and age 38 was significantly 
stronger for males than for females. The variance component part of the model was similar to 
the unadjusted Model 3, but the values for the model information criteria all showed an 
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Table 3.52. Adjusted linear mixed model for mean HbA1c 
 Model 4 Random Intercept & slope model 
Fixed effect parameters Estimate SE 95% CI 
β0 (Intercept) 27.67 0.62 (26.46, 28.88) 
Mean AL 0.09 0.18 (-0.27, 0.45) 
Smoker1 0.71 0.17 (0.37, 1.05) 
Marijuana Use2 
Less than weekly 























Male4 0.35 0.22 (-0.08, 0.78) 
Age 325 3.22 0.17 (2.89, 3.55) 













Random effect parameters Estimate SE 95% CI 
Variance (Age) 0.07 0.05 (0.02, 0.32) 
Variance (Intercept) 4.57 1.01 (2.96, 7.05) 
Covariance (Age, Intercept) 0.06 0.06 (-0.07, 0.18) 
Variance (Residual) 5.73 1.26 (3.72, 8.83) 
Model Information Criteria Estimate 
Log-likelihood of model -6410.60 
AIC 12857.20 
BIC 12961.41 
SE; standard error of the estimate. CI; confidence interval.  Statistically significant coefficients in bold type. 
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3.7 Summary of results 
 
The following is a brief summary of the main points of the results chapter. 
1) Attrition analysis 
Proportionately fewer individuals of low childhood SES, low SES at 26 and 32, and smokers 
at 32 were included in the periodontal GBTM. 
There were no differences between those included in, and those excluded from, the HbA1c 
GBTM. 
 
2) Description of the sample 
The proportion who smoked declined over the 12 years. 
Periodontal status worsened with age. 
Mean HbA1c increased with age, as did the prevalence of prediabetes, type 2 diabetes and 
dysglycaemia. 
The anthropometric measures all increased between ages 26 and 38. 
 
3) Cross-sectional associations  
Cross-sectional associations were found between periodontal status and covariates SES, 
smoking (both tobacco and marijuana), and oral health care at all three ages (associations 
generally became stronger with age). 
Cross-sectional associations were found between HbA1c and covariates smoking and 
anthropometric measures at most ages (associations generally became stronger with age). 
Some cross-sectional associations found between periodontal status and HbA1c at each age.  
 
4) Longitudinal associations 
No longitudinal associations were found between periodontitis at 26 and HbA1c at 32. 
Some longitudinal associations were found between periodontitis at 26 and HbA1c at 38. 
Some longitudinal associations were found between periodontitis at 32 and HbA1c at 38. 
Some longitudinal associations were found between HbA1c at 26 and periodontitis at 32. 
Some longitudinal associations were found between HbA1c at 26 and periodontitis at 38. 
No longitudinal associations were found between HbA1c at 32 and periodontitis at 38.  
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5) Group based trajectory modeling 
Periodontal GBTM 
Periodontal GBTM identified a 4-group trajectory model. 
Associations were found between periodontal trajectory group and male sex, low SES, 
current smoking, regular marijuana use, high plaque score group, and episodic use of dental 
services. Odds ratios for these variables showed an upward gradient across the trajectory 
groups from “Very low” to “High” 
Dysglycaemia at 32 and 38 was associated with an upward shift in the periodontal 
trajectories. These associations were statistically significant for the “High” trajectory at age 
38 only. 
HbA1c GBTM 
HbA1c GBTM identified a 3-group trajectory model. 
Associations were found between HbA1c trajectory group and male sex, smoking at 26, high 
WC group at 26 and high waist-height group at 26. Odds ratios for these variables showed an 
upward gradient across the trajectory groups from “Low” to “High” 
Periodontitis at 32 and 38 was associated with an upward shift in the HbA1c trajectories. 
However, none of the associations were statistically significant. 
 
6) Linear mixed models 
Mean AL LLM 
Associations were found between mean AL and age, male sex, plaque score group, and use of 
dental services. 
No association was found with mean HbA1c.  
There were interaction effects between age*use of marijuana weekly or more, age*smoking, 
age*male sex, age 32* routine use of dental services, and age 38* SES. 
Mean HbA1c LLM 
Associations were found between mean HbA1c and smoking, marijuana use weekly or more, 
BMI and age.  
No association was found with mean AL.  
There was an interaction effect between age 38*sex. 
 





The Dunedin Multidisciplinary Health and Development Study data have provided a unique 
opportunity to explore the putative bidirectional relationship between periodontal disease 
and dysglycaemia in an initially healthy population over 12 years from early adulthood into 
early middle age. The natural histories of both of these widespread chronic conditions were 
tracked using group based trajectory modeling, covariates for both conditions were 
identified, and a gradual decline in health status over the time period was noted. Both 
conditions were highly prevalent by age 38, and it was found that health status at 26 
predicted health status at 38. Some unadjusted cross-sectional and longitudinal associations 
were found between the two conditions. However, when fully-adjusted GBTM models were 
fitted, the influence of dysglycaemia on periodontitis was found to be minimal, and 
periodontitis was found to have no influence on HbA1c. A supplementary analysis using 
linear mixed effect modeling confirmed what the GBTM had found – there was no real 
relationship between the two conditions at this stage in the life course. 
 
 
4.1 Strengths and limitations 
The strengths of this study include the large sample size and the very high retention rate 
(over 95% of the surviving cohort) for all three assessments. This is due to the loyalty, 
commitment and goodwill of the Study members and their families, the mutual trust and 
respect between Study members and researchers, and a long history of confidentiality and 
non-intervention. Barriers to participation were minimised and Study members felt a sense 
of pride when they saw DMHDS research outputs in the media. The retention rates are 
exceptional for a longitudinal study, especially after 32 years, with many other longitudinal 
studies worldwide reporting much higher drop-out rates. 
 
The use of a birth cohort, and the high retention rate, means that the sample is representative 
of its source population (the South Island of New Zealand). The issue of whether the 
findings can be generalized to the whole New Zealand population, and to other populations 
(particularly the United States) must be considered. A 2006 paper provided broad support 
for the generalisability of findings from the Dunedin Study whereby Study members were 
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similar to their age matched peers in two nationally representative surveys on most of the 
health measures compared (Poulton et al., 2006). With respect to the periodontal data, this 
has been addressed by another paper using data from this sample (Thomson et al., 2006). It 
was concluded that findings from the DMHDS can be generalised to these populations. The 
prevalence of dysglycaemia in the cohort is consistent with data from the U.S. 
(Marcinkevage et al., 2013) and the U.K. (Wilmot et al., 2013), and it is therefore likely that 
the findings are generalisable to these populations.  
 
The Dunedin Study is also the longest-running longitudinal observational study of oral 
health in the world, and no other longitudinal study presents such a wealth of objective oral 
health data. Likewise, the collection of objective HbA1c and anthropometric data over such 
a lengthy period in this age group is exceptional. It is believed no other study has both 
periodontal and HbA1c data in an initially healthy cohort in this age group. It follows that 
this opportunity to concurrently track the natural histories of both periodontitis and 
dysglycaemia from young adulthood towards mid-life is unique. 
 
The use of GBTM to identify latent HbA1c trajectory groups is a further strength of this 
study. The principal advantage of GBTM over other trajectory modeling techniques is that it 
does not assume a priori the existence of trajectories of a specific form. Rather, it allows 
distinctive latent developmental trajectories to emerge from the data (Nagin, 2005). It 
facilitates the examination of factors that may determine trajectory group membership, and 
it enables the dissemination and communication of complex findings in a form which is 
readily understood by non-technical audiences, public health funders, politicians, general 
practitioners and the public. 
 
The study had some limitations that must be recognised. One is the under-representativeness 
of Māori people in the cohort with respect to the total New Zealand Maori (14.9% in the 
2013 census) population. However, the proportion (7.5%) who self-identified as Maori at 
age 26 in the Dunedin Study does match the proportion of Maori in the South Island. Pacific 
groups are also under-represented in the cohort. As both type 2 diabetes and periodontal 
disease disproportionately affect Pacific adults this may have led to an attenuation of the 
findings (Ministry of Health, 2010a; 2012). 
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The DMHDS data are right-censored. Data to age 38 have been gathered, but we have no 
information yet as to what will happen beyond this age. In other words, our observations are 
incomplete. It is likely that future periodontitis and dysglycaemia states will be more 
prevalent, extensive and severe than those recorded at 38, but we do not know for sure how 
they will develop over the years ahead. 
 
The ideal protocol for periodontal studies is the full-mouth examination of six sites per tooth 
(Papapanou, 2012; Savage et al., 2009). Although full-mouth periodontal examinations were 
carried out at ages 32 and 38, it was necessary to convert these to half-mouth data to allow 
longitudinal comparisons with the age 26 data. In addition, recordings were made from three 
sites only per tooth. These two factors have likely led to an underestimation of the 
prevalence of periodontitis, and possibly an attenuation of the strength of the associations 
between periodontitis prevalence and other parameters (although there is no way to know 
for sure). However, with respect to the sites per tooth, research has shown that of the three 
random half-mouth protocols in general use, the one used in the DMHDS (three-site mesio-
buccal, mid-buccal, and disto-lingual) produced less bias than the others (Susin et al., 2005). 
 
Self-report data were used to provide information on reasons for tooth loss, SES, tobacco 
and cannabis smoking status, alcohol use, physical activity and use of dental services; the 
issue of the reliability and validity of this self-report data must be addressed. With respect to 
tooth loss, the Florida Dental Care Study data found a telephone interview to be an effective 
method for gathering tooth count information at nominal and ordinal levels (Gilbert et al., 
1997). A Harvard School of Dental Medicine study found that asking participants the 
question “How many natural teeth do you have in your mouth now?” could accurately 
report their actual number of teeth, with a slight tendency towards underreporting (Pitiphat 
et al., 2002). Meanwhile, a study using data from the 2007 to 2009 Canadian Health 
Measures Survey concluded accurate estimates of the prevalence of cigarette smoking can 
be derived from self-reported smoking status data (Wong et al., 2012). Interview/examiner-
based assessments, as used in the Dunedin study, are more likely to yield valid data than 
“self-completed” data. Furthermore, Study members are familiar with interviews, are aware 
of the importance of accurate responses, and there is a long history of mutual trust and 
respect between participants and researchers. 
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Another potential limitation was the comparability of the data over the three ages. While it 
is common practice for long-term studies to freeze blood or serum, the issue of the 
comparability of frozen and fresh samples must be addressed. A recent study found a high 
correlation between HbA1c data from fresh, frozen and refrozen samples, particularly at 
lower (<42mmol/mol) values of HbA1c (Liotta et al., 2013). At age 26, only two Study 
members were found to have ≥41 mmol/mol HbA1c. These individuals both had Type 1 
diabetes, and were excluded from the current analyses. The remaining age 26 sample were 
all below 41 mmol/mol HbA1c, and so categorised as “low level”. We therefore concluded 
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4.2 The findings of this study 
The findings of this study can be summarised as: (1) a gradual decline in health status was 
seen between ages 26 and 38; (2) health status at age 38 was associated with health status at 
26; (3) predictors of periodontal disease experience included male sex, smoking, marijuana 
use, SES, plaque score and episodic use of dental services at age 26; (4) predictors of 
dysglycaemia included male sex, smoking, higher waist circumference and higher waist-
height ratio at age 26; and (5) no association was found between periodontitis and 
dysglycaemia in the fully-adjusted models. 
 
4.2.1 A gradual decline in health status 
The period from the mid-twenties to the end of the fourth decade of life generally signifies a 
time when people settle down, obtain a steady job or start a career, perhaps buy property, 
have a mortgage, begin to raise a family, and become a productive part of the society in 
which they live. It can also represent a time when a gradual decline in health status is seen 
in many individuals, setting the stage for poorer health in later years. The DMHDS cohort 
showed an overall deterioration in periodontal, glycated haemoglobin and anthropometric 
measures over the 12 years of the study. This section considers that deterioration, and 
compares the DMHDS data with those from other studies in similar age groups. 
 
By whatever measure was used (prevalence, extent or severity), periodontal status worsened 
with time, with the greatest deterioration seen between ages 32 and 38. This was despite a 
reduction in the proportion of sites with bleeding on probing, a reduction in mean plaque 
score, a reduction in the proportion of Study members in the “moderate” or “high” plaque 
score groups, and an increase in the proportion of them in the “very low” plaque score group 
between ages 26 and 38. In addition, the prevalence of risky health behaviours—cigarette 
smoking and marijuana use—dropped over the years (although the mean pack years 
increased, reflecting the cumulative effects of smoking in the cohort). This overall 
deterioration was also despite almost half the cohort following the “Very low” periodontitis 
trajectory with zero % sites with 4+mm AL at each of the three ages. Moreover, the “Low” 
trajectory group experienced only slight worsening in periodontal status over the 12 years. 
The greatest burden of declining periodontal health was concentrated in the 14.8% of the 
cohort who were in in the “Medium” and “High” groups.  
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A comparison of DMHDS periodontal disease data with data from other studies is difficult 
due to differences in study design, age groups examined, and methods of disease detection, 
measurement and categorisation (Savage et al., 2009). However, those that are comparable 
found prevalence estimates for 1+ sites with 4+mm AL that were generally consistent with 
those seen in the Dunedin Study. The Australian National Survey of Adult Oral Health 
2004-2006 reported that 48.8% of adults age 35-54 years had 1+sites with 4+mm AL, while 
the SHIP study found that 26.8% of participants age 20-29, and 61.5% of participants age 
30-39 had 1+sites with 4+mm AL (Holtfreter et al., 2009; Slade et al., 2007). Although the 
SHIP study’s prevalence of 61.5% for ages 30-39 was markedly higher than the DMHDS 
full-mouth prevalence of 43.9% at age 38, the prevalence of 26.8% for the age 20-29 group 
was consistent with the DMHDS full-mouth prevalence of 29.7% at age 32. The most recent 
NHANES periodontal data showed a 32.4% prevalence of 1+sites with 4+mm AL in the 30-
34 age group, and  53.5% in the 35-49 age group (Eke et al., 2012). The findings of the 
2009 New Zealand Oral Health Survey are consistent with the current study’s findings: the 
prevalence of 1+sites with 4+mm AL was 35.3% for the 25-34 age group; and 44.0% for the 
35-44 age group (Ministry of Health, 2010a). In particular, the consistency with the New 
Zealand Oral Health Survey gives confidence in the generalisability of the findings to the 
whole New Zealand population. 
 
A recent meta-analysis of 72 studies from 37 countries found that periodontitis prevalence 
increases gradually with age, showing a steep increase between the third and fourth decades 
of life, and plateauing from age 40 onwards (Kassebaum et al., 2014). However, this meta-
analysis consisted mostly of cross-sectional studies. A previous Dunedin Study paper 
tracked periodontal changes from 26 to 38 using GBTM (Thomson et al., 2013). In that 
paper the sample was made up of those participants with data at all three assessment points, 
and thus was a smaller sample size (N = 831). Nonetheless, the periodontitis prevalences, 
trajectory groups’ proportions and trajectory forms were similar to those of this study. In 
addition, the 2013 paper found strong associations between trajectory group and tobacco 
smoking at all assessments between ages 15 and 38.   
 
Mean HbA1c also increased steadily with age, with the great majority of Study members 
experiencing a rise in HbA1c level over the 12 years, and a small proportion (6.8%) 
experiencing a small reduction. The finding that mean HbA1c increased with age is not 
surprising, because this phenomenon has been seen elsewhere (Hashimoto et al., 1995; Pani 
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et al., 2008; Yang et al., 1997). However, most other studies focusing on HbA1c and age 
have examined older populations, and the magnitude of the change (an increase of 16.0% 
between 26 and 38) in this relatively young age group is noteworthy. What is remarkable is 
that most of this change happened at a very young age indeed, between 26 and 32, with 
lesser change seen between 32 and 38.  
 
The prevalence of dysglycaemia rose over this time from a negligible proportion to almost 
one in five Study members by age 38. This high prevalence is of great concern. While few 
Study members were actually diabetic by age 38, those categorised as dysglycaemic are at 
great risk of developing type 2 diabetes within a decade (Ackermann et al., 2011). The 
findings are consistent with those of a recent New Zealand study which found the 
prevalence of prediabetes to be 25.5% for the total NZ population over the age of 15, with a 
prediabetes prevalence of 18.9% for the 25-44 age group (Coppell et al., 2013). What the 
present study adds is that three distinctive patterns of glycaemia experience were able to be 
identified from age 26 through to age 38. This provided a different perspective on the 
natural history of dysglycaemia; rather than defining thresholds for normoglycaemia, 
prediabetes and diabetes, this study instead characterised its natural history in terms of a 
subpopulation’s development trajectory. 
 
Reflecting the deterioration in periodontal and glycaemic health, the anthropometric 
measures all increased between ages 26 and 38. Overall, the Study members became heavier 
and their mean waist circumference increased over the years spanning young adulthood into 
early middle age. Similar changes in this age group been comprehensively demonstrated in 
previous studies (Colditz et al., 1995; Jacobsen et al., 2001; Liu et al., 2012; Ostbye et al., 
2011). As with mean HbA1c and the prevalence of dysglycaemia, the greatest increases in 
the anthropometric measures were mostly between ages 26 and 32, with smaller changes 
between 32 and 38. Likewise, the proportion of those considered to be at greater risk of 
cardiometabolic complications also increased over the 12 years. The anthropometric risk 
group rates at age 38 were alarming; almost a quarter were categorised as obese; almost a 
fifth had a dangerously large waist circumference; over a third had a waist-hip ratio that 
classified them as having abdominal obesity; and almost half the cohort had a waist-height 
ratio that would be considered to put them at risk.  
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These anthropometric findings are not unusual. In New Zealand, the 2012/13 New Zealand 
Health Survey found that 27.5% of participants in the 25-34 age group were obese, as were 
34.1% in the 35-44 age group (Ministry of Health, 2013). Considering that the Health 
Survey sample had a higher proportion of Maori and Pacific groups (with those being at 
greater risk of being obese) than the DMHDS sample, the findings of the two studies are 
consistent. The 2011-2012 nationally representative National Health and Nutrition 
Examination Survey (NHANES) reported the prevalence of obesity to be 30.3% for US 
adults in the 20–39 age group. Similar findings were reported in the U.K. (Moody, 2014), 
where 26.0% of men and 26.3% of women in the 25-34 age group were categorised as 
obese. The latter survey found 21.0% of men and 33.0% of women in the age 25-34 age 
group to be in the waist circumference high-risk group; this was higher than the proportion 
seen at age 38 in the Dunedin Study.  
 
4.2.2 Health at age 38 was associated with health 12 years earlier 
This analysis of the Dunedin Study longitudinal data using GBTM clearly demonstrated that 
the risk of being in an unfavourable trajectory by age 38 was associated with health status at 
age 26. These findings correspond well with the life course approach to chronic disease 
epidemiology whereby later life outcomes are influenced by physical and social exposures 
during gestation, childhood, adolescence, and young adulthood (Kuh and Ben-Shlomo, 
2004). In theory, factors operating early in the life course of an individual may contribute to 
the risk of periodontitis or dysglycaemia many years later. Thus, health status at 26 may be 
regarded as an early warning of this cumulative disadvantage – years before more advanced 
disease becomes apparent. 
 
A higher risk of being in an unfavourable periodontal trajectory by 38 was associated with a 
greater extent of disease 12 years earlier. The extent of periodontitis at age 26, as defined by 
% sites with 4+mm AL, was significantly different for the four trajectories (0.00%, 1.30%, 
3.18% and 8.15% at 26 for the “Very low”, “Low”, “Medium” and “High” trajectory groups 
respectively). This implies that susceptibility to periodontal disease may be well established 
by early adulthood. 
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HbA1c levels at age 26 may have an important role in identifying those most at risk for 
dysglycaemia 12 years later. The three HbA1c trajectories did not start from the same age 
26 HbA1c level and then diverge; rather, they were distinguishable at age 26 (25.9 
mmol/mol, 29.9 mmol/mol and 33.4 mmol/mol for the “Low”, “Medium” and “High” 
trajectory groups respectively). Although these three starting levels are all within a 
normoglycaemic range, the risk of being in an unfavourable trajectory by age 38 was 
associated with the higher initial HbA1c level 12 years earlier. These findings suggest that: 
the path towards dysglycaemia can be identified much sooner than previously assumed; the 
roots of cardiometabolic disease may be established early in life; and the implications of this 
for our understanding of its natural history are important. Accordingly, the therapeutic and 
preventive implications are significant. 
 
4.2.3 Predictors of periodontal disease 
The use of the GBTM model generalisations allowed the linkage of baseline characteristics 
to the probability of group membership (Nagin, 2005; Nagin and Odgers, 2010). It was 
found that males, smokers, marijuana users, those of low SES, those who had poor oral 
hygiene, and those who were episodic users of dental services had the greatest odds of 
belonging to the two least favourable periodontal trajectory groups. The associations found 
between periodontal trajectory group and sex, tobacco smoking and low SES were 
consistent with the 2009-2010 National Health and Nutrition Examination Survey 
(NHANES) periodontal findings, where periodontitis experience was more prevalent and 
extensive in men, poorer and less-educated adults, and current smokers (Eke et al., 2012).   
 
4.2.3.1 Sex 
Disparities in the burden of periodontal disease by sex have been acknowledged (Albandar, 
2002; Eke et al., 2012; Shiau and Reynolds, 2010a). The prevalence of periodontitis was 
found to be significantly higher in males than in females in the German SHIP-0 sample 
(Zhan et al., 2014). It is unclear whether sex differences in periodontal prevalence are due to 
male sex being a marker for riskier oral health habits (smoking, marijuana use, poor oral 
hygiene, episodic use of dental services) or whether there is an intrinsic susceptibility to—
and a plausible biologic basis for—the greater prevalence of periodontitis in males, or both 
(Shiau and Reynolds, 2010b). The present study found male sex to be a predictor of “Low”, 
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“Medium” and “High” periodontal trajectory membership when the model adjusted for low 
SES only. When other predictors were added to the model (smoking, marijuana use) the 
association between male sex and the “High” periodontal trajectory group disappeared, but 
it remained for the “Low” and “Medium” groups. It is possible that a lack of statistical 
power (due to the small sample size of the high periodontal trajectory group) may have led 
to a Type 2 error for this group. 
 
4.2.3.2 Smoking 
Smoking has long been recognised as a risk factor for periodontal disease, although the 
precise biological mechanisms of that effect are unclear (Bergstrom, 2006; Genco and 
Borgnakke, 2013; Jansson and Lavstedt, 2002; Johannsen et al., 2014; Palmer et al., 2005; 
Thomson et al., 2007; Tonetti, 1998; Warnakulasuriya et al., 2010; Zeng et al., 2014). What 
is clear is: the consistency of findings across many studies in different populations, 
countries and age groups; the strength and the biological gradient of the association; the 
temporal sequence of smoking and periodontal disease; and its biologic plausibility (Genco 
and Borgnakke, 2013). This study adds to the weight of evidence, with strong associations 
and clear gradients between smoking at baseline and the odds of membership in the “Low”, 
“Medium” and “High” periodontal trajectory groups. The linear mixed model for mean AL 
found an interaction between smoking and age, whereby the association between smoking 
and mean AL became stronger over time. 
 
4.2.3.3 Marijuana use 
The GBTM found marijuana use was associated with membership of the periodontal 
“Medium” trajectory group, but not the “High” trajectory group (as with the associations 
between male sex and the “High” trajectory group, this may have been due to Type 2 error). 
The linear mixed model for mean AL found an interaction between marijuana use and age, 
whereby the association between marijuana use weekly (or more) and mean AL became 
stronger over time. There were only two other papers found that examined marijuana use as 
a risk factor for chronic periodontitis in humans. Thomson et al found marijuana use to be a 
risk factor for attachment loss at age 32 while a Chilean paper found the opposite to be true 
for adolescents (Lopez and Baelum, 2009; Thomson et al., 2008). However, a recent animal 
study did find an association between marijuana exposure and alveolar bone loss in rats 
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(Nogueira-Filho et al., 2011). Further research into these associations in diverse settings is 
required. 
 
4.2.3.4 Low SES 
That low SES is a risk factor for poorer health has been comprehensively established (Kuh 
et al., 2002; Poulton et al., 2002; Power et al., 2005; Wadsworth, 1997). With respect to 
periodontal health, a Dunedin Study paper found longitudinal associations between low 
childhood SES and a greater prevalence and extent of periodontitis at age 26, and Morita et 
al. reported a significant social gradient by job classification in periodontal status in a 
Japanese sample (Morita et al., 2007; Thomson et al., 2004). A SHIP study found 
longitudinal associations between education and income levels and the progression of 
periodontitis over a five-year period (Buchwald et al., 2013). A recent British paper using 
data from the 2009 UK Adult Health Survey suggested that income inequalities in 
periodontal disease were mediated by education and smoking (Steele et al., 2015). The 
current study found a clear gradient across the periodontal trajectory groups although only 
the association with the “High” trajectory group membership was statistically significant. 
The pathways between low SES and periodontitis risk are undoubtedly complex. For 
example, it is possible education is a proxy for oral health behaviours (oral hygiene 
practices, use of dental services, dietary factors). The low-SES–periodontitis link is one that 
requires further investigation. 
 
4.2.3.5 Plaque score  
The role of dental plaque in the initiation and progression of destructive periodontitis is 
currently unclear. Systematic reviews have concluded that there are insufficient well-
designed randomised controlled trials to reach conclusions on the beneficial effects of 
repeated oral hygiene instruction in the prevention or control of periodontitis (Hujoel et al., 
2005; Pastagia et al., 2006). Of course, it does not follow that oral hygiene instruction will 
necessarily result in a reduction in dental plaque. In this respect, two recent reviews are of 
interest. Both examined the role of professional mechanical plaque removal (PMPR) by 
dental professionals on a regular basis in the prevention of periodontitis (Needleman et al., 
2015; Trombelli et al., 2015). Trombelli et al found that study participants who regularly 
complied with the PMPR programme had minimal variations in plaque scores in contrast to 
irregular compliers who showed a substantial increase (Trombelli et al., 2015). Meanwhile, 
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Needleman et al found low to moderate strength of evidence that PMPR, especially if 
combined with oral hygiene instructions, produced generally greater reductions in plaque 
than no treatment (Needleman et al., 2015).  
 
The DMHDS paper on marijuana use reported the prevalence of destructive periodontal 
disease to be inconsistently related to dental plaque, and found no association between 
dental plaque and incident destructive periodontal disease (Thomson et al., 2008). In this 
instance, plaque score was measured cross-sectionally. Another Dunedin Study paper which 
recorded plaque longitudinally demonstrated clear gradients in more prevalent and extensive 
periodontitis across dental plaque trajectory groups from high to low (Broadbent et al., 
2011). The present study’s findings on plaque score group were inconclusive. Bivariate 
analyses found a clear gradient across the periodontal trajectory groups for membership of 
the high plaque score group at 26, 32 and 38. However, the fully adjusted model found that 
membership of the high plaque score group at 26 was associated with membership of the 
“Low” and “Medium” periodontal trajectory groups but not the “High” trajectory group. 
Clearly, more research is needed on the role of plaque in the initiation and progression of 
periodontitis. 
 
4.2.3.6 Episodic use of dental services 
In contrast, the fully adjusted model found that those categorised as episodic users of dental 
services at age 26 had greater odds of belonging to the “High” periodontal trajectory group, 
but not the “Medium” or “Low” groups. DMHDS data have been used to examine 
associations between dental visiting patterns and dental caries and missing teeth (Crocombe 
et al., 2012; Thomson et al., 2010). However few studies have reported on associations 
between dental visiting patterns and periodontal status, and the findings from those which 
have done so have been inconclusive (Davenport et al., 2003).  
 
It is clear that adults vary widely in their susceptibility to periodontitis, and only a subset 
will suffer from severe periodontitis (Genco and Borgnakke, 2013). The early identification 
of those who are at greatest risk of progression to destructive disease would be 
advantageous. However, this is not straightforward. The initiation and progression of 
destructive chronic periodontitis involves a complex interplay of genetic and epigenetic 
factors, psychosocial and behavioural influences, and environmental exposures. This study 
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has provided a novel perspective to the identification of this group by the use of GBTM to 
(1) identify those at greatest risk of poor periodontal health, and (2) identify early adulthood 
predictors of that risk. 
 
4.2.4 Predictors of dysglycaemia 
As with the periodontal data, the use of the GBTM model generalisations allowed the 
linkage of baseline characteristics to the probability of HbA1c group membership (Nagin, 
2005; Nagin and Odgers, 2010). While any attempt to categorise glycaemic risk must be 
regarded as somewhat arbitrary, GBTM differs from the conventional practice of defining 
thresholds for normoglycaemia, prediabetes and diabetes; essentially, those are stages in the 
natural history of dysglycaemia rather than separate diseases. GBTM instead characterises 
risk in terms of a subpopulation’s developmental trajectory, and so provides a different 
perspective on identifying those most at risk. It was found that being male, or being a 
member of the high WC group or the high waist-height group at 26, was associated with 
membership of the HbA1c “High” trajectory group, and that being a smoker at 26 was 
associated with membership of either the HbA1c “Medium” or “High” trajectory group. 
Males, smokers, and those who had an unhealthily large WC or waist-height ratio, had the 
greatest odds of belonging to the “High” HbA1c trajectory group. Conversely, females, non-
smokers, and those with a healthy WC or waist-height ratio had the greatest odds of 
following a favourable trajectory from age 26 to 38.   
 
4.2.4.1 Sex 
Little research on sex differences in HbA1c levels has been carried out, so it is difficult to 
compare findings between this study and others. The ongoing Trial Evaluating 
Cardiovascular Outcomes with Sitagliptin (TECOS) study reported no sex differences in 
baseline HbA1c; however, the sample comprised older individuals with Type 2 diabetes 
(Bethel et al., 2015). A comparable sample in a US study yielded similar findings; no sex 
differences in HbA1c were seen (Strom Williams et al., 2014). Finally, the 2005–2008 
National Health and Nutrition Examination Surveys (NHANES) reported no sex differences 
in prediabetes prevalence as defined by HbA1c ≥39 mmol/mol (James et al., 2011). No 
research examining sex differences in HbA1c levels in the third and fourth decades was 
identified. Accordingly, it is believed this study is the first to demonstrate a longitudinal 
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This study confirms previous research on smoking as an independent and modifiable risk 
factor for dysglycaemia. It found the odds for a smoker at 26 of belonging to the “Medium” 
HbA1c trajectory group to be almost double those for a non-smoker, and the odds for a 
smoker at 26 of belonging to the “High” HbA1c trajectory group to be over three times 
those for a non-smoker. These strong associations are consistent with the EPIC-Norfolk 
study, which reported strong cross-sectional associations between smoking and HbA1c in a 
large population-based sample (Sargeant et al., 2001). A dose-response relationship was 
seen between HbA1c and both the number of cigarettes smoked daily and cumulative 
smoking exposure as measured by pack-years. They are also comparable to 1999-2008 
NHANES data demonstrating associations between HbA1c and self-reported smoking and 
blood cotinine12  levels (Clair et al., 2011). Those studies were both cross-sectional, so a 
temporal relationship could not be determined.  
 
A longitudinal dose-response association was found between smoking exposure and 
reported diagnosis of Type 2 diabetes in the male Physicians’ Health Study (Manson et al., 
2000). Likewise, a cohort study of male Japanese steel workers over eight years found a 
longitudinal dose-response association between smoking exposure and dysglycaemia as 
defined as HbA1c ≥43 mmol/mol or taking anti-diabetic medication (Teratani et al., 2012). 
A US study found a longitudinal dose-response association between smoking exposure and 
the transition from normoglycaemia to IFG (Rafalson et al., 2009). The participants in all of 
these longitudinal studies were middle-aged or older; the longitudinal study in which 
HbA1c was used as an outcome did not include females, and the longitudinal study which 
did include females did not use HbA1c as an outcome. Finally, a comprehensive meta-
analysis of prospective studies by Willi et al. found evidence for a longitudinal association 
between smoking and IFG, OGTT and Type 2 diabetes (Willi et al., 2007). Unfortunately, 
no studies with HbA1c as an outcome were included in that meta-analysis. Consequently, 
while smoking is well established as a risk factor for dysglycaemia (as measured by IFG, 
OGTT, or diabetes incidence in the middle aged and older people), the influence of smoking 
                                                 
12A nicotine metabolite 
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on HbA1c levels in younger populations has not been investigated. Thus, it is believed that 
the current study is the first to demonstrate a longitudinal association between smoking and 
HbA1c levels over the third and fourth decades of life in a representative and initially 
healthy population. 
 
4.2.4.3 Anthropometric measures 
Generally, the anthropometric parameters followed a pattern whereby those in the “High” 
HbA1c trajectory group had higher mean values at all three ages than those in the “Low” 
group, with the same being true of the anthropometric dichotomous variables. This is not 
surprising, and is in agreement with current research. There is convincing evidence that 
excessive body weight and central adiposity are risk factors for dysglycaemia (World Health 
Organization, 2003). However, debate continues as to which characteristic is most closely 
linked to that risk (Ashwell et al., 2012; Feng et al., 2012; Janssen et al., 2004; Lee et al., 
2008; Truswell, 2012; Tulloch-Reid et al., 2003; Vazquez et al., 2007).  
 
Weight gain in adulthood should be considered to be a predictor of cardiometabolic risk 
(Colditz et al., 1995). A recent meta-analysis found weight gain (particularly between ages 
18 and 24 years rather than 25 years and older) was associated with a greater risk of later 
developing Type 2 diabetes (Kodama et al., 2014). 
 
The BMI was originally developed as the “Quetelet Index” in 1832. This index, with minor 
variations, continues to be widely used today as an expression of the link between excess 
relative weight and morbidity (Eknoyan, 2008; Narayan et al., 2007; Tulloch-Reid et al., 
2003). It is associated with general obesity; height and weight are easy to measure; and it is 
considered to be a good predictor of type 2 diabetes risk (Tulloch-Reid et al., 2003). 
However, it does not distinguish fat from muscle, or take account of body fat distribution. 
 
WC correlates with central adiposity – a known risk factor for type 2 diabetes (Feng et al., 
2012; Janssen et al., 2004; Onat et al., 2004; Pouliot et al., 1994). It is simple and 
inexpensive to measure, and predicts diabetes risk better than BMI (Feng et al., 2012; 
Janssen et al., 2004), but it does not take differences in height into account (Browning et al., 
2010). In addition, there are different thresholds for males and females, and for different 
ethnic groups.   
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Waist-hip ratio is currently used less often. It attempts to quantify relative distribution of fat 
(individuals with more abdominal fat are at greater cardiometabolic risk than those who 
carry more weight around the hips). However, research is divided on the utility of the waist-
hip ratio in predicting type 2 diabetes risk (Liu et al., 2011; Vazquez et al., 2007). Weight 
change does not generally lead to a pronounced change in this ratio, since both waist and hip 
measurements can increase/decrease with weight gain/loss. In addition, it requires two 
measurements which are both more prone to measurement error than either weight or height 
measurement. In one study, BMI, WC and waist-hip ratio were all found to have similar 
associations with type 2 diabetes (Vazquez et al., 2007). Another found that, while BMI, 
WC and waist-height ratio were all found to be associated with fasting plasma glucose, 
waist-hip ratio was not (Liu et al., 2011).  
 
Waist-height ratio has become more popular in recent years. Like WC, it correlates well 
with central adiposity, it is the same for imperial or metric scales, and only a tape measure is 
required. Unlike WC, it accounts for different heights. This minimises the requirement to 
have different thresholds for the different sexes and ethnic groups, with a “one size fits all” 
value of 0.5 (Browning et al., 2010; Hsieh et al., 2003). One study found that BMI, WC and 
waist-height ratio similarly predict metabolic risk (Liu et al., 2011); others found waist-
height ratio to be a better screening tool for risk than either BMI or WC (Ashwell et al., 
2012; Browning et al., 2010; Savva et al., 2013). However, a recent meta-analysis found 
that waist-height ratio was better than BMI and waist-hip ratio in predicting incident 
diabetes, but no better than WC alone (Kodama et al., 2012). 
 
The findings of the present study add to the body of research regarding anthropometric 
measures, and are consistent with studies reporting associations between the central 
adiposity measures, WC and waist-height ratio, and cardiometabolic risk (Ashwell et al., 
2012; Browning et al., 2010; Feng et al., 2012; Janssen et al., 2004; Kodama et al., 2012; 
Lam et al., 2015; Liu et al., 2011; Savva et al., 2013). In agreement with these papers, this 
study found associations between both WC and waist-height ratio and membership of the 
HbA1c “High” trajectory group.  
 
Some researchers have found a combination of waist-height ratio and BMI to be the best 
predictor of risk (Lam et al., 2015). This study found that not to be the case in the DMHDS 
cohort. Membership of the high WC group predicted HbA1c “High” trajectory group 
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membership better than the combination of high WC group membership and high BMI 
group membership, and membership of the high waist-height ratio group predicted HbA1c 
“High” trajectory group membership better than the combination of high waist-height ratio 
group membership and high BMI group membership. However, it is possible that a 
combination of measures may prove to be a better predictor of risk as the cohort ages.  
 
The odds ratio for the high WC group membership was greater than for the high waist-
height ratio group membership. However, the wide 95% confidence intervals for the high 
WC group may indicate a degree of imprecision for the finding; the number in the high WC 
group at 26 was small (N=29). The narrower 95% confidence intervals for the high waist-
height ratio group indicate greater precision for this finding. 
 
It is believed there has been only one other prospective study (Ware et al., 2014) examining 
waist-height ratio using HbA1c as an outcome measure. This study used South African data 
from the Prospective Urban Rural Epidemiology (PURE) study. Baseline measurements 
were taken in 2005 (N=1519, mean age 51.2 years for men, 50.7 years for women), and the 
follow-up was five years later in 2010. It found associations between waist-height ratio at 
baseline and HbA1c levels five years later. A lack of generalisability to the source 
population was a serious limitation for this study. The overall retention rate was 60.4% over 
the five years, but excluding 308 participants who had dysglycaemia at baseline from the 
prospective analysis for HbA1c resulted in an actual retention rate of only 40.0%.  
Accordingly, it is believed that the present study is the first to report longitudinal 
associations between waist-height ratio and HbA1c in a representative cohort (with the 
added advantages of a long observation period over the third and fourth decades of life, and 
an excellent retention rate). 
4.2.5 No relationship between periodontitis and dysglycaemia  
The use of the GBTM model generalisations allowed the identification of effect modifiers 
associated with deviations from the group trajectory (Nagin, 2005; Nagin and Odgers, 
2010). In this way, the influence of HbA1c on the periodontitis trajectories, and the 
influence of periodontitis on the HbA1c trajectories, in the fourth decade of life were 
explored. 
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Having dysglycaemia at age 38 was associated with an upward shift of the “High” 
periodontal trajectory. Dysglycaemia which occurred during the course of the “High” 
trajectory altered the direction of that trajectory, and set it on a steeper upward path than it 
would have followed if that condition had not occurred. The shift was from a mean 56.2% 
sites with 4+mm AL at 38 (no dysglycaemia at 38) to a mean 68.3% sites with 4+mm AL 
(dysglycaemia at 38). This represents a 21.5% relative increase in the mean % sites with 
4+mm AL for dysglycaemia at 38 over no dysglycaemia at 38. However, these GBTM 
findings were not replicated in the linear mixed model analysis, which found no relationship 
between HbA1c and the mean % sites with 4+mm AL.  
 
This difference in findings between GBTM and LMM may have been because the extent of 
periodontal experience (mean % sites with 4+mm AL) was used in the GBTM analysis 
while the severity of periodontal experience (mean AL) was used in the LMM analysis. Or 
it may have been due to the fundamental differences in the way the two methods handle the 
data. GBTM gathers individuals into subgroups that show statistically similar trajectories 
with individuals being assigned a probability of group membership (Nagin, 2005). 
Covariates are handled in two ways; baseline covariates can be linked to the probability of 
group membership, and events that occur during the course of the trajectory can be 
examined for their impact on the trajectories’ paths. Linear mixed modeling assumes all 
individuals follow the same basic developmental pattern with random variation around that 
pattern; it takes the hierarchical nature of the data into account; and it allows for the 
simultaneous estimation of the influence of covariates at tooth and person level (Tu et al., 
2013; Zeng et al., 2014). It is likely that the dissimilarity in the GBTM and LMM findings is 
due to a combination of the methodological differences and the different variables used. 
 
Having periodontitis during the fourth decade of life was not found to have any influence on 
the HbA1c trajectory groups; a non-statistically significant minimal difference in mean 
HbA1c was seen between those with periodontitis at ages 32 and 38, and those without 
periodontitis at these ages. This finding was repeated in the linear mixed model analysis, 
which found no relationship between the mean % sites with 4+mm AL and HbA1c. 
 
Most researchers agree that individuals with poorly controlled diabetes have a greater risk of 
destructive periodontitis (Azarpazhooh and Tenenbaum, 2012; Bascones-Martinez et al., 
2011; Cullinan et al., 2009; D'Aiuto et al., 2005; Grossi and Genco, 1998; Kandelman et al., 
                                                                                                                                                             Dara Shearer 
167 
 
2008; Khader et al., 2006; Kuo et al., 2008; Lakschevitz et al., 2011; Lalla and Papapanou, 
2011; Löe, 1993; Mealey, 2006; Mealey and Oates, 2006; Mealey and Ocampo, 2007; 
Papapanou, 1996; Preshaw et al., 2012; Salvi et al., 2008; Taylor, 2001; Williams et al., 
2008). There is also substantial evidence that a bidirectional relationship exists between 
periodontitis and type 2 diabetes; the chronic inflammation of periodontitis may influence 
glycaemic control in susceptible individuals, with each condition potentially exacerbating 
the other. However, research to date has reported conflicting findings, with some studies 
suggesting that periodontitis may influence HbA1c levels, IGT, glycaemic control in those 
with type 2 diabetes or diabetes risk (Borgnakke et al., 2013; Choi et al., 2011b; Demmer et 
al., 2008; Demmer et al., 2010; Grossi and Genco, 1998; Ide et al., 2011; Lamster et al., 
2014; Morita et al., 2012; Nesse et al., 2009; Saito et al., 2004; Saito et al., 2006; Taylor et 
al., 1996; Zadik et al., 2010), and others finding no associations (Marugame et al., 2003; 
Saito et al., 2005). The corollary of a bidirectional relationship between periodontitis and 
diabetes is that treatment of periodontal disease in those with poorly-controlled diabetes 
may improve their glycaemic control. Once again, the evidence is conflicting but mostly 
positive (Borgnakke et al., 2014; Darre et al., 2008; Engebretson and Hey-Hadavi, 2011; 
Grossi et al., 1997; Khader et al., 2010; Kiran et al., 2005; Koromantzos et al., 2011; 
Simpson et al., 2010; Teeuw et al., 2010). However, others have found no effect 
(Engebretson et al., 2013; Janket et al., 2005; Jones et al., 2007; Yun et al., 2007). 
 
Most research has been carried out on participants who already had type 2 diabetes (or the 
study had diabetes incidence as an outcome), on middle-aged or older people, on children 
and adolescents with Type 1 diabetes, or on population-based samples with the full range of 
adult age groups. There has been little research on an initially healthy sample and 
concentrating specifically on early dysglycaemia/prediabetes as a predictor for periodontitis, 
or on periodontitis as a predictor for early dysglycaemia/prediabetes. Thus, comparisons 
between the present study and others are difficult. The three studies by Saito and colleagues 
on Japanese samples had inconsistent findings: a greater risk of progression to IGT with 
greater periodontal probing depth (Saito et al., 2004); no associations between IGT and 
either deep pocketing or severe attachment loss in a female-only sub-sample of the previous 
study (Saito et al., 2005); and associations between alveolar bone loss and IGT in a different 
sample (Saito et al., 2006). A 2010 SHIP paper found periodontitis at baseline in healthy 
individuals to be associated with HbA1c progression five years later (Demmer et al., 2010). 
Choi et al. found a dose-response relationship between periodontitis and IFG in a NHANES 
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III sample (Choi et al., 2011b). Another study found associations between higher HbA1c at 
baseline and the risk of developing periodontitis five years later, and between periodontitis 
at baseline and the risk of higher HbA1c five years later (Morita et al., 2012). Lamster et al. 
found that participants with previously unidentified prediabetes demonstrated periodontitis 
experience at a level between those observed for normoglycaemic participants and 
participants with type 2 diabetes (Lamster et al., 2014). In contrast, a recent SHIP-Trend 
study found no association between prediabetes and the extent of teeth with 4mm+ AL or 
mean probing depth (Kowall et al., 2015). Meanwhile, the Continuous NHANES 2009-2010 
survey found associations between severe periodontitis and IGT, but not IFG, and no 
associations between moderate periodontitis and either IGT or IFG (Arora et al., 2014). Of 
these studies, only three were longitudinal. One was retrospective (Saito et al., 2004) and 
two were prospective (Demmer et al., 2010; Morita et al., 2012). For each of these 
longitudinal studies, participation/retention rates were poor, so the findings were not 
generalisable to the source populations. 
 
Therefore, it is believed the current study is the first to examine the longitudinal 
bidirectional associations between periodontitis and dysglycaemia, as measured by HbA1c, 
at an early stage in the glycaemia continuum. Some unadjusted cross-sectional and 
longitudinal associations were found between the two conditions over 12 years. However, in 
the fully adjusted models, the influence of dysglycaemia at age 38 on periodontitis was 
found to be minimal, and having periodontitis at age 32 or 38 had no influence on HbA1c 
levels. In addition, a supplementary analysis using linear mixed effect modeling confirmed 
no associations between mean AL and mean HbA1c over the twelve years. It must therefore 
be acknowledged that there was no real relationship between the two conditions at this stage 
in the life course. 
 
Why was no relationship found between the two conditions in this study while some of the 
other studies did find associations? There is no way of knowing for sure, but it is possible to 
speculate. First, the age groups in the other studies were both older and (with the exception 
of the 2006 Saito et al paper) had a wider range of ages. The Saito studies had participants 
aged 40 years and older (Saito et al., 2004; Saito et al., 2005) and 50-55 years (Saito et al., 
2006). Both the SHIP and the NHANES III samples were 20 years and older (Choi et al., 
2011b; Demmer et al., 2010). The Morita et al sample was aged 30-69 years; the Columbia 
University study sample was age 40 and over if Caucasian, and age 30 and over if non-
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Caucasian or Hispanic; the Continuous NHANES 2009-2010 sample was ages 30-80; and 
the SHIP-Trend sample was ages 20-82 (Arora et al., 2014; Kowall et al., 2015; Lamster et 
al., 2014; Morita et al., 2012).  
 
The current study focused on the 12 years between ages 26 and 38; this is a time of life 
when the foundations of poor health are being laid down, but it may also be a developmental 
epoch in which it is just too early to see clear bidirectional associations between 
periodontitis and dysglycaemia. While the prevalence of both conditions was high in the 
Dunedin cohort by age 38, the experience of neither was very severe. This study 
investigated dysglycaemia as a predictor of periodontitis at an earlier stage in the life course 
than had much previous research, and in an initially healthy cohort (there were only two 
individuals with prediabetes at age 26). Therefore, it is not surprising that dysglycaemia was 
found to exert only minimal influence on periodontitis in the fourth decade. That this 
influence was exerted on those already at risk of poorer periodontal outcomes (those in the 
“High” periodontal trajectory) supports the concept that developmental history not only 
modifies the response to impacts, but may also define the magnitude of that response (Elder, 
1998). Disadvantage may accumulate throughout life, with those most disadvantaged 
diverging further from those less disadvantaged with each subsequent challenge. Likewise, 
much of the research into the influence of periodontal disease on dysglycaemia/glycaemic 
control has been carried out on participants with diabetes, and has been in older populations. 
The present study examined the influence of periodontitis at a much earlier stage in the life 
course – and found no effect. Since both periodontitis and dysglycaemia generally worsen 
with time, it is possible that such associations may develop as the cohort ages (Hashimoto et 
al., 1995; Kassebaum et al., 2014; Pani et al., 2008; Yang et al., 1997).  
 
Second, different studies have used different definitions of dysglycaemia. Most papers used 
IGT as an indicator of dysglycaemia (Choi et al., 2011b; Kowall et al., 2015; Saito et al., 
2004; Saito et al., 2005; Saito et al., 2006); changes in mean HbA1c were used in two 
studies (Demmer et al., 2010) (Morita et al., 2012); and HbA1c levels recorded by a point-
of-care device were used in one (Lamster et al., 2014). Another study found that whether 
there were associations or not depended on how dysglycaemia was assessed: either by IGT 
or IFG (Arora et al., 2014). The present study used both mean HbA1c and dysglycaemia as 
defined by ≥39 mmol/mol HbA1c (American Diabetes Association, 2011). While no 
method of measurement is perfect, research indicates (and many organisations are 
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recommending) that HbA1c be used for screening and diagnosis of diabetes (American 
Diabetes Association, 2014; Hare et al., 2012; Santos-Rey et al., 2010; The International 
Expert Committee, 2009; World Health Organization, 2011b). 
 
Third, there was even more variation among studies in how periodontitis experience was 
defined. Globally, there is a lack of standardisation and agreement in establishing criteria for 
the diagnosis of the condition, so comparisons among studies are problematic (Hugoson and 
Norderyd, 2008; Leroy et al., 2010; Page and Eke, 2007). Within the studies examining the 
bidirectional associations between periodontitis and diabetes, periodontitis was variously 
assessed by the Community Periodontal Index of Treatment Need (CPITN or CPI) (Morita 
et al., 2012), clinical attachment loss (AL) and pocket depth (Arora et al., 2014; Choi et al., 
2011b; Demmer et al., 2010; Kowall et al., 2015; Saito et al., 2004; Saito et al., 2005), 
pocket depth only (Lamster et al., 2014), and by alveolar bone loss determined using 
radiography (Saito et al., 2006). Most periodontal examinations (including the age-26 data 
in the present study) were half-mouth only (Choi et al., 2011b; Demmer et al., 2010; Kowall 
et al., 2015; Saito et al., 2004; Saito et al., 2005); full-mouth recordings were made in only 
two studies, and they were both cross-sectional (Arora et al., 2014; Lamster et al., 2014). 
For the current study, it was necessary to convert the age 32 and 38 measures to half-mouth 
data in order to allow longitudinal comparisons with the age 26 data. Furthermore, AL data 
were gathered from only three sites per tooth, whereas some of the other studies had 
recordings from four or six sites per tooth. Together, these may have led to an 
underestimation of the prevalence of periodontitis, and possibly a reduction in the strength 
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4.3 Implications of the findings 
This section discusses the theory, research, practice and policy implications of the findings 
of this study, and makes recommendations based on the findings. The findings of this study 
contribute substantially to our understanding of two very common disorders, periodontitis 
and dysglycaemia, and fill a gap in the theory of how they develop during the third and 
fourth decades. They underline the need for future research onwards into the fifth decade of 
life to further understand their evolution, their associations with one other, and with their 
covariates. Clinicians require clear, down-to-earth, valid and evidence-based guidelines on 
how best to assess an individual’s risk within clinical practice. The findings reinforce the 
importance of smoking and central adiposity as risk factors for poor health outcomes, and 
suggest these risk factors may have an impact from an early age. The formulation of 
effective public health policy requires comprehensive and objective information on the 
magnitude of health problems and their likely future trends. In this way, governments can 
make the decisions now for investment in necessary health research, health workforce 
development and physical infrastructure requirements, as well as planning for the most 
appropriate and efficient treatment and preventive interventions. The findings of this study 
imply that planning for the future burden of disease, smoking reduction policies and 
interventions, and measures to tackle our obesogenic environment should be included in the 
main priorities. 
 
4.3.1 Planning for the future burden of disease 
Non-communicable diseases including cardiovascular diseases, chronic respiratory diseases, 
cancer, diabetes, autoimmune disorders, and oral diseases exact a huge disease burden 
worldwide (World Health Organization, 2011a). These diseases have reached epidemic 
proportions, and their prevalence is projected to increase, particularly in developing 
countries (Abegunde et al., 2007; Nikolic et al., 2011). The current study has found a high 
prevalence of both periodontal disease and dysglycaemia by the end of the fourth decade. 
The burden of both these conditions in the decades ahead has implications for both 
workforce planning and the cost of healthcare in the future. 
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4.3.1.1 Future burden of periodontal disease 
The future burden of periodontitis is evident when the decline in edentulism, increases in 
life expectancy, and advances in restorative dentistry mean that higher retention of teeth in 
the middle-aged and older people is inevitable. Teeth that in past years would have been lost 
to dentures are now being retained, resulting in more teeth being at risk of periodontitis for a 
longer period (Shearer et al., 2011). The current study has found periodontal disease to be 
already both highly prevalent and extensive by the end of the fourth decade. By age 38, 
almost half the Dunedin cohort had 1+ sites with 4+mm AL; a third had 2+ sites with 4+mm 
AL, and there was a mean 5.1% of sites with 4+mm AL. It is probable that few Study 
members will become edentulous in the future; the prevalence of edentulism in New 
Zealand has dropped steadily since 1976 (Ministry of Health, 2010a). In Australia, 
projections for the prevalence of edentulism vary (depending on the assumptions made in 
the models) between 2.7% and 3.1% for the year 2021; and between 0.4% and 1.0% for the 
year 2041 (AIHW Dental Statistics and Research Unit, 2007). Thus, there will likely be a 
substantial future burden of periodontal disease in this cohort.  
 
Globally, the proportion of people who would expect to keep their teeth for life is 
increasing, and many will not have access to comprehensive and ongoing periodontal care.  
In later years, many will face the irritation and pain of loose teeth, reduced functional 
capacity, sensitivity, halitosis, unaesthetic appearance, and associated loss of self-esteem. 
Most worrying, the extraction of teeth may not ultimately be avoided. Rather, it may be 
delayed until well into old age, and the future workforce will have to meet the challenge of 
difficult tooth extractions in a medically-compromised and frail elderly population.  
 
Future workforce planning needs to consider and provide for the oral health needs of older 
people. Geriatric dentistry is often seen to be less attractive than other aspects of general 
dental practice (Antoun et al., 2008). The inclusion of a geriatric care module within the 
undergraduate programme, continuing dental education for existing practitioners, and a 
post-graduate degree in gerodontology may go some way towards addressing this issue 
(Thomson and Ma, 2014). In addition to tackling the issue of geriatric care (and to attempt 
to avoid some of the problems outlined above), the future of the periodontal care workforce 
will also need to be addressed to facilitate timely and accessible care for the projected rise in 
the dentate population with periodontitis. This includes assessing the most appropriate mix 
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of specialist periodontists, dental hygienists and oral health therapists to best manage all 
aspects of periodontal care. 
 
4.3.1.2 Future burden of dysglycaemia 
The prevalence of dysglycaemia in the Dunedin cohort is of great concern. While few Study 
members had type 2 diabetes at age 38, almost one in five were categorised as having 
prediabetes by that age, and those individuals are at great risk of developing type 2 diabetes 
within a decade (Ackermann et al., 2011). Ackermann et al. calculated the probability of 
developing type 2 diabetes within 7.5 years for individuals with ≥39 mmol/mol HbA1c to be 
41%. It may be assumed the incidence and prevalence of type 2 diabetes in New Zealand 
will rise markedly in the coming years. 
 
Globally, the prevalence of type 2 diabetes has risen over recent years and is projected to 
rise substantially in the future (Boyle et al., 2010; The International Diabetes Federation's 
Diabetes Atlas.; Webber et al., 2014; Wild et al., 2004). The burden and economic cost of 
diabetes and its complications are already significant (Centers for Disease Control and 
Prevention, 2011). However, this cost is forecast to rise substantially in the future, with 
consequential morbidity, mortality, suffering, reduced productivity, and increased use of 
scarce healthcare resources (American Diabetes Society, 2008; Davis et al., 2006; Fradkin 
and Rodgers, 2008; Huang et al., 2009). 
 
Policy makers will have to understand and plan for these costs over the next decades. For 
example, the diabetes-related healthcare costs are expected to increase from $113 billion in 
2009 to $336 billion in 2034 (Huang et al., 2009). Policy makers also need to urgently fund 
and implement effective preventive interventions to try to minimise future increases in type 
2 diabetes prevalence. Likewise, future diabetes care workforce needs (including 
endocrinologists, diabetes nurses and educators, dieticians, podiatrists, bariatric and renal 
specialists, ophthalmologists and more) must be assessed, planned, and trained. 
 
4.3.2 Early identification of those at risk 
Almost 20 years ago, Burt outlined a three-tiered approach to prevention involving: (1) 
population strategies aimed at the whole population; (2) targeted strategies are aimed at 
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sections of the population considered to be most at risk; and (3) individually targeted 
strategies aimed at the high-risk individual (Burt, 1998). Individuals differ widely in their 
vulnerability to non-communicable diseases, which are driven by a complex range of 
interconnected risk factors including genetic and familial factors, sociodemographic 
influences, economic factors, and modifiable lifestyle choices. Premature death and 
suffering could be greatly reduced, and economic and social burdens lessened, by the early 
identification and timely treatment of those most at risk. It makes sense to attempt to target 
those at highest risk of disease for intensive preventive measures; these can be very 
effective in reducing disease prevalence and severity (Axelsson et al., 1991; Löe, 2000; 
Stamm et al., 1991). The cost of early prevention is generally cost-effective compared to the 
cost of later treatment, and allows for the most effective use of healthcare resources. 
However, the identification of those groups most at risk is not necessarily straightforward. 
 
This study has provided a novel perspective to the identification of those most at risk of two 
non-communicable diseases—destructive chronic periodontitis and type 2 diabetes—by 
characterising risk in terms of a subpopulation’s development trajectory. In the DMHDS 
cohort, periodontal and glycaemic health status at 38 was predicted by periodontal and 
glycaemic health status respectively at 26. The study has not only added to the body of 
evidence for the role of the classic risk factors of smoking and obesity, but it has also 
suggested that they may contribute to disease risk at an earlier stage in life than previously 
presumed. These findings should provide clinicians and public health policy makers with a 
good theoretical basis for developing effective screening and intervention programmes 
earlier in life rather than later – which often can be just too late. 
 
4.3.3 Smoking reduction programmes must be a priority 
Cigarette smoking was first linked to poor health outcomes 65 years ago (Doll and Bradford 
Hill, 1950). Since then, the volume of research demonstrating the association between 
smoking and a host of diseases has been overwhelming, and it leaves little doubt that 
smoking is one of the most hazardous modifiable risk factors known. 
 
This study has demonstrated that smoking at age 26 as a risk factor for the poorest 
periodontal outcomes 12 years later, and as a risk factor for the change from 
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normoglycaemia along the continuum to dysglycaemia. To date, smoking as a risk factor for 
type 2 diabetes has not received a great deal of publicity. It is believed this is the first time 
an association between smoking during the third decade and dysglycaemia 12 years later has 
been demonstrated, and it provides smokers with another reason to quit. In the DMHDS 
cohort, periodontitis and dysglycaemia share smoking as their strongest and most consistent 
risk factor. It is becoming increasingly obvious that an evidence-based approach to the 
primary prevention of these two conditions should include smoking prevention and 
cessation, and this realisation reconfirms the need for a common risk factor approach 
(Sheiham and Watt, 2000). This concept suggests that the control of a small number of risk 
factors may have a substantial and cost-effective impact on a large number of disease 
outcomes (Sheiham and Watt, 2000). This calls for greater collaboration between oral 
healthcare providers, diabetologists, cardiologists, oncologists and primary care providers in 
lobbying for more legislation and funding aimed at reducing smoking prevalence. 
 
Legislation could include more restrictions on where smoking is permitted, tax and price 
measures to reduce tobacco consumption, the introduction of standardised packaging of 
tobacco products, and the introduction of tobacco retail licensing and registration, whereby 
tobacco retailers and wholesalers must obtain a license to sell tobacco products. Currently, 
the minimum legal age for buying cigarettes and other tobacco products in New Zealand is 
18. Recently, the Californian State Senate approved a bill that would raise the minimum 
legal age from 18 to 21. It is estimated such a measure would likely prevent or delay 
initiation of tobacco use by adolescents and young adults, and substantially reduce smoking 
prevalence (IOM (Institute of Medicine), 2015). Should New Zealand also consider such a 
measure? 
 
Additional measures to reduce smoking prevalence could include funding for further social 
marketing campaigns, general medical and dental practitioners paid to provide ongoing 
cessation counselling, and increased funding for the Quitline nicotine replacement therapy 
programme. 
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4.3.4 Central adiposity measures as predictors of dysglycaemia  
There is convincing evidence that excessive body weight and central adiposity are risk 
factors for dysglycaemia (World Health Organization, 2003). However, the question as to 
which measure is most closely linked to that risk has not been resolved (Ashwell et al., 
2012; Browning et al., 2010; Feng et al., 2012; Janssen et al., 2004; Kodama et al., 2012; 
Lee et al., 2008; Liu et al., 2011; Truswell, 2012; Tulloch-Reid et al., 2003; Vazquez et al., 
2007). Clinicians and epidemiologists would welcome clear guidance on which measure 
(preferably a quick and easy one with minimal potential for error) will most reliably predict 
risk in their patients and study participants. 
 
This study confirms the two central adiposity measures WC and waist-height ratio to be 
valid clinical predictors for future dysglycaemia risk. These findings have implications for 
both clinical and public health practitioners; they underline the importance of the central 
adiposity measures (WC and waist-height ratio) for patients, and reinforce the “keep your 
waist circumference to less than half your height” public health message. It will be of 
interest to busy clinicians that the addition of BMI did not enhance the predictive utility of 
these measures of central adiposity in this cohort. Moreover, the findings suggest that 
routine screening using WC and waist-height ratio from the middle of the third decade may 
help to identify those most at risk of unfavourable future outcomes. It may be appropriate to 
encourage primary care providers and clinicians to do this. While the use of waist-height 
ratio to assess cardiometabolic risk is relatively recent, the findings of this study indicate its 
use should be encouraged. Currently, the New Zealand Guidelines Group recommends the 
use of BMI and WC for cardiovascular risk assessment and type 2 diabetes screening (New 
Zealand Guidelines Group, 2012). It is proposed that waist-height ratio should also be 
recommended in future guidelines. 
 
The high prevalence of obesity by age 38 in the Dunedin cohort (and the sharp increase 
between ages 26 and 38) adds to the widespread concern about the rising prevalence of 
obesity globally, and underlines the need for effective and comprehensive public health 
programmes to reduce obesity prevalence and its consequences. There is a need to move 
away from victim blaming and instead focus on public health interventions that change the 
obesogenic environment. Instead of blaming individuals for eating too much and exercising 
too little, we should be advocating for legislation and policies that make “the healthy choice 
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the easy choice” (Ashe et al., 2011; Koelen and Lindstrom, 2005). Measures proposed 
include a tax on unhealthy foods, removing GST on fruit and vegetables, introduction of a 
traffic light nutrition labelling system, legislating for only healthy food to be available in 
schools, limiting the sale and advertising of sugar sweetened beverages (SSBs), 
implementing SSB-free policies in workplaces and public institutions, ensuring all New 
Zealand families have enough income to buy healthy food, and removing barriers to 
physical activity. These policies may go some way towards addressing the very complex 
underlying issues that contribute to the obesity epidemic.  
 
4.3.5 No relationship between periodontitis and dysglycaemia  
This study found no substantial relationship between periodontitis and dysglycaemia during 
the fourth decade of life. This “negative finding” adds to the theoretical understanding of 
how these two conditions interrelate, and it gives rise to new hypotheses. For example, it is 
possible that one condition may need to reach a particular threshold of severity to impact on 
the other. There are important implications for future research. It is essential to continue to 
track the natural history of both conditions in order to understand how they develop and 
interact over the next decades of life. The DMHDS cohort is in a unique position to continue 
to track trajectories of periodontitis and HbA1c onward into middle age. Data from the 
middle of the fifth decade should be available from 2018, and they will facilitate the further 
elucidation of the bidirectional links, complex associations and temporal relationship 
between periodontal disease and dysglycaemia as the cohort ages. Building on the 
foundations of the present study, the further examination of the longitudinal associations 
between these two conditions and their covariates—and their associations with each other—
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4.4 Negative findings and the research journey 
 
“I can now rejoice even in the falsification of a cherished theory, because even this is a 
scientific success” (Eccles, 1989).  
 
It is probable that every researcher begins a project in the hope that his/her findings will 
substantially contribute to the sum of knowledge. Generally, those findings are envisaged as 
being positive, and it is usually disappointing when this turns out to be not the case. Often, 
negative findings tend not to be greeted with the same enthusiasm by journal editors and the 
press as positive findings are. The most newsworthy findings have the greatest chance of 
being published. 
 
I have now been through the experience of having a negative finding for a major component 
of my thesis (the finding that there was no relationship between periodontitis and 
dysglycaemia in the fourth decade) and I have, of course, experienced feelings of 
disappointment and frustration. However, I am reassured by the words of Karl Popper 
“Every genuine test of a theory is an attempt to falsify it or to refute it” (Popper, 2014). In 
this, I have succeeded. I understand that knowing what is not true is as important as 
knowing what is. Negative findings do contribute to the sum of knowledge. What is 
important is that they are recognised as such. The proportion of negative findings papers 
that have been published has dropped in recent years from 29.8% in 1990 to 14.1% in 2007 
(Fanelli, 2011). This positive findings bias is something that must be reversed. Negative 
results should be shared with the broader academic community. Failure to report them is a 
barrier to knowledge and understanding, and it distorts the scientific literature.    
 
The concept of a PhD thesis as a “research journey” has been used so often that it is in 
danger of becoming clichéd. Even so, it is a reasonable way of visualising the process of 
beginning a research project and seeing it through to the end. However, the journey is not a 
straightforward process of travelling directly from beginning to end. There are many stops 
and starts along the way. It is iterative; often, one returns to an earlier stage in the journey, 
travels it again, and finds something different each time. There are interruptions, 
distractions, false starts, blind alleys, and plenty of pitfalls along the way. Some days, the 
destination seems too far away, and the journey too long. But as the journey now draws to 
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an end, the words of Henry Miller come to mind: “One’s destination is never a place, but 
rather a new way of looking at things” (Miller, 1957). I believe that the journey to this 
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4.5 Summary and conclusions 
This study has tracked the natural history of two conditions—periodontitis and 
dysglycaemia—from the middle of the third decade to the end of the fourth decade of life. It 
provides strong evidence for a gradual decline in health status during this time, and found 
that both conditions were highly prevalent by age 38. It found that: (a) periodontal status, 
male sex, smoking, marijuana use, low SES, high plaque score and episodic use of dental 
services at age 26 were predictors of periodontal status 12 years later; and (b) glycated 
haemoglobin levels, male sex, smoking, high waist circumference and high waist-height 
ratio at age 26 were predictors of dysglycaemia 12 years later. No relationship was found 
between periodontitis and dysglycaemia at this stage in the life course. The findings 
contribute substantially to our understanding of the two conditions and fill a gap in the 
theory as to how they develop during the third and fourth decades. The findings reinforce 
the importance of smoking and central adiposity as risk factors for poor health outcomes, 
and suggest that these factors may have an impact from an early age. The replication of 
these findings by other researchers in diverse settings is welcomed. Given the high 
prevalence of both conditions at this relatively early stage in life, it is suggested that 
planning for the future burden of disease, earlier routine cardiometabolic screening, 
smoking reduction policies and interventions, and measures to tackle the obesogenic 
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